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SUMMARY
An investigation into the early cell biology changes in response to non-genotoxic carcinogens 
was carried out. The hypolipidaemic drug and peroxisome proliferator, clofibric acid was found 
to produce a significant hepatomegaly and to induce rat hepatic cytochrome P4504A isozyme(s) 
and peroxisomal p-oxidation at both the protein and molecular level. Also induced by this 
compound were the nuclear protooncogenes c-fos and c-myc, both of which are involved in the 
process of cellular growth control. This compound however, failed to increase transcription of 
the protooncogenes Ha-ras, Ki-ras, mos, ErbAl. It was concluded that the induction of c-myc 
and c-fos was related to the observed hepatomegaly and hypothesised that this induction may 
be characteristic of non-genotoxic carcinogens, in particular, peroxisome proliferators.
Therefore, the specificity of this induction to clofibric acid and rat liver was investigated. The 
transcriptional activation of c-myc, c-fos and c-jun was examined in susceptible and non- 
susceptible species (rat and guinea pig respectively) and tissues (liver, kidney, heart and lung). 
The response of these species and tissues to clofibric acid was compared to their response to 
phenobarbitone. A marked induction of the afore-mentioned genes was apparent in those tissues 
which exhibited an increase in cell mass in response to the treatment regimes - there was no 
such correlation with tissues undergoing organelle proliferation or mixed function oxidase 
induction. Although the ability of peroxisome proliferators to induce sustained enhancement of 
cell proliferation correlates with the degree of carcinogenicity (Marsman et al, 1988, Bieri et al, 
1986), it was concluded that the early proliferative responses examined here are not exclusively 
predictive of non-genotoxic carcinogenesis.
Recent work has indicated that the Peroxisome Proliferator Activated Receptor (Issemann & 
Green, 1990) plays a key role in regulation of early gene changes involved in peroxisome 
proliferator-induced non-genotoxic carcinogenesis. I report the establishment of an in vitro 
model of peroxisome proliferator-associated effects in our laboratory and the use of this model 
to substantiate the PPAR-transfection work of Issemann et al (1993).
I have demonstrated that the PPAR acts cooperatively with Retinoid X receptor in my in vitro 
model and dramatically increases the ability of PPAR to cause transcription of specific target 
genes including constitutive acyl CoA oxidase.
In order to examine the regulation of the PPAR itself, one of the potential mechanisms for 
steroid hormone regulation, namely autoinduction, was investigated. The effect of a series of 
classical microsomal oxidase inducers (including peroxisome proliferators) on the abundance of 
PPAR mRNA was examined. My results strongly suggest that PPAR is inducible by those 
compounds known to be peroxisome proliferators (clofibrate and the perfluorinated fatty acids, 
PFDA & PFOA). Although no ligand binding to the PPAR has been shown to date, it is 
possible that the peroxisome proliferators themselves are ligands for the PPAR suggesting an 
autoregulatory mechanism of PPAR induction. Further, a functional correlation between PPAR 
induction and CYP4A1 transcription is suggested. It is hypothesised that the involvement of 
such a feedback loop readily explains the magnitude of enzyme induction response to 
peroxisome proliferators.
The above results were used to draw conclusions as to the early stages of the mechanism of 
non-genotoxic carcinogenesis with a view to the definition of a diagnostic fingerprint for 
potential non-genotoxic carcinogens.
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CHAPTER 1 
INTRODUCTION
1.1 Hepatotoxicity
Anatomically the liver lies on the main pathway by which substances absorbed from the 
intestine pass into the systemic circulation. Due to the biochemical capacity of the liver to 
metabolise both endogenous compounds and xenobiotics, this organ is affected by a very large 
number of xenobiotics and indeed is the organ most frequently affected in toxicological and 
carcinogenicity studies on rodents (Rowe et al, 1959; Weil & McCollister, 1963).
However, the liver also has a large capacity for self-repair such that many lesions observed in 
the liver reverse rapidly on cessation of treatment. This adaptability to insult allows the liver to 
act efficiently to remove low levels of toxins from the body without compromising its capacity 
to perform other vital endogenous functions. Hepatotoxicity only becomes apparent when the 
dose of toxin is sufficiently high or prolonged to interfere with the ability of the organ to 
perform its role in endogenous metabolism.
While human liver cancer is rare in Europe and North America (and is normally a late 
complication of long-established cirrhosis (McSween, 1985)), primary hepatocellular carcinoma 
is one of the three most common causes of cancer mortality worldwide, accounting for 250,000 
to 1,000,000 deaths annually (London, 1981).
1.2 Classical Mechanisms of Chemical Carcinogenesis
Willis (1967) described a tumour as ' an abnormal mass of tissue, the growth of which 
exceeds, and is uncoordinated with, that of normal tissues and persists in the same excessive 
manner after cessation of the stimuli which evoked the change'. Carcinogenesis can thus be 
characterised by sequential molecular, metabolic and morphological changes that result in a 
deficiency of cellular differentiation and loss of normal growth control.
The process of carcinogenesis is generally accepted to be a multi-stage process. Operationally, 
these stages have been defined as initiation, promotion, progression and metastasis (Figure 1.1)
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Tumour initiation can be defined as a rapid irreversible specific genetic change (i.e. a mutation 
in key genes involved in regulation of cell growth) in a single cell occurring spontaneously or 
induced by a carcinogen. Chemical initiators generally interact directly with the DNA forming 
adducts which then cause mutations during DNA replication or repair. These 'genotoxic' 
chemicals are detectable in in vitro mutagenicity assays such as the Ames Salmonella 
typhimurium transformation assay (Ames et al, 1975). Cells affected by initiators are stem cells 
which coexist in normal tissue with mature cells and cells committed to differentiation. When 
stem cells divide, they form a new stem cell and a committed cell which may then divide itself to 
form fully differentiated daughter cells. When a daughter cell undergoes an initiating event, the 
mutated cell is called an 'intermediate' which will not itself progress to tumour formation but if 
subjected to further genetic or epigenetic changes ('tumour promotion') may lead to a fully 
transformed cancer cell.
Tumour promotion is usually defined as induction of the clonal expansion of initiated cells by 
interaction of the promoting agent (for example, growth factors, hormones or xenobiotics) with 
receptors and signal transduction processes involved in the control of cell cycling (Stevenson et 
al, 1990). Promotion is reversible, at least at early stages, and requires continuous exposure to 
high doses of the promoter for a relatively prolonged time period. This classification is, 
however, simplistic when applied to the liver because the classical hepatic 'promoters' are 
almost all carcinogenic in their own right when administered to mice over a lifetime (Hinton, 
1994)
Progression refers to the malignant conversion of benign lesions (Pitot, 1989). This process 
can occur naturally and may be enhanced by direct-acting genotoxic tumour initiators and/or cell 
proliferation (Columbano et al, 1991) Tumour invasion of adjacent normal tissue and 
métastasés are the final stages of malignant progression.
This multistage model of carcinogenesis is supported by rodent models. Application of the 
genotoxin dimethylbenzanthracene to mouse skin results in a point mutation of codon 61 of the 
Ha-ras oncogene, an initiating event (Brown et al, 1986) (see section 1.2.1). This initiation can
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be promoted by application of 12-0-tetraphorbol-13-acetate producing papillomas (Brown et al, 
1986). Equally, investigations into the genesis of human colon cancer have been shown to 
comprise five distinct events including oncogene activation and loss of tumour suppressor 
genes (Fearon and Vogelstein, 1990) This lends additional weight to the multistage model of 
carcinogenesis.
1.2.1 Molecular Events in Carcinogenesis
Analysis of the transformed phenotype has enabled three broad classes of genes involved in the 
transition from a normal cell to a malignant one to be defined. The first of these classes is the 
oncogenes which are defined as genes whose abnormal expression or altered gene product 
directly determines the production of a malignant phenotype. The second class of genes are the 
tumour suppressor genes which normally act to control cell proliferation and whose loss or 
inactivation is associated with tumorigenesis. Thirdly, there is a group of genes involved in 
DNA repair which, when mutated produce a predisposition to cancer. Discussion of this third 
class is essentially outside the scope of this chapter. The oncogenes are currently the most 
extensively investigated of the three groups and subsequent discussion of the molecular basis of 
carcinogenesis will centre upon this group.
1.2.1.1 Oncogenes
The cause-effect relationship between oncogene activation and carcinogenesis is supported by 
several lines of evidence including (i) the derivation of oncogenes of acutely transforming 
retroviruses from cellular protooncogenes (transduction) (ii) the induction of malignant 
transformation by transfection (iii) oncogenesis by slow-acting retroviral genomic insertion next 
to a cellular protooncogene (iv) increased expression and amplification of protooncogenes in 
human cancer cells (Slamon, 1987) and (v) involvement of loci for protooncogenes in 
chromosomal breaks and translocations in malignant cells (Slamon et al, 1987).
Oncogenes may arise from different sources : cellular (c) oncogenes are mutated forms of 
normal cellular genes involved in growth control, known as protooncogenes. The transcription 
of cellular oncogenes in the normal cell is tightly controlled and occurs at the appropriate stages
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of cell growth and differentiation and is therefore essential to the proper functioning of the cell. 
Oncogenes may also have viral (v) origins or come from DNA tumour viruses. The mechanism 
of conversion from protooncogene to oncogene is critical to neoplastic transformation but is 
poorly understood. However, it is known that mutations that deregulate the expression or 
activity of enzymes involved in the signal transduction processes of cell growth and 
differentiation or that suppress the expression of negative cell cycle control factors are key 
events in the process of carcinogenesis. Figure 1.2 shows a schematic representation of the 
functional characteristics of oncogenes.
The key classes of oncogenes will now be discussed in greater detail.
Growth factors bind to complexes on the extracellular domain of receptors embedded in lipid 
membranes. Binding of growth factor triggers signal transduction events which serve firstly to 
prepare the cell for growth and differentiation and secondly to direct the metabolic change. The 
first oncogene shown to encode a part of a growth factor was the c-sis oncogene which is 
similar to the (3-chain of platelet-derived growth factor (PDGF) (Doolittle et al, 1983; Waterfield 
et al, 1983). Other growth factor oncogenes of this sort include int-2 and hstl/2 which encode 
forms of the fibroblast growth factor (FGF). Oncogenic growth factors can achieve cell 
transformation by autocrine release of growth factors from tumour cells, alteration of the 
receptor responsible for recognising the growth factor or competition with signalling pathways 
normally activated by growth factor receptors. In addition, tumours may secrete growth- 
inhibitory factors (for example transforming growth factor p, TGFp) which may inhibit the 
activity of immune cells which protect against tumour development (Smith et al, 1993).
The two main families of tyrosine-kinase-containing receptors are (i) those that have no ligand 
binding site, are attached to the inner membrane surface and have a cytoplasmic domain for 
example abl, src, yes, and (ii) those with extracellular ligand binding and transmembrane and 
cytoplasmic domains for example neu,fms, met (Hunter, 1991). Members of each of these
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categories have structurally conserved kinase domains and can undergo autophosphorylation on 
the tyrosine residue (Yarden and Ullrich, 1988). The function of the membrane associated non­
receptor group is unclear although Smith et al (1993) suggested that these receptors may form 
transient signalling systems by association with different classes of ligand-binding trans­
membrane receptors for example, mas. Transformation may occur by increasing this affinity for 
mfl^-type receptors causing deregulation of signalling. The second family of tyrosine kinases 
comprises polypeptides which span the plasma membrane and transmit an intracellular signal 
directly following ligand binding to their extracellular domains. Smith et al (1993) reasoned that 
receptor activation is a consequence of either receptor aggregation or a conformational change in 
the receptor. It follows that a genetic mutation resulting in aggregation, increased tyrosine 
kinase activity or increased ligand binding may enhance the transforming properties of the 
receptor.
A large number of plasma membrane receptors lack intrinsic enzymatic activity and transmit 
extracellular signals to inside the cell via activation of guanine nucleotide-binding proteins (G- 
proteins). Receptor stimulation causes the bound GDP on the G-protein to be exchanged for 
GTP, which results in the G-protein-mediated activation of second messenger systems on the 
cytoplasmic surface of the plasma membrane. The activation is terminated by the intrinsic 
GTPase activity of the G-protein which converts bound GTP to GDP. One of the most studied 
G-proteins is the ras oncogene, point mutations of the Harvey-ras gene having been reported in 
human bladder and urinary tract carcinomas (Tabin et al, 1982) and of the Kirsten-ras gene in 
lung and colon carcinomas (McCoy et al, 1983). Mutations which for example, either reduce 
the intrinsic GTPase activity of ras, increase the exchange rate between GDP and GTP, or 
prevent ras interaction with factors which stimulate GTP hydrolysis, would maintain ras 
proteins in an active state. Those ras protein molecules stabilised in the active form would 
therefore have a prolonged interaction with the intracellular effector system which could lead to 
deregulation of signal transduction.
After transduction from the membrane surface, signalling pathways continue to be regulated by 
phosphorylation. The cytoplasmic serine/threonine kinases, for example mos and raf, are
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soluble cytoplasmic members of this cascade which are thought to become oncogenic due to 
mutations deleting sequences within the gene that code for regulatory domains of the protein 
resulting in an overexpression of kinase activity (Houslay, 1991). Activation of the mil/raf 
protooncogene has been shown to occur through truncation of the 5' coding region (Schultz et 
al, 1988). The action of the cytoplasmic kinases may be to phosphorylate key nuclear 
transcription factors so as to modify either their ability to bind to DNA or to activate gene 
transcription.
The nuclear oncoproteins have been defined as trans-acting factors that bind DNA-regulatory 
elements and stimulate or repress transcription (Eisenman, 1989). Transcriptional changes are 
caused either by the increase in the absolute quantity of a transcription factor or the modulation 
of its activity by post-translational modification (Mitchell and Tijan, 1989). The molecular 
mechanisms by which gene expression is altered and controlled are still unclear, however, it is 
known that phosphorylation directly controls the activity of certain transcription factors (Hunter 
and Karin, 1992). Modulation of transcription factor activity can take place in the absence of 
protein synthesis and has been demonstrated for several transcription factors (Sen and 
Baltimore, 1986, Yamamoto era/, 1988).
The most intensively studied of the nuclear oncogenes is the cellular myc family. The 
expression of the myc family is required to maintain proliferation, indeed Kelly et al, (1983) 
have shown expression to be necessary if not sufficient for full entry into the cell cycle. 
Further, decreased myc transcription is consistent with differentiation (Cole, 1986). Myc 
transactivation is enhanced by phosphorylation at ser and it follows prolonged action of 
upstream cytoplasmic serine/threonine kinases for example ra f and mos may potentiate 
oncogenic activity. The transforming potential of the myc family is activated by many 
mechanisms including gene amplification, insertional mutagenesis and chromosomal 
translocation (Smith et al, 1993). The net result of these rearrangements is deregulated 
expression linked to myc overexpression. This overexpression uncouples expression of myc 
from its normal physiological regulators and thus may deregulate control of exit from the cell 
cycle or terminal differentiation.
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The fOS andjun oncogene families encode nuclear phosphoproteins which are found to be 
associated in several transcriptional complexes (Sassone-Corsi et al, 1988). The fos  oncogene 
is oncogenically activated by insertion of transcriptional enhancers around the gene that 
increases expression and by altering 3'-non-coding regions that control mRNA degradation 
rates (Lee et al, 1988). Gius et al (1990) showed that the phosphorylation of the C-terminal 
domain of Fos trans-represses the expression of the fos  gene.
Jun was first identified by Curran et al (1985) as a Fos-associated cellular protein in Chinese 
Hamster Ovary cells. Jun has subsequently been shown to be a major component of the AP-1 
(Fos-Jun) transcription complex (Curran and Franza, 1988) which regulates the transcription of 
several genes involved in normal growth and induction of neoplasia by tumour promoters. AP- 
1 transcription regulation occurs via binding of the AP-1 protein to the palindromic DNA 
sequence TGACTCA (Risse et al, 1988). Jun protein can induce transcription when activated 
by kinase-specific phosphorylation on ser^J and sef^.  The protein can also be phosphorylated 
at Thr23l, Ser^^J and Ser 249^  the net effect being inhibition of DNA-binding and gene 
expression (Alvarez et al, 1991). Mutation resulting in the inability to phosphorylate Jun at any 
of these sites in the DNA-binding domain may result in constitutive activation of the jun-DNA  
binding domain and overexpression of AP-1 controlled genes.
1.2.1.2 Tumour Suppressor Genes
The tumour suppressor genes regulate cell proliferation and differentiation by suppressing 
growth at control points within the cell cycle and as such, may play an important part in the 
normal regulatory programme induced by growth hormones to negatively control the cycle 
(Sager, 1989). The biochemical functions of tumour suppressor genes remain to be defined but 
it is known that slowing of the cell cycle ensures the fidelity of cell division. Therefore any 
genetic mutation which disrupts the growth promoting/growth inhibiting equilibrium may result 
in a metabolic shift towards transformation. Anti-oncogenes such as Retinoblastoma, the Wilms 
Tumour gene (WT-1) and certain genes involved in colorectal cancer in adults appear to act 
recessively requiring the loss or inactivation of both copies for tumour development.
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Individuals who possess one copy of an anti-oncogene would have an increased propensity to a 
particular cancer. Anti-oncogenes were first exemplified in the 1970's by the model for 
retinoblastoma (Rb) gene action (Knudsen, 1971), where a recessive homozygous genotype 
leads to childhood cancer.
1.3 Non-Genotoxic Carcinogenesis
A considerable number of chemicals which increase the incidence of tumours in the liver give 
no direct evidence for mutagenicity in either prokaryotic (Ashby & Tennant, 1988, Ashby et al, 
1989) or eukaryotic (Williams et al, 1989) tests. The mechanism by which these chemicals 
increase incidence of cancer is the subject of widespread investigation, however, it seems that 
the non-genotoxic carcinogens act by either causing persistent liver damage and/or the sustained 
induction of microsomal or peroxisomal enzymes with hepatomegaly. This broad classification 
will now be discussed.
1.3.1 Tissue-Damaging Agents
The importance of hepatic damage in the development of hepatocellular carcinoma was first 
recognised when patients with cirrhosis of the liver were found to be at greater risk of 
developing hepatocellular carcinoma than those without cirrhosis (McSween and Scott, 1973). 
The best characterised examples of agents whose action results in persistent liver damage and 
sustained restorative cell division are carbon tetrachloride and chloroform (although numerous 
other examples exist). Edwards & Dalton (1942) showed that oral administration of a 
hepatotoxic dose of carbon tetrachloride produced extensive centrilobular necrosis in mice 
within 24 hours of administration. When administered at the same dose 3 times weekly for 8-10 
months, lesions formed in the regenerated parenchyma displayed the property of autonomous 
growth and were called 'hepatomas'. Liver tumours were only observed at dose levels which 
were hepatotoxic and since carbon tetrachloride does not produce genetic damage (Simmon et 
al, 1977), the chronic tissue injury must have played an important role in the neoplastic 
transformation. Equally, chloroform produced liver tumours in mice at dose levels known to 
produce severe hepatocellular necrosis (Reitz et al, 1980). In this latter experiment, no liver
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tumours appeared in animals treated with sub-hepatotoxic doses. Extensive genotoxicity testing 
of chloroform has failed to reveal any direct DNA damage.
1.3.2 Non-Tissue-Damaging Agents
1.3.2.1 Hepatomegaly
Treatment with the non-tissue-damaging non-genotoxic carcinogens produces persistent liver 
enlargement and mitogenesis but no evidence of cell damage (Hess et al, 1965). The early 
stages of hepatomegaly (defined as an increase in liver to body weight ratio) are associated with 
a burst of mitogenesis (as indicated by cells in S-phase) but later stages appear to be more 
associated with cellular hypertrophy (Beckett et al, 1972, Reddy et al, 1979). The hypertrophic 
phase is characterised by anincreased turnover of intracellular constituents for example, of 
peroxisomes, smooth endoplasmic reticulum (ser) or mitochondria and concomitant induction 
of a range of liver enzymes (Hawkins et al, 1987). Both the hyperplastic and hypertrophic 
phases seem to be threshold-related (Grasso and Hinton, 1991).
Hyperplasia is first evident at 24 hours after commencement of administration of a peroxisome 
proliferator, for example 2-diethylhexyl phthalate (DEHP), as measured by an increase in 
[^H]thymidine incorporation into newly synthesised DNA. This mitotic wave of DNA synthesis 
peaks at the third day and, in the case of DEHP, will subsequently revert to normal levels. 
However, the more potent peroxisome proliferators such as Wy-14,643 and methylclofenapate, 
will continue to stimulate cell proliferation for as long as they are administered (Marsman et al, 
1992, Barass et al, 1993). This phase is important in risk assessment of these compounds as 
cell proliferation has been closely linked to carcinogenesis.
Liver growth continues and reaches a steady state within 14 days of treatment and is sustained 
as long as the agent is administered. Rao and Reddy (1987) reported continuation of this steady 
state level for up to 25 months of treatment with ciprofibrate. However, the liver will return to 
the normal state between 2-3 weeks following the withdrawal of the compound (Svoboda and 
Azamoff, 1966).
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The broad functional distinction of non-tissue-damaging non-genotoxic carcinogens, based on 
the subcellular organelle exhibiting the greatest degree of change will be used for further 
analysis of this class of compounds, however, it should be noted that there is some doubt as to 
whether this classification reflects real differences in mechanism of toxicity or, indeed, 
carcinogenicity (Grasso and Hinton, 1991).
Section 1.5 gives a detailed discussion of the first of these categories, the compounds causing 
peroxisome proliferation. The remaining two categories are discussed below.
1.3.2.2 Compounds Inducing Microsomal Oxidases
Proliferation of the smooth endoplasmic reticulum (ser) is normally, perhaps always, associated 
with induction of the various groups of drug metabolising enzymes which are responsible for 
xenobiotic metabolism and excretion, in particular the P450 isoforms. In addition, the vast 
majority of these agents also cause liver enlargement (hepatomegaly) which occurs alongside 
enzyme induction during the first few days of administration of the inducer. The burst of 
mitosis is transient, maximising by day 3 and returning to basal levels by one week of 
administration. Maximum liver size and enzyme activity appear to be attained by 5-6 days of 
treatment in rats and 5-15 days in mice and both effects appear to be dose related, although they 
do not occur in parallel. The time at which the maximum liver size is attained appears to change 
very little and tends to be inversely related to dose (Kunz et al, 1966). In general, the time 
course of the pleiotropy of changes induced by phenobarbitone is similar to that observed with 
peroxisome proliferators (see section 1.5).
Phénobarbital and other compounds such as butylated hydroxytoluene, which cause an increase 
in the CYP2B subfamily also cause an increase in hepatic tumour incidence in male mice when 
administered at high doses. This effect is, however, species specific, phénobarbital alone being 
insufficient for neoplastic transformation in the rat. However, phénobarbital has been shown to 
enhance the development of malignantly transformed clones in in vitro epithelial cell cultures 
from the livers of rats fed the initiator, 2-acetylaminofluorene (2-AAF) (Kitagawa et al, 1980). 
Since this discovery that phénobarbital can act as a tumour promoter, a wide variety of
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xenobiotics which induce phase I drug metabolising enzymes (for example cyproterone acetate 
and chlorinated biphenyls) have been shown to also act as tumour promoters.
1.3.2.3 Compounds Causing Mitochondrial Proliferation
The antihistamine drug methapyrilene and certain close analogues cause marked proliferation of 
mitochondria and liver enlargement in the short term (Reznic and Lijinsky, 1981). In longer 
term studies in rats, a high incidence of hepatocellular carcinoma and cholangiocarcinoma was 
seen (Lijinsky et al, 1980) although this effect was seen to be specific to the rat (the compound 
being non-tumorigenic in hamster, guinea pig or mouse). Whilst methapyrilene is negative in 
most in vivo and in vitro mutagenicity tests (Mirsalis, 1987), there is evidence of binding of the 
compound to cell proteins and suppression of DNA synthesis. (Copple et al, 1992). Indications 
that methapyrilene can bind to DNA in vitro (Lampe and Kammerer, 1987) may cast doubt over 
its classification as non-genotoxic. Steinmetz et al (1988), however, argue that since 
methapyrilene induces S-phase DNA synthesis in hepatocytes, possibly in response to its 
hepatotoxic effects, it may therefore induce chronic cell proliferation resulting in cancer (see 
section 1.7.3).
1.4 The Cytochrome P450 Gene Superfamily.
The cytochrome P450 superfamily comprises a family of atypical b-type haemoproteins with a 
common prosthetic group and mechanism of catalysis which, along with the flavoprotein 
NADPH-cytochrome ^ P450 reductase, constitutes the microsomal mixed function oxidase 
system (MFO) (Guengerich, 1991). The cytochromes P450 (referred to as 'P450's') are 
characterised by the absorption spectra of the ferrous (Fe^+)-carbon monoxide complex which 
has an absorbance peak at 450nm (Klingenberg, 1958). The superfamily displays a diverse 
range of endogenous substrate specificities (including bile acids, steroids, prostaglandins and 
fatty acids) indicating a central role in the oxidative and peroxidative metabolism of endogenous 
molecules. In addition, the MFO also plays a primary role in the Phase I metabolism of 
xenobiotics including drugs & environmental pollutants and therefore serves predominantly to 
detoxify and enhance elimination of xenobiotics from the body (Gonzalez, 1992).
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Extensive research over 30 years since Klingenberg and Garfinkle's original findings and the 
extensive application of new molecular biology techniques has revealed the existence of multiple 
isoforms of P450 with broadly overlapping substrate specificities and differential inducibilities 
of these activities. Classification of the isoforms according to substrate specificity has therefore 
quickly become inappropriate and in 1987 Nebert et al suggested a nomenclature based upon the 
evolution of the enzyme superfamily. Using computer-aided primary amino acid sequence 
alignment data, the degree of amino acid sequence similarity between individual isoforms was 
used to define families and subfamilies of P450 isoenzymes. Families (designated an Arabic 
number) are defined as proteins having greater than a 40% amino acid sequence similarity. In 
mammals, those proteins that are greater than 55% identical are placed in the same subfamily 
(designated a capital letter) and the subfamily members are numbered according to order of 
discovery. According to this classification, by 1993, 36 P450 gene families had been identified 
(12 of which exist in all mammals) and these families comprise 221 genes and 21 pseudogenes 
isolated from 31 eukaryotes and 11 prokaryotes.
For all P450 genes and cDNA's the italicised root symbol 'CKP ' is used, followed by the 
family number, the subfamily letter and then the individual gene number. The mRNA and 
enzyme are denoted in capital letters without italics (Nelson et al, 1993). This nomenclature will 
be used throughout this thesis.
1.4.1 Cytochrome P450-Catalysed Reactions
The cytochrome P450 monooxygenase system's primary role is to introduce a polar hydroxyl 
group into xenobiotic molecules which facilitates subsequent Phase II detoxification of the 
compound by conjugation. The net result is an increase in elimination of xenobiotics from the 
body (Gibson & Skett, 1986). There is, however, the possibility that oxidation of some 
xenobiotics may generate electrophiles which have been implicated in toxicity and neoplastic 
change (Guengerich, 1988).
The oxygenation reactions catalysed by P450 are diverse and include aliphatic and aromatic 
hydroxylations, heteroatom oxygenation, heteroatom release (dealkylation) and epoxidation
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(Gibson & Skett, 1986). Substrate oxidation by cytochromes P450 is achieved by the cleavage 
of molecular oxygen and subsequent incorporation of one of the resulting atoms into the 
substrate molecule and reduction of the other to water :
RH + O2 + NADPH/H+ >ROH + H2 O + NADP+
where RH represents the substrate.
The chemistry of this reaction is thought to be invariant and can be defined as a catalytic cycle 
(Gibson & Tamburini, 1984) and is shown in Figure 1.3. The actual specific activity of a 
particular isoform is, however, dictated by the nature of the substrate and the P450 apoprotein 
structure (Guengerich, 1991).
The active site of cytochromes P450 consists of an iron protoporphyrin IX prosthetic group 
with a cysteine thiol residue from the apoprotein providing the fifth ligand. The sixth ligand is 
either a second amino acid residue or an exchangeable water molecule (Gibson and Skett, 
1986). According to crystal field theory, the haem iron can exist in a hexacoordinated (low 
spin) or pentacoordinated (high spin) state (Gibson and Tamburini, 1984). The two states are 
normally in equilibrium (the hexacoordinated form predominating). Changes in spin state are 
observed on substrate binding.
The first and most studied step illustrated in the cycle is substrate binding which perturbs the 
spin state equilibrium of the cytochrome resulting in an increase in absorbance between 380- 
390nm with a concomitant decrease between 417 and 422nm, known as a type I spectral change 
(Schenkman et al, 1981). This step facilitates the uptake of the first electron as the higher spin 
state produced has a higher, more electropositive mid-redox potential (Sligar et al, 1979). The 
uptake of the first electron is the committed step in the cycle. To initiate the oxidative reaction, 
molecular oxygen is bound to the ferrous P450. The transfer of the second electron from 
NADPH-cytochrome P450 reductase or possibly cytochrome bg as an additional electron donor 
in mammalian systems. The next, relatively poorly understood step involves the splitting of the 
oxygen-oxygen bond with the uptake of two protons and the generation of activated oxygen and
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(RH)Fe+(0^-)
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(RH)Fe^(tf-)
Figure 1.3 The Cytochrome P450 Catalytic Cycle
RH represents the substrate, ROH the hydroxylated product. Fe represents the active site 
haem iron atom.
Numbered steps are described in the text.
Adapted from White and Coon, 1980; Gonzalez, 1992
17
the release of water. This oxygen insertion into the substrate is thought to involve hydrogen ion 
abstraction from the substrate and recombination of the resulting transient hydroxyl and carbon 
radicals to give the product. Dissociation of the hydroxylated substrate then restores the P450 to 
the ferric state.
1.4.2 Mechanisms of Induction & Regulation of the Cytochrome P450 
Superfamily
During evolution of the P450 superfamily, the adaptation of endogenous roles (such as steroid 
hormone and bile acid synthesis) to detoxification of pharmacological agents and environmental 
pollutants became necessary - an adaptation to an increasing diversity of xenobiotic challenge. 
Equally, responsiveness of the enzyme system evolved, detoxification being supplied only 
when necessary, in response to xenobiotics. This regulation of the P450 superfamily is 
apparent at both transcriptional and post-transcriptional levels and exhibits significant variation 
across isoforms.
Arguably, the quantitatively most predominant mechanism of regulation of cytochromes P450 is 
transcriptional gene activation which provides a closely coupled mechanism of enzyme 
induction. Post-transcriptional mechanisms include mRNA and protein stabilisation or 
degradation that may be mediated through phosphorylation states of the enzyme (Goldfarb, 
1990). In addition, Gonzalez (1989) described the tissue-specific pattern of expression of the 
P450 isoforms and resulting differences in isoform compositions and activities in various 
tissues.
All eukaryotic genes are under the control of transcription factors that bind to sequences in their 
5' non-coding regions, which act as promoters, enhancers and suppressors. These transcription 
factors are contained within four families of DNA-binding proteins that are characterised by the 
presence of various sequence motifs including zinc fingers and leucine zippers (Churchill & 
Travers, 1989).
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The best studied cytochrome P450 gene family with respect to regulation is CYPIA which is 
controlled by the transcription activating factor, the Ah receptor (Burbach et al, 1992). The Ah 
receptor is able to bind aromatic hydrocarbons such as tetrachlorobenzodioxin (TCDD), the 
prototypical inducer of CYPlAl and the ligand-receptor complex has been shown to bind to 5'- 
flanking sequences of TCDD-responsive genes.
In addition, a repressor protein has been identified and appears to associate with the Ah receptor
winhibiting binding to its respon^ element (Watson et al, 1992). There are therefore mechanistic 
similarities between the TCDD receptor and the steroid hormone receptor superfamily (see 
section 1.6).
A number of other P450 isozymes are regulated at the transcriptional level. Phénobarbital acts 
as a transcriptional activator (Hardwick et al, 1983) stimulating the transcription of 
phenobarbital-inducible genes. Also, a receptor has been identified whose normal ligand is 
affected by phénobarbital treatment (Waxman and Azamoff, 1992). Phénobarbital has been 
shown to stimulate the binding of a protein to a conserved 17 base pair sequence within the 5' 
regulatory sequences of phenobarbital-inducible genes (He et al, 1991) but resultant 
transcriptional activation has not been shown. The mechanism remains to be clarified.
Specific members of the steroid hormone receptor superfamily may therefore be responsible for 
mediation of P450 regulation. This hypothesis is certainly consistent with xenobiotic- 
metabolising P450's evolving from ancestral steroid hormone-metabolising forms.
1.4.3 The Cytochrome P4504A  Subfamily.
The CYP4A gene family encodes a group of enzymes which catalyse the hydroxylation of the 
terminal (co-) carbon, and to a lesser extent, the co-1 position of saturated and unsaturated fatty 
acids (Bjorkhem and Hamberg, 1971). co-hydroxylation is an important step in metabolism of 
saturated fatty acids, prostaglandins, leukotrienes and other eicosanoids (Ellin et al, 1972;
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Powell, 1984). Initially, Cû-hydroxylation was only thought to be important during ketotic states 
such as diabetes and starvation (Wada et al, 1971) when the activity of the co-hydroxylase was 
seen to be increased in rat livers. However, subsequent investigations have shown co- 
hydroxylation to be important in the activation and inactivation of eicosanoids, thus playing an 
important role in the cellular homeostasis of these compounds (McGiff, 1991). The 
hydroxylated fatty acid products are further oxidised to dicarboxylated acids by alcohol and 
aldehyde dehydrogenase, chain-shortened by peroxisomal p-oxidation and excreted as C6-C10 
dicarboxylic acids.
To date, 22 members of the CYP4A family have been identified in five mammalian species, 
which fall into 6 subfamilies (A-F) (Nelson et al, 1993). The CYP4A genes are constitutively 
expressed in liver, kidney, intestine, colon, heart, lung and brain (Hardwick, 1991). (see Table 
1.4).
The cDNA for the first (and subsequently most widely studied) member of the CYP4A family 
CYP4A1, was cloned and characterised by its ability to co-hydroxylate lauric acid (Hardwick et 
al, 1987; Earnshaw et al, 1988). Kimura et al (1989a,b) sequenced the genomic clone of 
CYP4A1 and two closely related members of the subfamily, CYP4A2 and CYP4A3. These 
three isozymes are coordinately regulated at the messenger RNA level by oxyisobutyrate 
hypolipidaemic drugs (Gibson et al, 1982; Sharma et al, 1988a), phthalate ester plasticizers 
(Sharma et al, 1988b) and chlorinated phenoxy acid herbicides (Bacher and Gibson, 1988) 
amongst other structurally diverse compounds. CYP4A1 is also inducible by high fat diets 
(Capdevila er a/, 1992).
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Table 1.4. The CYP4 Gene Family
G ene/P rotein Trivial Name Species Tissue Expression
CYP4A1 LAco, P452, IVAl Rat liver, kidney
CYP4A2 IVA2, k-5, k-2 Rat liver, kidney
CYP4A3 IVA3, DM-2 Rat liver, kidney
CYP4A4 p-2, LPGco Rabbit liver, kidney, lung.
uterus, placenta
CYP4A5 KDB3, kd Rabbit kidney, liver, small
intestine
CYP4A6 ka-1, KDA6, LPGA(o_ % Rabbit kidney, liver
CYP4A7 ka-2, R4, KDB18, Rabbit kidney, liver, small
LPG(o-2 intestine
CYP4A8 PPl, KPl Rat prostate, kidney
CYP4A9 HL14 Aeon Human liver
Cyp4al0 A 14, clone 1 Mouse liver, kidney
CYP4A11 HK(o Human
Cyp4al2 clone 2 Mouse
CYP4A13 Guinea Pig
CYP4B1 Lung P450, p-2-like, L-2 Human lung
HLCFl Rabbit lung and liver
Form 5 Rat lung and liver
CYP4C1 Cockroach fat body
CYP4D1 4D1 Fruit Fly
CYP4E1 Fruit Fly
CYP4F1 A3 Rat hepatic tumours
CYP4F2 4F2 Human
CYP4F3 LTBco Human
Adapted from Nelson et al (1993). Lower case letters in the gene name indicates the mouse gene. 
'PG' : prostaglandin
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1.5 Peroxisome Proliferation
Induction of CYP4A1 isozymes by the compounds described in section 1.4.3 is invariably
accompanied by proliferation of the subcellular organelle, the peroxisome, in susceptible
the majority of
species (Cohen & Grasso, 1981; Gibson et al, 1982). E q u a lly ,x en o b io tic s  or treatments 
investigated thus far which cause peroxisome proliferation are also inducers of CYP4A1. These 
structurally highly diverse compounds have recently been reviewed by the European Chemical 
Industry Ecology and Toxicology Centre (ECETOC, 1992), Bentley et al (1993) and Ashby et 
al (1994). Figure 1.5 illustrates the structural diversity of the peroxisome proliferators.
1.5.1 Peroxisomes
Peroxisomes were originally described by Rouiller & Bernhard in 1956 as single membrane- 
bound cytoplasmic organelles (approximately 0.2-0.6|xm in diameter) with a finely granular 
matrix. An electron-dense crystalloid core containing urate oxidase and other hydrogen 
peroxide-producing enzymes including acyl CoA oxidase and D-amino oxidase led De Duve to 
name this organelle, the peroxisome (De Duve & Baudhuin, 1966). Human peroxisomes are, 
however, smaller than rodent peroxisomes and appear to lack the crystalloid core. Fahimi et al 
(1993) proposed that peroxisomal enzymes are synthesized on free ribosomes, enter pre­
existing peroxisomes and new peroxisomes are produced by budding from the pre-existing 
organelles. Peroxisomes are distributed throughout almost all eukaryotic cells (Mannaerts and 
Van Veldhoven, 1993), but show particular abundance in those cells involved in lipid 
metabolism (Gorgas, 1987). In animals they are most abundant in the liver and kidney, 
accounting for 2.5% of total liver protein (Leighton et al, 1968) and approximately 1.5% of the 
parenchymal cell volume (Weibel et al, 1969).
Biochemically, peroxisomes have been shown to contain a variety of enzymes (dependent upon 
tissue and species) which participate in peroxidative and oxidative reactions, in particular the 13- 
oxidation of fatty acids and the synthesis of ether glycerolipids, cholesterol and dolichols. 
Peroxisomal (3-oxidation enzymes differ from their mitochondrial counterparts with respect to 
catalytic and molecular properties. For example, peroxisomal p-oxidation enzymes are
2 2
Cl
CH.
I ^
O—C—COOH 
I
CH.
CH CH S —CHo— COOH
Clofibric Acid Wy -14,643
CH.
CHo
COOCH2-  CH(CH2)3CH3 
COOCH^— CH(CH2 ) 3 CH3
c n ^
I
CH.
Cp3(CF2)gC00H
CF3(CF2)6C00H
DEHP [Di-(2-ethylhexyl)phthalate] PFDA (perfluoro-n-decanoic acid) 
PFOA (perfluoro-n-octanoic acid)
CH2CH2CH3
CH3 CH2 CH2 CH COOH 0
COOH
OCOCH.
Valproic acid Acetyl salicylic acid
Figure 1.5 Structures of Peroxisome Proliferators
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potassium cyanide-(KCN) insenstive in vitro and do not require carnitine unlike the carnitine- 
dependent KCN-sensitive mitochondrial system (Lazarow, 1982).
1.5.2 Peroxisomal p-Oxidation
Prior to entry into the peroxisomal p-oxidation spiral, fatty acids are activated to their CoA 
derivatives by two long chain fatty acyl CoA synthetases (one more active towards long chain 
fatty acids, and one more active towards very long chain (C>20) fatty acids) located in the 
smooth endoplasmic reticulum (Singh and Poules, 1988). Entry of the fatty acyl CoA into the 
peroxisome, unlike the mitochondrion, is not dependent upon carnitine acyl-CoA transferases, 
and may occur by diffusion through the peroxisomal membrane or via a specific transport 
mechanism, although the mechanism has yet to be defined (Mannaerts et al, 1979).
The peroxisomal P-oxidation sequence is shown in Figure 1.6. The first rate-limiting oxidation 
step is catalysed by an FAD-containing acyl CoA oxidase generating FADH2  which is 
subsequently reoxidised by molecular oxygen to hydrogen peroxide. The hydrogen peroxide 
produced is then decomposed by catalase. The second (hydration) and third (dehydrogenation) 
steps are catalysed by a trifunctional enzyme (Osumi and Hashimoto, 1979). In addition, this 
latter enzyme displays enoyl CoA isomerase activity required for the oxidation of unsaturated 
fatty acids (Palosaari and Hiltunen, 1990). The dehydrogenase component of this enzyme 
reduces NAD+ which diffuses out of the peroxisome thereby maintaining the NADH/NAD+ 
ratio. The final step of the p-oxidation pathway is catalysed by 3-ketoacyl-CoA thiolase and 
carnitine acyl transferase then transports the chain-shortened fatty acids out of the peroxisome 
(Markwell et al, 1976).
Peroxisomes and mitochondria systematically break down saturated and unsaturated fatty acids 
via similar reactions in which the same acyl-CoA intermediates are formed. However, unlike 
mitochondrial P-oxidation, the peroxisomal equivalent is not coupled to an electron transport 
chain (Lazarow and de Duve, 1976) so that the energy that is released in the first step via 
hydrogen peroxide production, is lost as heat. This loss of energy (the peroxisome being only 
half as efficient as the mitochondrion in energy conservation) has led to speculation that the
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peroxisome may play a role in thermogenesis (Kramar et al, 1978). However, the two systems 
may function coordinately, long chain fatty acids which are poorly oxidised by mitochondria 
being good substrates for the peroxisomal system (Fahimi and Sies, 1987). In support of this, 
it is known that children suffering from Zellweger’s syndrome (characterised by lack of 
peroxisomes) or adrenoleukodystrophy (characterised by defective transport of enzymes into 
the peroxisomes), show a marked accumulation of long chain fatty acids in adrenals and the 
nervous system (Singh et al, 1981).
High fat diets (resulting in lipid overload) and administration of peroxisome proliferator 
xenobiotics result in an increase in peroxisomal number and volume and an induction of the 
enzymes of the peroxisomal p-oxidation spiral. The proliferated peroxisomes are heterogenous 
containing fibrillar striations, cavitations and double-walled tubules, some being devoid of a 
crystalloid core (Schulte-Hermann, 1979). The rate-limiting enzyme in the p-oxidation spiral, 
acyl CoA oxidase is induced up to 30-fold (Lazarow and DeDuve, 1976) resulting in a 
substantial increase in the capacity of the pathway. In addition the trifunctional enzyme is 
induced 30-50 fold (Lalwani et al, 1981). Short chain acetyl CoA transferase, responsible for 
removal of acetyl CoA from the peroxisome is also inducible (20-160 fold) in parallel with 
peroxisome proliferation (Reddy and Lalwani, 1984). In contrast to the induction of these 
enzymes, catalase is very slightly induced (2-fold at most) (Moody and Reddy, 1976) and urate 
oxidase not at all (Lock et al, 1989).
Peroxisome proliferation has been shown to be a species and tissue-specific phenomenon. It is 
well established that rats and mice are highly responsive to peroxisome proliferators (Hawkins 
et al, 1987). Hamsters are responsive to a lesser extent (Reddy et al, 1982) and guinea pigs, 
dogs and primates are relatively insensitive (Reddy and Lalwani, 1984).
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1.5.3 Mechanisms of Peroxisomal Enzyme Induction
The underlying mechanism responsible for the pleiotropic effects of peroxisome proliferators 
remains to be clearly defined. Classically, two mechanisms have been proposed although the 
two mechanisms need not be mutually exclusive.
1.5.3.1 Substrate Overload Theory
Capdevila et al (1992) showed that high fat diets in rodents can induce both peroxisome 
proliferation and induction of CYP4A. These findings indicate that the liver responds adaptively 
to increased metabolic load initiating a coordinated induction of fatty acid metabolising enzymes 
(Kozuka et al, 1991). This and other evidence has led to the substrate-overload mechanism of 
peroxisome proliferation.
The earliest observable change upon administration of a peroxisome proliferator is an 
accumulation of small lipid droplets similar to those found in hyperphagia, which are possibly 
associated with alterations in fatty acid metabolism (Mitchell et al, 1986). Two alternate 
mechanisms may result in the accumulation of lipid, although the structural diversity of the 
peroxisome proliferators implies that these compounds may act at many different loci to perturb 
lipid metabolism.
The first mechanism indicates that lipid accumulation is due to inhibition of medium chain fatty 
acid oxidation by inhibition of acyl CoA transferase in the mitochondrion (Lock et al, 1989, 
Elcombe and Mitchell, 1986). This mechanism is supported by the action of valproic acid 
(Becker and Harris, 1983) and 2-ethylhexanol (Badr et al, 1990) which is a metabolite of the 
peroxisome proliferator, DEHP.
The second mechanism proposed to explain lipid accumulation is sequestration of essential 
coenzyme A by the peroxisome proliferator itself (Bronfman et al, 1989). One -  feature 
of the majority, but not all of the known peroxisome proliferators is that they contain either a 
carboxyl function or a group which can be metabolised to a carboxyl function. Bronfman et al 
(1986) amongst others, demonstrated that many xenobiotic carboxylates are metabolised to the
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coenzyme A thioester, but p-oxidation of these thioesters is inhibited by steric hinderance. 
Indeed, Mitchell et al (1985) found that CoA concentrations in isolated hepatocytes decreased 
significantly upon addition of mono(2-ethylhexyl)phthalate (MEHP). The resulting 
accumulation of fatty acids may then result in (i) adaptive induction of peroxisome proliferation 
and (ii) CYP4A1 induction. Lock et al (1989) showed that CYP4A1 is inducible by medium 
chain fatty acids in isolated hepatocytes.
Sharma et al (1988a, b) suggested that CYP4A1, induced directly by peroxisome proliferators 
or via lipid accumulation would result in increased levels of co-hydroxylated fatty acids and 
dicarboxylic acids (by the action of cytosolic alcohol and aldehyde dehydrogenases). These 
dicarboxylic acids would then be taken up by the peroxisome and preferentially metabolised by 
peroxisomal p-oxidation enzymes (induced in response to the increased metabolic load).
It is important to consider the chronology of these events. Milton et al (1990) proposed that the 
induction of CYP4A1 occurs prior to the induction of peroxisomal p-oxidation enzymes such as 
acyl CoA oxidase. More particularly, the CYP4A1 induction was seen to be biphasic, an initial 
increase in CYP4A1 mRNA levels at 30 minutes returning to control levels at 2 hours and then 
a more prolonged increase in this induction between 18 and 24 hours. The peroxisomal enzyme 
acyl CoA oxidase was induced monophasically at 24 hours. The transcription of CYP4A1 
mRNA was shown by in vivo treatment with cycloheximide to be independent of protein 
synthesis. However, cycloheximide did inhibit the transcription of acyl CoA oxidase mRNA 
(Gibson 1992, Bieii et al, 1991). This suggests the requirement of protein (perhaps CYP4A1?) 
synthesis for induction of acyl CoA oxidase.
This finding is supported by the work of Ortiz de Montellano et al (1992) who showed that fatty
acids and dicarboxylic acids only weakly induce CYP4A1 and peroxisomal p-oxidation. There
are two possible explanations for this latter observation, namely (i) availability of fatty acids and
dicarboxylic acids at the site of action due to rapid metabolism, and (ii) the relationship between
CYP4A1 and peroxisomal p-oxidation is casual - the apparently coordinated response being due
to structurally similar regulatory elements in the 5' flanking sequence of these genes (Cannon &
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Eacho, 1991). This second mechanism may explain the common effect of structurally highly 
dissimilar compounds - acting by influencing a common perturbation of lipid metabolism.
1.5.3.2 Receptor-Mediated Theory
Discovery of a saturable pool of nafenopin binding sites in rat liver cytosol led Lalwani et al 
(1983) to propose that the extensive modulation of hepatocyte characteristics seen in 
peroxisome proliferation could be due to activation of specific genes through a receptor- 
mediated mechanism. Subsequent observations which supported this initial postulate include (i) 
the rapidity and magnitude of inducibility of the peroxisomal p-oxidation genes (Reddy et al, 
1986) and their coordinate transcriptional activation, (ii) the species and tissue-specific nature of 
the response (Reddy et al, 1984, Rao et al, 1986) - transplanted hepatocytes remain responsive, 
(iii) the inducibility of peroxisome proliferation in isolated hepatocytes (Gray et al, 1982). Also, 
molecular modelling studies showed a good correlation between the potencies of chemicals 
inducing peroxisomal P-oxidation in cultured hepatocytes and the electronic structural 
parameters of chemicals derived from molecular orbital calculations (Lewis et al, 1987) further 
suggesting that a receptor might exist that could bind to these structures.
The validity of Lalwani's binding protein as a receptor which mediates the effects of 
peroxisome proliferators was questioned by Milton et al (1988). This group attempted to link 
the relatively common carboxylic acid function of peroxisome proliferators (or a group that can 
be metabolised to a carboxylic acid function (Kozuka et al, 1991)) to the amino function of 
affinity column sepharose beads. This work failed to identify any specific binding of nafenopin 
or ciprofibrate to rat hepatic microsomal or cytosolic fractions. Milton et al (1988) suggested 
that the binding protein identified by Lalwani et al was serum albumin (molecular weight 68kd 
compared to Lalwani's estimate of 70kd).
Subsequent work by Alvares et al (1990) identified the purified protein as homologous with the 
heat shock protein 'HSP70' family which are known to play a role in the regulation of steroid 
hormone receptor-mediated responses.
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1.6 The Peroxisome Proliferator-Activated Receptor
1.6.1 The Nuclear Steroid Hormone Receptor Superfamily
The nuclear steroid hormone receptor superfamily is a group of over 30 structurally similar 
DNA binding proteins which serve to regulate the transcription of specific target genes when 
bound to responsive elements in the 5' regulatory region of the gene (O'Malley 1991, 
Gronemeyer 1992). Members of this family include receptors for estrogen (ER), vitamin D3 
(VDR) and thyroid hormone (TR) and share a similar mechanism of action, shown in Figure 
1.7.
There is significant evidence that heat shock proteins associate with steroid hormone receptors, 
dissociation occurring on ligand binding to the receptor. This dissociation then allows formation 
of receptor homodimers or heterodimers with other members of the steroid hormone receptor 
superfamily. Subsequent translocation of the receptor complex to the nucleus and binding to 
DNA causes alterations in transcription of specific target genes. In support of this, HSP90 has 
been shown to be associated with the glucocorticoid receptor (Danielson, 1991) and with the Ah 
receptor (Denis et al, 1988). HSP70 is known to modulate protein folding (Rothman 1989) and 
may therefore be responsible for conformational changes in the receptor during the activation 
process, but its exact role remains to be clarified (Landers and Spelsberg, 1992).
Leucine zipper regions at the N-terminal region of each protein allow dimer formation, whilst 
zinc finger motifs allow DNA binding. The steroid hormone receptor also contains a C-terminus 
adjacent to the major groove of the DNA helix which allows target recognition, and a nuclear 
location signal (NLS) which acts as a transcriptional activating factor (TAF) (Gronemeyer, 
1992).
The conservation of these domains across members of the receptor family allows construction 
of chimaeric receptors - a technique exploited by Issemann and Green (1990) which led to the 
discovery of the Peroxisome Proliferator Activated Receptor.
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1.6.2 The Peroxisome Proliferator Activated Receptor
Issemann and Green (1990) reported the cloning and characterisation of a novel member of the 
steroid hormone receptor superfamily which was shown to be activated in transient transfection 
assays by peroxisome proliferators. Interestingly, the rank order of receptor activation for the 
series of compounds tested by Issemann and Green correlated well with carcinogenic potencies 
and the ability to cause activation of cytochromes P450 and other drug metabolising enzymes. 
Further, distribution data showed a marked correlation of PPAR tissue localisation with tissue 
responsiveness to peroxisome proliferators. However, the study failed to demonstrate any DNA 
or peroxisome proliferator binding properties for the intact PPAR.
Subsequent to this work, a sub-family of the PPAR has been shown to exist and members have 
been identified in rat (97% homology) (Gottlicher et al, 1992), 3 forms in Xenopus laevis (77, 
55 and 50% homology) (Dreyer et al, 1992) and human (85% homology) (Sher et al, 1993). In 
addition, Gebel et al (1992) reported the immunodetection of a PPAR in rat liver cytosols. A 
PPAR-like receptor isolated from a human osteoblastoma cell line termed Nuc-1 has also been 
isolated and found to have 64% homology to the Issemann and Green’s PPAR (Schmidt et al, 
1992). This may indicate the presence of another family of related PPAR's.
1.6.3 Nuclear Steroid Hormone Receptor Response Elements
The nuclear steroid hormone receptors control transcription of specific target genes by binding 
to specific DNA sequences in the 5’ regulatory region of these target genes. These binding sites 
have been shown to consist of imperfect tandem repeats of palindromic sequences (Carlberg et 
al, 1993). In 1991, Osumi et al identified the responsive element for the PPAR (the PPRE) in 
the 5' flanking region of the acyl CoA oxidase gene. This was shown to consist of an imperfect 
repeat sequence.
5'(-573bp)CG TGACCT TTGTCCT GG (-555bp)3'
Rat acyl CoA oxidase PPRE
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PPRE's have also been identified in the rat 3-ketoacyl CoA-thiolase (Kliewer et al, 1992), rat 
enoyl CoA hydratase/3-hydroxyacyl CoA dehydrogenase (Zhang et al, 1992), fatty acid binding 
protein (Issemann et al, 1992) and in the rabbit CYP 4A6 (Muerhoff et al, 1992).
The direct repeat of a hexanucleotide sequence separated by a single nucleotide (DRl) seen in 
the PPRE is also characteristic of other nuclear steroid hormone receptor response elements. 
Umesono et al (1989) examined the direct repeat spacing of the heterodimers of RXR with 
VDR, TR and RAR and found them to be 3, 4 and 5 respectively. The homodimers of these 
receptors will bind alternative spaced elements, for example RXR (DRl) and VDR (DR6) 
(Green, 1993). Therefore, although these receptors can all recognise the same half-site motif, 
they discriminate between target elements through the arrangement and spacing of their motifs.
In summary, the evidence seems to indicate a clear role for the PPAR in the regulation of the 
peroxisome proliferative response. Despite the apparent conflict between the substrate overload 
and receptor-mediated theories, the two theories need not be mutually exclusive. Long chain 
polyunsaturated fatty acids have been shown to activate the PPAR although no direct binding 
has been shown (Gottlicher et al, 1992, Keller et al, 1993). The activation of the PPAR may 
therefore be dependent upon a product of CYP4A1 metabolism - implying a role for both 
mechanisms in xenobiotic-induced peroxisome proliferation.
Figure 1.8 shows a possible unifying mechanism for xenobiotic-induced peroxisome 
proliferation.
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Figure 1.8. Possible unifying mechanism for peroxisome proliferation 
(Taken from ECETOC, 1992)
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1.7 Peroxisome Proliferator-Induced Hepatocarcinogenicity
1.7.1 Oxidative Stress Hypothesis
Reddy et al (1980) proposed that peroxisome proliferation could lead to an imbalance between 
hydrogen peroxide production and degradation i.e. between oxidase and catalase activity. 
Oxidases such as fatty acyl CoA oxidase are markedly induced (20-30 fold) compared to the 
relatively low induction of the hydrogen peroxide scavenger, catalase (Moody and Reddy, 
1976). The resulting over-production of hydrogen peroxide within the cell and increased 
formation of oxygen radicals could be responsible for oxidative DNA damage. Gibson (1989) 
proposed that the ratio of induced enzymes (CYP4A and peroxisomal p-oxidation enzymes) to 
detoxification enzymes (catalase and GPX) may be a good indicator of species susceptibility to 
hepatocarcinogenesis. This 'imbalance' model has gained support from a number of 
independent observations. In vitro, hydrogen peroxide has been shown to react with DNA 
producing 8-hydroxydeoxyguanosine adducts which may cause DNA polymerase to produce 
erroneous incorportation of nucleotides into the replicating strand (Kuchino et al, 1987). Tagaki 
et al (1990) showed a less than 2-fold increase in levels of 8-hydroxydeoxyguanosine in rats 
treated with DEHP and DEHA for 1-2 weeks. This may result in tumour initiation, however, at 
present too little is known about variations in endogenous 8-hydroxydeoxyguanosine levels to 
assess the biological significance of this effect. In addition, peroxisomes from rats induced with 
Wy-14,643 have been shown to cause single strand breaks in isolated DNA (Fahl et al, 1983).
Studies with fenofibrate and di(2-ethylhexyl)phthalate show histologically enlarged lysosomes 
containing lipofuscin which accumulateyprogressively in the liver (Mitchell et al, 1985). 
Lipofuscin results from the polymerisation of oxidised lipid with protein within the lysosome 
thus giving some evidence that intracellular peroxidative activity is taking place. This finding 
may add support to Reddy's hypothesis of excess hydrogen peroxide formation being 
implicated in tumour formation.
However, despite the evidence to support this theory, one of the most potent peroxisome 
proliferators, W y-14,643 administered to rats at 0.1% (w/w) in the diet failed to initiate
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hepatocarcinogenesis in a growth selection (partial hepatectomy and carbon tetrachloride) 
protocol (Cattley et al, 1989a).
1.7.2 Promotion of Spontaneous Lesions Hypothesis
Schulte-Hermann et al (1981, 1983) suggested that selective promotion of spontaneously 
initiated cells may explain the production of tumours following long term exposure of rats to 
non-genotoxic compounds. The theory was supported by evidence that nafenopin will stimulate 
DNA synthesis preferentially in spontaneous and diethylnitrosamine-induced enzyme-altered 
foci and will also stimulate tumour formation in old rats much more rapidly than in young rats 
(Kraupp-Grasl et al, 1990). However, Cattley (1989b) reported that the effect of the 
peroxisome proliferator Wy 14,643 on developing foci of altered cells during promotion is 
histologically different from that of the tumour promoter, phenobarbitone suggesting that 
peroxisome proliferator promotion may involve a different mechanism than classical 
phenobarbitone-type tumour promotion. It should be noted that Siglin et a l{\99 \)  showed that 
chronic exposure to phenobarbitone promotes hepatic tumour formation in the female B6C3F1 
mouse, but inhibits tumorigenesis in the male mouse. This differential effect was shown to 
correlate with the ability of the compound to stimulate DNA synthesis in preneoplastic foci in 
each sex. Siglin's group postulated that the initiating carcinogen treatment used may result in 
different populations of cells in different genders - perhaps giving rise to different populations 
of foci possessing different susceptibilities to tumour promotion.
Tumour promoters, for example, phenobarbitone have been shown to inhibit programmed cell 
death (apoptosis), cessation of treatment resulting in an increase in the number of apoptotic 
bodies in the cell. Peroxisome proliferators have also been shown to inhibit apoptosis (Bursch 
et al, 1984). Therefore the promotion of spontaneous lesions by non-genotoxic carcinogens 
may be due to a combination of clonal expansion of selected preneoplastic cells, a 
mitoinhibitory effect on surrounding normal cells and inhibition of programmed cell death in the 
foci.
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1.7.3 Sustained Tissue Growth Hypothesis
As described in section 1.3.2.1, all non-genotoxic carcinogens produce a hepatomegaly 
associated with an initial cellular hyperplasia followed by cellular and organ hypertrophy. This 
liver enlargement is associated with an induction of S-phase DNA synthesis and mitotic activity. 
DNA synthesis can be reproduced in primary hepatocyte cultures and thus, can be seen to be a 
direct property of the compound (Butterworth et al, 1984).
In general terms, the amount of irreparable DNA damage is a function of the level of cell 
division as rapid cell division may 'fix' DNA damaging events by not allowing enough time for 
efficient DNA repair. Equally, mutation is more likely to occur in dividing cells than in 
quiescent cells because single-stranded DNA is, by nature of its structure, more sensitive to 
damage than double stranded DNA. Cell division also allows mitotic recombination for 
example, non-disjunction, gene conversion and any gene duplication occurring during rapid cell 
division may cause erroneous expression of protooncogenes (Ames and Gold, 1990). 
Therefore, any agent which causes increased mitogenesis may be indirectly mutagenic (and 
consequently carcinogenic) because it increases the probability of converting any endogenous 
DNA damage into mutations. Cell proliferation would also result in the multiplication of the 
cells carrying the mutation ('clonal expansion') and thereby promote the preneoplastic lesion. It 
is reasonable to infer that this proliferation may also be involved in the progression of 
preneoplastic lesions to the neoplastic state but to date very little is known about this stage 
(Columbano et al, 1991).
Epidemiological evidence suggests that increased cell proliferation is implicated in the genesis of 
many human cancers (Preston-Martin et al, 1991). The incidence of hepatocarcinogenicity after 
chronic administration of peroxisome proliferators to rodents appears to correlate better with 
mitogenicity than with increased peroxisomal number/volume, induction of peroxisomal 13- 
oxidation enzymes or hydrogen peroxide production. W y-14,643 and clofibric acid 
administered at doses known to produce the same level of peroxisome proliferation, produced 
100% and 25% incidence of hepatocellular carcinoma respectively (Marsman et al, 1992). 
Measurement of tritiated thymidine incorporation in the same study showed an 80-fold increase
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above control with Wy-14,643 after one week, and remained elevated 10-20 fold for 22 weeks. 
The initial mitotic burst in response to clofibrate reached approximately 10-fold above control 
levels after one week but then returned to basal levels. This evidence strongly suggests a key 
role for sustained cell proliferation in the genesis of hepatocellular carcinoma.
The mechanism by which this proliferation occurs is unclear. However, it seems reasonable to 
assume that the mechanism must involve those genes involved in cell growth, the 
protooncogenes. Thompson et al (1986) have shown that liver regeneration after partial 
hepatectomy is controlled by the ordered sequential expression of hepatic cellular 
protooncogenes. Transcription of c-fos, c-myc and p53 was shown to increase sequentially 
during the prereplicative phase which precedes DNA synthesis. Bentley et al (1987) also 
showed that upon nafenopin administration for seven days, induction of c-fos and c-myc 
nuclear protooncogenes occurred within a few hours of treatment and continued at their induced 
levels until cessation of treatment. Protooncogene induction in response to peroxisome 
proliferators was further investigated by Cherkaoui-Malki eta l (1990) who showed a marked 
induction of both c-myc and Ha-ras in clofibrate-treated rats at 2 and 52 weeks exposure. These 
results indicate that the mechanisms which control peroxisome-proliferator-induced cell growth 
may, at least in part, be the same as those which control normal regenerative cell division.
1.8 Assessment of Human Risk
It is often possible to identify threshold levels below which genotoxic carcinogens are inactive 
in tumour formation and from such values, regulations can be made governing safe exposure 
limits. It is generally believed that any marked peroxisome proliferation is predictive of 
carcinogenic potential in rodents. However, as discussed, the phenomenon of peroxisome 
proliferation is sex and species specific.
A number of studies have been conducted on patients who have been treated with 
hypolipidaemic drugs to examine the relevance of this effect to humans and thereby aid risk 
assessment. The only report of substantial increases in peroxisomal number was in a report by 
Hanefield et al (1983) who found that after 3-4 months of hypolipidaemic therapy patients
38
showed a 50% increase in peroxisomal number and a 23% increase in peroxisome volume 
density. The results of this study however, were not statistically significant. A multitude of 
other attempts to clinically evaluate the effect of prolonged exposure of hypolipidaemic drugs 
have revealed no significant indication of peroxisome proliferation (Gariot et al, 1983, De La 
Iglesia et al, 1982, Oliver et al, 1978).
On the basis of the limited number of human studies performed, it has been argued by some 
researchers that the risk posed by peroxisome proliferators to humans is negligible (ECETOC 
1992, Bentley et al, 1993, Ashby et al, 1994). However, until peroxisome proliferation has 
been seen as necessary for progression to carcinogenesis, this argument seems less convincing. 
Therefore, in order to more effectively assess the human risk presented by the peroxisome 
proliferators, and indeed, the non-genotoxic carcinogens as a whole, we need a far greater 
understanding of the relationship between microsomal oxidase induction, peroxisome 
proliferation, cell proliferation and carcinogenesis.
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1.9 Objectives of the Present Investigation.
To date, there is no available prescreen for new compounds for non-genotoxic carcinogenic 
potential. In order to investigate the feasibility of such a prescreen, a clear understanding of the 
molecular mechanisms of non-genotoxic carcinogenesis is essential.
The project described in this thesis was therefore designed to further elucidate this mechanism. 
In this light, the following aims were defined:
1. Examination of the role of protooncogenes at early time points of non-genotoxic 
carcinogenesis, in order to provide additional mechanistic insight.
2. Investigation of these effects in susceptible and non-susceptible tissues and species.
3. Examination of the role of the Peroxisome Proliferator Activated Receptor in the early 
stages of peroxisome proliferator-induced hepatocarcinogenesis
The research was conducted with the aim of expanding our current knowledge of the nature and 
specificity of early markers of non-genotoxic carcinogenesis in relation to the eventual 
appearance of tumours. Ultimately the information gleaned from this work would aid the 
assessment of the non-genotoxic potential of novel compounds.
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CHAPTER 2 
MATERIALS & METHODS
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2.1 MATERIALS.
2.1.1 Chemicals
All chemicals purchased were of the highest purity available.
Amersham International Pic., Little Chalfont, U.K. : Rapid Hybridisation buffer, 
Hybond N nylon membrane.
BDH Chemicals Ltd., Dagenham, U.K. : Ammonium acetate, bromophenol blue, 
isoamylalcohol, isopropanol, lauric acid, lithium chloride, methylene blue, potassium cyanide, 
sodium acetate, sodium carbonate, sodium chloride, sodium dithionite, sodium hydrogen 
carbonate, Triton X-100.
Biorad, Richmond, U.S.A.: Mixed bed ion exchange resin.
Boehringer Mannheim, Lewes, U.K. : Agarose, IPTG, Poly A & C, Tris HCl, X-gal. 
Difco Laboratories, U.S.A. : Bacto-Agar.
Fisons Scientific, Loughborough, U.K. : ch lo ro fo rm , d ie th y le th e r ,
dimethylsulphoxide, dipotassium hydrogen phosphate, ethanol, formaldehyde, formamide, 
glacial acetic acid, hydrochloric acid, hydrogen peroxide, glycerol, glycine, methanol, 
'Optiphase', potassium dihydrogen orthophosphate, sodium acetate, sodium hydroxide, 
sucrose, toluene.
Gibco BRL, Paisley, Scotland : All mammalian cell culture media, A,HindIII DNA.
Oxoid Ltd., Basingstoke, U.K. : Bacto-tryptone and yeast extract.
Pharmacia, Uppsala, Sweden : Dextran T70, Ficoll, Nick Columns.
Sigma Chemicals Company Ltd., Poole, U K : Activated charcoal, ampicillin, bovine 
serum albumin (BSA) fraction V, calcium chloride, 4-chloronaphthol, coenzyme A (CoA), 
dextran sulphate, diaminobenzidine (DAB), diethylpyrocarbonate (DEPC), dithiothreitol (DTT), 
EDTA, ethidium bromide, flavin adenine dinucleotide (FAD), guanidinium isothiocyanate, 
magnesium chloride, 2-mercaptoethanol, MOPS, nicotinamide, nicotinamide adenine 
dinucleotide phosphate (NADP+/NADPH), nicotinamide adenine dinucleotide (NAD+/NADH), 
ONPG, palmitoyl CoA, phosphate buffered saline, polyvinylpyrolidine, salmon sperm DNA, 
sodium bicarbonate, spermidine trihydrochloride, TE-saturated phenol, xylene cyanole.
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2.1.2 Test Compounds
Clofibric acid was supplied by Sigma Chemicals and the sodium salt prepared by titration of 
clofibric acid with an equimolar amount of sodium hydroxide and subsequent drying of the salt 
using a freeze dryer (Freezemobile 6 , Virtis Co., New York). Phenobarbitone sodium was 
supplied by BDH Chemicals. 9-cis retinoic acid and Wy-14,643 were kindly provided by 
Dr. Art Levin, Hoffmann La Roche, USA and Dr. Brian Lake, BIBRA, Carshalton 
respectively. Dexam ethasone was supplied by Sigma Chemicals, Dorset, U.K. 
Perfiuorodecanoic & perfiuorooctanoic acids (recrystallised, 99.5% pure) were kindly 
provided by Captain B. Jamot, US Air Force, Ohio, USA.
The sources for other materials and kits are given in the text.
2.1.3 Radiochemicals
i) Deoxycytidine 5'[a-32p]-triphosphate, triethylammonium salt. Specific activity 
SOOOmCi/mmol : ICN Flow, High Wycombe, U.K.
ii) [l-l4c]-lauric acid. Specific activity 52.8mCi/mmol : ICN Flow, High Wycombe, U.K.
2.1.4 Antibodies
The primary antibody to rat CYP4A1 was raised in sheep as previously described (Sharma, 
1988a). Prof R. Wolf (University of Dundee) kindly provided primary antibody to CYP2B1.
2.1.5 cDNA Probes and Plasmid Vectors
The 2.1kb CYP4A1 cDNA isolated as described earlier (Eamshaw et al, 1988) was kindly 
donated by Dr S. Hood (University of Surrey). The l.Skh CYP2B cDNA was provided by 
Dr. M. Milton (University of Surrey).The PPAR cDNA in plasmid pSG5, pBluscript 
plasmid, pCHllO plasmid, and the PPRE-containing acyl CoA oxidase sequence
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(pACO(-1273/-471)G.CAT) were all kindly donated by Dr Stephen Green, Zeneca. Prof. 
Pierre Chambon, (Institut de Chimie Biologique, Strasbourg) and Prof. Alan Paine (St. 
Bartholomews Hospital, London) kindly provided the RXR and c-jun cDNA's respectively.
All other oncogene cDNA & genomic DNA probes and vectors were kindly provided by the 
Human Genome Mapping Project DNA Probe Bank (HGMP). A complete listing of all cDNA 
probes supplied by HGMP is given in Appendix I.
2.1.6 Bacterial Strains
The genotype of the Escherichia coli bacterial cells used in this work is described in Table 2.1. 
Table 2.1 : E.Coli bacterial strain, genotype and use (see section 2.6.1)
Bacterial Strain Genotype U se
JM1090
(Promega)
recAl,endAl, gyrA96, thi-, hsdRlT (r^- 
,mk+), supE44, relAl, X-, D(lac-proAB), 
[F'traD36, pro AB, lacK ZDM15]
Host strain for transformation 
with vector DNA sequences.
2.1.7 Mammalian Cell Lines
H4IIEC3 rat Reuber Hepatoma epithelial cells (ATCC designation CRL 1600) were kindly 
supplied by Alison Wolfreys (Biochemical Toxicology, Unilever Research, Colworth, U.K).
2.1.8 Restriction Endonucleases
Restriction enzymes used were supplied by Gibco BRL and are listed in Table 2.2.
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Table 2.2 Restriction enzymes used in the preparation of cDNA probes for 
analysis of RNA (see Section 2.7.1). The symbol (^) indicates the site at which the enzymes 
cuts the DNA.
Restriction Enzyme Restriction Site
Acc 1 GT^MKAC
Bam HI G'^GATCC
ECo R1 G'^AATTC
Hind n i A^AGCTT
NCo 1 C^CATGG
Pst 1 CTGCA^G
Sac 1 GAGCT^C
Sal 1 G^TCGAC
Sma 1 CCC^GGG
Xho 1 C^TCGAG
Note : M represents A or C, K represents G or T
2.2 Animal Studies : Husbandry & Treatment Procedures
Male Wistar albino rats (University of Surrey strain) weighed 200-250g at the commencement 
of treatment. Rats were assigned to treatment groups using a randomised procedure based on 
body weight. Animals were housed in polypropylene cages with sawdust bedding (RS Services 
Ltd.) and were allowed free access to unlimited tap water and chow (CRM Diet, Special Diet 
Services, Cambridge). Male Dunkin-Hartley albino guinea pigs (Porcellus Animal Breeding 
Ltd., Heathfield, U.K) weighed 350-400g at the commencement of treatment and were housed 
in wire cages with hay bedding. Guinea pigs were allowed free access to unlimited water and 
chow (FAD 1 guinea pig diet. Special Diet Services, Cambridge.).
The study of the effects of the DEN/PB initiation/promotion protocol was performed at the 
Environmental Safety Laboratory, Unilever Research. For this study only, male Charles River 
albino Wistar rats initially weighing 145-155g were housed in polypropylene cages with 
stainless steel mesh floor and lid. Animals were allowed free access to tap water and chow
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(ESL modified AIN-76 A diet). All animals were subjected to a 12 hour light/dark cycle at an 
ambient temperature of 22°C and 55% humidity and were acclimatised for a minimum of 3 days 
prior to commencement of treatment.
Dosing regimes for specific studies are detailed in the appropriate results chapters.
2.3 Animal Autopsy & Sample Preparation.
2.3.1 Homogenate & Microsomal Fraction Preparation
Animals were weighed and killed at the appropriate time points by cervical dislocation. Tissues 
were removed carefully and weighed. After excision, whole tissue samples were snap frozen 
immediately in liquid nitrogen for RNA extraction. Sections of tissue were also fixed in neutral 
phosphate-buffered formalin (10% (v/v) formalin, pH 7.0) for histological analysis (see section 
2.3.2). The weights of the remaining tissues were then recorded and tissues placed in ice cold 
saline solution (0.9%, w/v). Livers were perfused with ice cold saline solution (0.9%, w/v) in 
order to minimise contaminating haemoglobin, and the kidneys decapsulated. Tissues were then 
blotted dry and scissor-minced in 0.25M sucrose such that the tissue constituted the following 
percentages (w/v) of the final solution : liver 25%, kidney 15%, heart 10%, lung 10%. The 
samples were then homogenised using a motor-driven Potter-Elvejhem glass-teflon 
homogeniser (3 return strokes) to produce whole tissue homogenates. Aliquots (1ml) of whole 
homogenate were taken for peroxisomal enzyme determinations and stored at -80°C until use.
Subsequent preparation of microsomal fractions was performed by a modification of the method 
of Omura & Sato (1965). The homogenates were centrifuged at 13,800g for 30 minutes at 4°C, 
the supernatants decanted and recentrifuged at 102,000gfor 1 hour at 4°C. The resulting 
microsomal pellets were resuspended in ice cold 50mM potassium phosphate buffer pH 7.25, 
2 0 % (v/v) glycerol using a motor-driven Potter-Elvejhem glass-teflon homogeniser. 
Resuspension volumes were dependent upon the mass of tissue : liver 5ml, kidney 4ml. Heart 
and lung samples were pooled ( 6  animals per group) and resuspended in 3 ml and 6 ml 
potassium phosphate buffer (prepared as before) respectively. All microsomal samples were 
stored as 0.5ml aliquots in 1.5ml Eppendorf tubes at "80°C until use.
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2.3.2 Tissue Processing for Immunocytochemistry
Tissues for histological analysis were fixed in 10% (v/v) neutral buffered formalin (4% (v/v) 
formaldehyde, 4.5g/l NaH2 ? 0 4 .2 H2 0 , 6.5g/l Na2 HP0 4 ) for one week. A piece of tissue (2- 
3mm in thickness) was cut from each sample and placed in a Tissue-Tek processing cassette 
(R.A.Lamb, London). Cassettes were then processed using a Histokinette automatic tissue 
processor (British American Optical Co. Ltd, Slough). Tissues were transferred automatically 
between dehydration, clearing and wax impregnation as follows ( 2  hour incubation per step):
1. Dehydration : 70, 85, 95, 100, 100, 100% (v/v) alcohol.
2. Clearing : toluene, twice
3. Wax Impregnation: paraffin wax, 58°C, twice
Tissues were transferred to a third wax bath from which the tissue was blocked out into metal- 
based moulds (R.A.Lamb, London). 5mm sections were cut from the blocks using an 
American Optical Spencer 280 Rotary Microtome and mounted on glass microscope slides. 
Finally, slides were dried on a drying hotplate and stored in an incubator at 37°C until further 
processing.
2.4 Methods Relating to Protein Analysis
2.4.1 Determination of Microsomal Protein Concentration
Microsomal protein was determined using a BioRad™ dye-binding assay method (Bradford, 
1976), using bovine serum albumin as standard. The assay was performed according to the 
reagent manufacturer’s guidelines (Biorad, 1989). In summary, the dye reagent (Coomassie 
Brilliant Blue G-250, phosphoric acid, methanol) was prepared by five-fold dilution of the dye 
reagent concentrate in distilled water and filtration through Whatman No. 1 filter paper prior to 
use. Diluted dye solution (5ml) was added to 0.1ml of bovine serum albumin protein standards 
(20-140|ig protein) and to suitable dilutions of samples. After vortexing and incubation at room 
temperature for a minimum of 5 minutes, tubes were assayed spectrophotometrically at 595nm 
against a reagent blank. All tubes were prepared in duplicate and a correlation coefficient of 
>0.995 for the standard curve was regarded as acceptable for interpolation of sample protein 
concentrations. Sample protein concentrations were expressed as the average of two readings in 
mg protein/ml sample.
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2.4.2 Total CO-Discernible Cytochrome P450 Assay.
Total cytochrome P450 was determined as the carbon monoxide-Fe^+ complex by the method 
of Omura & Sato (1965).
Microsomes prepared as described were diluted 1:20 with 50mM potassium phosphate buffer 
pH 7.25 containing 20% (v/v) glycerol, to give approximately 0.5-1.0mg protein per ml. The 
haemoprotein was reduced to the Fe^+ form by the addition of a few grains of sodium 
dithionite and the sample split between two plastic cuvettes. A baseline was recorded between 
400-500nm on a Kontron 860 dual beam spectrophotometer. The sample cuvette was bubbled 
with carbon monoxide (1 bubble per second for 40 seconds) and the 400-500nm spectrum 
measured. The total cytochrome P450 content was calculated using the difference extinction 
coefficient (450-490nm) of 91mM-^cm-l, and specific content expressed as nmoles cytochrome 
P450 per mg protein.
2.4.3 Lauric Acid Hydroxylase Assay
The hydroxylation of lauric acid in the 11 (co-l) and 12 (to) positions was measured by HPLC 
using the method of Orton and Parker (1982).
The assay system consisted of lOOmM [l^cj-lauric acid and O.lmCi [l^C]-lauric acid (specific 
activity 50mCi/mmol) in 50mM Tris HCl, pH 7.4 and microsomes (Img of protein) in a final 
volume of 1.96ml. The reaction mixture was preincubated for 5-10 minutes at 37°C and the 
reaction started by addition of 40pl of 40mM NADPH. After 10 minutes, the reaction was 
terminated by acidification with 200|xl 3M HCl. The incubations were extracted using 10ml 
diethylether with rotary mixing for over 10 minutes. The tubes were centrifuged at lOOOg for 5 
minutes to separate the two phases and the upper organic phase removed to a clean test tube. 
The extract was evaporated to dryness under nitrogen and stored at -20°C prior to analysis by 
HPLC.
The dried extracts were reconstituted in 150pl of methanol: water:glacial acetic acid (55:45:0.05 
by volume) and lOOpl injected onto a reverse phase (C l8 ) microbondapak MCH-10 column 
(30cm X 0.4cm, Varian Associates Ltd., Walton-on-Thames, U.K). The metabolites were 
eluted using a linear gradient of methanol:water:glacial acetic acid (55:45:0.05 by volume) to
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100% (v/v) methanol over 15 minutes at a flow rate of 1 ml/minute and detected by a Berthold 
LB503 on line radiodetector interfaced to automated data capture software.
The rates of hydroxylation were calculated from the fractional conversion of lauric acid to the 
1 1 - and 1 2 -hydroxy products.
2.4.4 Pentoxyresorufin O-Depentylase Assay
Pentoxyresorufin-O-depentylase activity was determined by the method of Burke et al (1985) 
with reference to a resorufin standard. To monitor the 0-depentylation of pentoxyresorufin 
substrate by the CYP2B family, the reaction rate was measured directly by the increasing 
fluorescence of the reaction mixture as displayed on a chart recorder. Fluorescence is entirely 
due to the cytochrome P450-dependent formation of resorufln.
O.IM Tris-HCl pH 7.8 was prewarmed to 37°C and a 2ml aliquot placed in a 4ml fluorimeter 
cuvette. Rat liver/kidney microsomes (50pl) or guinea pig liver/kidney microsomes (25pl) or 
lOOjxl heart/lung microsomes (providing Img protein per sample) were added to the buffer with 
5|il of pentoxyresorufin substrate (285.7|ig/ml DMSO) and the solution mixed by inversion of 
the cuvette. A baseline was then recorded for 1 minute. The reaction was started by addition of 
lOfxl 50mM NADPH in 1% (w/v) NaHCOg. Reactions were followed at 37°C using a Perkin- 
Elmer Model 3000 spectrofluorimeter using an excitation wavelength of 510nm and emission 
wavelength of 586nm. The increase in fluorescence of the sample was recorded for a minimum 
of 2 minutes or until no further increase was seen. Calibration of the fluorimeter was carried out 
by addition of a lOpl aliquot of resorufin (0.2mg/ml in 100% (v/v) ethanol) to 2ml Tris buffer 
and noting the resultant chart recorder deflection.
The O-depentylase activity of microsomes was calculated using the following equation:
nmoles resorufln produced/min/g tissue =
nmoles standard x scale (standard) x AAsample x dilution
AA standard scale (sample)
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2.4.5 KCN-Insensitive Palmitoyl CoA p-oxidation Assay.
Cyanide-insensitive palmitoyl CoA oxidation of whole cell homogenates was carried out 
according to Bronfman et al (1979). The oxidation of palmitoyl CoA results in the reduction of 
FAD and NAD+. In mitochondria, these are reoxidised by the electron transport chain, the 
terminal cytochrome of which can be blocked by cyanide. In peroxisomes, FADH is reoxidised 
by molecular oxygen but the NADH accumulates. The assay of NADH production in the 
presence of cyanide therefore serves as a measure of the peroxisomal p-oxidation system as the 
fatty acyl CoA oxidase is the first and rate-limiting step in the spiral.
A coenzyme reaction mixture containing CoA (75|iM), FAD (180|iM), NAD+ (555|iM), 
nicotinamide (141mM), DTT (4.2mM), KCN (3mM) and BSA (225pg/ml) in 60mM Tris-HCl 
buffer pH8.3 was freshly prepared and stored on ice. A 40|xl aliquot of tissue homogenate 
(approximately 1 mg protein) was solubilised with an equal volume of 60mM Tris-HCl buffer 
(pH8.3) containing 1% (w/v) Triton X-100 at 37°C for 2 minutes. 2 ml reaction mixture and 
0.9ml Tris buffer was added to the solubilised homogenate and the solution incubated for 5 
minutes at 37°C. The sample was then divided equally between sample and reference cuvettes 
and the reaction initiated by addition of a 20|il aliquot of palmitoyl CoA (75pM). The change in 
absorbance at 340nm was recorded at 37°C using a Kontron dual beam spectrophotometer. 
Results were expressed as nmol NADH produced/min/mg protein using a molar extinction 
coefficient of 6220M"^cm’l for NADH at 340nm.
For extrahepatic tissues, 200pl homogenate (3-lOOmg protein) was solubilised with 200|il of 
600mM Tris-HCl pH 8.3 containing 1% (v/v) Triton X-100. After 5 minutes solubilisation at 
37°C, the homogenate was microfuged briefly at 10,000g and the supernatant removed for 
assay as above.
2.4.6 SDS Polyacrylamide Gel Electrophoresis of Microsomal Proteins
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate 
solubilised microsomal proteins according to size. Electrophoresis (Laemmli, 1971) and 
transfer of the electrophoresed proteins onto nitrocellulose sheets (Burnette, 1981) were carried 
out using a Phast™ System (Phast System™ Users Manual, Pharmacia, Uppsala, Sweden).
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The PhasfTM unit allows microprocessor control of both separation and development processes 
according to preprogrammed methods.
Liver microsomes from each group were pooled on an equiprotein basis and diluted to O.lpg/pl 
in sample solubilisation buffer (62.5mM Tris-HCl pH 6 . 8  containing 2.3%(w/v) sodium 
dodecyl sulphate, 5% (v/v) 2-mercaptoethanol and 0.001% (w/v) bromophenol blue). The 
proteins and molecular weight markers (Amersham) were then denatured by boiling for three 
minutes in a boiling water bath. Table 2.3 shows the proteins used as size standards and 
corresponding sizes.
Ipg solubilised microsomal protein per sample was drawn into a Phast Gel™ sample applicator 
comb by capillary action and loaded by lowering onto preprepared, 0 .4 5 mm thick 
polyacrylamide gels bonded to a polyester backing. Proteins were electrophoresed through a 
13mm porous stacking gel and then into a 32mm acrylamide gel (12.5% (v/v) acrylamide, 
0.112M acetate, 0.112M Tris HCl pH 6.4) and run at 20mA constant current for approximately 
20 minutes. Buffer strips consisting of 0.2M tricine, 0.2M Tris-HCl, 0.55% SDS pH 8.1, in 
2 % (w/v) agarose) resting on either end of the gel served to transfer voltage and current to the 
gel from the anode/cathode. Prestained molecular weight markers (Amersham) were used as 
standards to determine size of the proteins of interest.
Table 2.3 Molecular weight markers
Protein Molecular Weight (kD)
Myosin 2 0 0 0 0 0
Phosphorylase B 97400
Bovine Serum Albumin 69000
Ovalbumin 46000
Carbonic anhydrase 30000
Trypsin inhibitor 21500
Lysozyme 14300
After this time, the proteins were electrophoretically transferred from the gel to nitrocellulose 
using a Phast Transfer™ system by applying a current of 25mA for 15 minutes. 3M Whatman
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paper soaked in transfer buffer (25mM Tris HCl, 192mM glycine, 20% methanol pH 8.3) was 
placed on one side of the gel to transfer current through the gel from cathode to anode. After 
transfer, filters were stored at 4°C in transfer buffer prior to immunodetection.
2.4.7 Coomassie Blue Staining & Western Blotting
Immunodetection of target proteins on the nitrocellulose sheet was performed according to 
Burnette (1981). After electrophoretic transfer, the nitrocellulose sheet was immersed in 
phosphate-buffered saline containing 1% (w/v) BSA and 0.2% (v/v) Triton X-100 (PBSBT) 
for 2 hours at room temperature with constant swirling. The filter was then incubated in fresh 
PBSBT containing primary antibody at appropriate dilution (see Results chapters) for one hour 
at room temperature. After subsequent washing of the filter 3 times for 5 minutes in PB ST 
(omitting the BSA), secondary antibody labelled with horseradish peroxidase was added at the 
appropriate dilution in PBSBT and incubated for 90 minutes at room temperature. Finally, after 
three 5 minute washes in PBS, the immunochemical stain was developed by adding substrate 
(0.5mg/ml diaminobenzidine in O.IM Tris-HCl pH 7.5). Immediately prior to addition, 
hydrogen peroxide (30 vols) was added to the substrate to give a final dilution of 1:5000. 
Development of the stain was stopped at the appropriate intensity by thorough washing in 
distilled water. After air-drying the filter, relative intensities of the bands were measured by 
scanning densitometry.
Coomassie Blue staining (Neuhoff et al, 1985) was used to stain electrophoresed proteins in 
acrylamide gels. This procedure was carried out according to the protocol outlined in the Phast 
System™ Users Manual (Pharmacia, Uppsala, Sweden).
2.4.8 Immunocytochemistry
Immunocytochemistry was performed using a Vectastain Elite ABC kit (Vector Laboratories, 
Peterborough, U.K). Tissue sections prepared as described (see section 2.3.2) were 
deparaffinised and hydrated through a graded alcohol series (xylene, 1 0 0 % (v/v) ethanol, 96% 
(v/v) ethanol). Slides were then rinsed for 5 minutes in distilled water prior to incubation for 30
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minutes in 0.3% (v/v) hydrogen peroxide in methanol to quench endogenous peroxidase 
activity. Slides were then washed in 1 x PBS (phosphate buffered saline) for 20 minutes. 
Blocking of the sections was performed by incubation of the sections for 20 minutes with 
diluted normal serum from the host species of the secondary antibody. Excess serum was then 
blotted from the sections and subsequently incubated with primary antiserum at appropriate 
dilution in 1 x PBS overnight at 4°C. Primary antiserum was washed from the slides for 10 
minutes using wash buffer (1 x PBS, 2.5% (w/v) NaCl, 0.5% (v/v) Triton X-100) and 
replaced by biotinylated secondary antibody at appropriate dilution in PBS for 30 minutes. 
Again, the antibody was removed by washing in wash buffer (as above). The sections were 
then incubated for 30 minutes at room temperature with Vectastain ABC™ reagent. After a 
further wash step (as above), slides were incubated in diaminobenzidine substrate solution 
(0.5mg/ml DAB (Sigma) in O.IM Tris-HCl pH 7.5, 1:5000 H2 O2  (30vols) added immediately 
before use) for 2-7 minutes until sufficient intensity of staining was seen. At this point 
visualisation was stopped by washing in copious amounts of tap water.
Tissue sections were counterstained by incubation in Haematoxylin solution Gill #3 (Sigma) for 
one minute followed by rinsing for 15 seconds in tap water. Slides were then destained for 15 
seconds in acid alcohol (absolute ethanol containing a few drops of concentrated HCl) and 
rinsed in tap water for a further 15 seconds. Incubation in saturated lithium carbonate for 15 
seconds was followed by rinsing in tap water (as above). Tissue sections were then dehydrated 
using a graded alcohol series (96% (v/v) ethanol, 100% (v/v) ethanol, xylene, 20 seconds twice 
in each). Processed sections were mounted using DPX mountant in 80% (v/v) xylene (BDH) 
removing air bubbles from the sections. After drying in a fume hood for 1 hour, slides were 
examined using light microscopy (detailed in Chapter 5).
2.5 Ribonucleic Acid Procedures
For all nucleic acid procedures described in sections 2.5-2.9, solutions, glassware and 
plasticware were sterilised for 20 minutes at 120°C in a Rodwell series 32 automatic autoclave 
in order to destroy contaminating bacteria and nucleases. Unless otherwise stated, solutions 
were sterilised by the addition of 0.1% (v/v) diethylpyrocarbonate (DEPC) approximately 20
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minutes prior to autoclaving. Solutions containing SDS were prepared by autoclaving the 
solution prepared without the SDS, followed by addition of an appropriate volume of a 20% 
(w/v) SDS stock solution prepared in sterile distilled water.
2.5.1 Total RNA Extraction from Whole Tissues
For Study I (see Chapter 3), total RNA was isolated from frozen tissue by a lithium chloride 
precipitation, phenol/chloroform extraction adapted from Cathala eta l (1983). In subsequent 
studies (see Chapters 4, 5 and 7) this method was replaced by an RNazol B method 
(Biogenesis). The method uses a guanidinium isothiocyanate RNase inhibition and 
phenol/chloroform extraction according to Chirgwin et al (1979). Relative advantages and 
disadvantages of the two methods are given in section 4.6.
2.5.1.1 Lithium Chloride/Guanidinium Isothiocyanate Extraction
Snap frozen tissue was finely ground in liquid nitrogen in a precooled pestel & mortar and the 
powder transferred to a 50ml polyproylene tube on ice. To 1 g of tissue, 8 ml lysis buffer ( 5M 
guanidinium isothiocyanate, 50mM Tris-HCl pH 8.0) and 0.5ml 2-mercaptoethanol was added 
immediately and the suspension homogenised using a Polytron (Kinematica GmbH, 
Switzerland) for 20-30 seconds, avoiding generating excess heat or foam. The homogenates 
were then transferred to 250ml centrifuge buckets and following addition of 60ml, 4M lithium 
chloride and mixing, samples were incubated at 4°C overnight. Suspensions were then spun at 
ll,000g for 90 minutes at 4°C. The supernatant was then discarded and the pellet rinsed by 
resuspension in 30ml, 3M lithium chloride. Samples were then respun for 60 minutes as above. 
The supernatant was again discarded and the pellet resuspended by incubation with 15ml 
solubilisation buffer (0.1% (w/v) SDS, ImM EDTA, lOmM Tris-HCl pH 7.5) for 45 minutes 
at room temperature, vortexing every 1 0  minutes.
The solution was then decanted into 15 ml polypropylene tubes and 5ml TE-saturated phenol 
(see Appendix I) added and the tubes mixed immediately. The resulting emulsion was then spun 
at 12,900g for 20 minutes at 4°C. The colourless aqueous top layer was removed from the 
lower phenol layer avoiding the white protein precipitate on the interface and then phenol
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extraction of the aqueous layer repeated as above until no further white protein interface could 
be seen. Subsequent extractions using phenol : chloroform : isoamylalcohol (25:24:1 by 
volume) and then chlorofom : isoamylalcohol (24:1 by volume) was carried out to remove 
residual phenol.
RNA was precipitated from the final aqueous solution using 1/10th volume 3M sodium acetate 
and 2 volumes ice cold 100% (v/v) ethanol at "20°C overnight. The precipitated RNA was 
pelleted by centrifugation at 16,000g for 30 minutes at 4°C and then washed with 70% (v/v) 
ethanol. RNA pellets were then dried in a Univap centrifugal evaporator (Uniscience Ltd.) for 
20 minutes at 43°C. The pellets were then resuspended in an appropriate volume of DEPC- 
treated distilled water and stored at '80°C until use.
2.5.1.2 RNAzol B Extraction
The RNAzol B isolation procedure (Biogenesis, Bournemouth, U.K.) is based upon the 
method of Chirgwin et al (1979) and was carried out according to the manufacturer's 
recommended protocol.
lOOmg snap frozen tissue was finely ground in liquid nitrogen in a precooled pestel and mortar. 
The ground tissue was transferred to a precooled 15ml polypropylene tube and 2ml RNAzol B 
solution added. The suspension was then homogenised using a Polytron (Kinematica GmbH, 
Switzerland) avoiding generation of excess heat and foam. After addition of 0.2ml chloroform, 
the samples were shaken vigourously for 15 seconds and incubated on ice for 5 minutes. After 
subsequent centrifugation at 12,000g for 15 minutes at 4°C, the colourless upper aqueous layer 
was removed from the lower blue phenol/chloroform phase and placed in a clean 15ml 
polypropylene tube. An equal volume of isopropanol was added to the aqueous phase and the 
samples stored for 15 minutes at 4°C.
The samples were then recentrifuged at 12,000g for 15 minutes at 4°C and the RNA precipitate 
formed a yellow-white pellet at the bottom of the tube. The supernatant was removed and the 
pellet washed once in 8 ml 75% (v/v) ethanol by vortexing and centrifugation at 7,500g for 8  
minutes. The pellet was dried in a Univap centrifugal evaporator (Uniscience Ltd.) for 20 
minutes at 43°C and then resuspended in a suitable volume of TEN buffer (O.IM NaCl, lOmM
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Tris.HCl (pH 8.0) ImM EDTA (pH 8.0)). Incubation at 65°C for 10-15 minutes assisted 
resuspension. RNA samples were stored at "80°C until use.
2.5.2 Assessment of RNA Concentration
For assessment of RNA concentration in solution, RNA aliquots were diluted 1:500 in DEPC- 
treated distilled water in 0.5ml quartz cuvettes. The samples were scanned between 200 and 
320nm using a Kontron-Uvikon 860 dual beam spectrophotometer. Nucleic acids and protein 
have absorbance maxima at 260 and 280nm respectively. An absorbance ratio (A26o/A280nm) of 
1.9-2.0 was indicative of pure RNA. The concentration of RNA was determined using the A2 6 O 
value, as 1 absorbance unit at this wavelength corresponds to an RNA concentration of 40pg/ml 
(SambrookgraZ, 1989).
2.5.3 Assessment of RNA Integrity by Gel Electrophoresis.
Integrity was further confirmed by 1% (w/v) agarose gel electrophoretic separation of RNA 
species using a deionised formamide/formaldehyde denaturing system by an adaptation of the 
method of Lehrach et al (1977). Formaldehyde denaturing gels (final volume 50ml) were 
prepared by heating 0.5g agarose in 25ml sterile distilled water and addition of 6.3ml 37% (v/v) 
deionised formaldehyde (pH<4) and 3.5ml 10 x running buffer (4M MOPS pH 7.0, O.IM 
sodium acetate, lOmM EDTA pH 8.0). The set gel was transferred to an electrophoresis tank 
containing 1 x running buffer (as above). RNA samples were prepared as 20pg RNA, 2|xl 10 x 
running buffer, lOpl deionised formamide, 3.5|xl deionised formaldehyde, 2pl ethidium 
bromide (0.5|Xg/ml) and 3pl loading buffer (4% (w/v) bromophenol blue, 4% (w/v) xylene 
cyanole, lOmM EDTA pH 8.0, 50% (v/v) glycerol). The samples were incubated at 65°C for 15 
minutes prior to loading. The gel was run at 100mA constant current until the indicator dye had 
run approximately 3/4 the length of the gel.
Three clear bands corresponding to 28S, 18S and 5S ribosomal RNA species visualised under 
UV illumination were evidence of intact RNA samples.
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2.5.4 Slot Blotting
Slot blotting was carried out routinely by the method of White and Bancroft (1982). Total RNA 
samples were diluted in sterile distilled water to give a stock solution of 0.2mg/ml. This was 
serially diluted to give 20, 10, 5, 2.5, 1.25, 0.625pg RNA/lOOpl water. 300pl denaturing mix 
(6.15M deionised formaldehyde : 20 x SSC (3M sodium chloride, 0.3M sodium citrate pH 8.0) 
1:1 mixture) was added to each dilution. Yeast tRNA (0.2mg/ml) used as a negative control was 
prepared in the same way and all samples were incubated at 65°C for 15 minutes prior to 
application to nylon membrane.
The slot blotting manifold (Millipore Corporation, U.K) was assembled according to 
manufacturer's instructions using Hybond N™ nylon membrane (Amersham International, 
U.K) and 3M Whatman filter paper soaked in 10 x SSC (as above). The denatured RNA 
samples were applied to the wells and vacuum applied to 'puli' the samples onto the membrane. 
Wells were then washed using 400|Li1 aliquots of 10 x SSC. The filter was then removed from 
the apparatus, air-dried for 15 minutes and finally the RNA was crosslinked onto the filter by 
UV irradiation of the filter (RNA side down) at 300nm for 3 minutes. The filters were then 
stored wrapped in Saran wrap at 4°C until use.
2.5.5 Northern Blotting
Northern blots were performed using 1% (w/v) agarose gel electrophoresis of RNA samples 
with a formaldehyde/formamide denaturing system as described above. For Northern blotting, 
however, ethidium bromide was omitted from the sample preparation (see section 4.5). The gel 
constituent volumes quoted above were scaled up or down depending upon the size of gel 
required. The RNA was then transferred from the gel to a nylon membrane using a modification 
of the method described by Alwine et al (1977).
The gel was rinsed in distilled water for 5 minutes to remove residual formaldehyde and the 
Northern blotting apparatus set up as follows. A glass plate was placed on top of 4 large rubber 
bungs in a glass tray containing 20 xSSC (transfer buffer). A sheet of Whatman paper soaked 
in 20 X SSC placed over the glass plate served as a wick for the transfer buffer. The gel was 
placed on the Whatman paper and surrounded by plastic sheets to avoid 'short-circuiting' of the
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gel. The gel was then covered with nylon membrane, three sheets of Whatman paper and a 
stack of paper towels. Finally, a 1kg weight was placed on the stack of tissues. Transfer of 
RNA species to the nylon membrane was allowed for 36 hours. After this time, filters were UV 
crosslinked for 3 minutes at 300nm to fix the RNA species onto the membrane and then stored 
in a sealed plastic bag containing sterile 5 x SSC at 4°C.
2.5.6 Methylene Blue Visualisation of RNA
After blotting and fixing of RNA onto filters, the blots were immersed and agitated in methylene 
blue stain (0.03% (w/v) methylene blue in 0.3M sodium acetate pH 5.2) for one minute. The 
blot was then washed in distilled water for 1 - 2  minutes to reduce background staining and 
visualise the RNA. Photography of the blots was performed under ordinary light (see section 
2.6.4) and, where necessary, migration of RNA transcripts marked with a permanent pen. 
Quantitative evaluation of the blots was performed at this stage by scanning densitometry. The 
stain was then removed by washing for 3-10 minutes in 1% (w/v) sodium dodecyl sulphate 
(SDS)/lxSSPE (0.18M NaCl, lOmM NaH2 P0 4  ^ ImM Na2 .EDTA pH7.7). The blot was then 
prehybridised or stored at 4°C wrapped in Saran Wrap until use.
2.6 Preparation of cDNA Probes.
2.6.1 Preparation of Competent Cells
25ml Luria Bertaini (LB) Medium (lOg/1 Bacto-tryptone, 5g/l Bacto-yeast extract, 5g/l NaCl, 
pH 7.5) was inj^oculated with a single colony of the appropriate strain of E. Coli to be made 
competent (JM1090) and incubated at 30°C overnight with vigorous shaking. 5ml of the 
iiyfoculum was then added to 500ml of the above culture medium in a 3 litre conical flask. The 
culture was then shaken at 30°C until the absorbance at 600nm had reached 0.45-0.55 units. 
After chilling on ice for 2 hours, the cells were then centrifuged at 2,500g for 15-20 minutes at 
4°C. The supernatant was removed and the pellet resuspended in 10-20ml trituration buffer 
(lOOmM CaCl2 , 70mM MgCl2 , 40mM sodium acetate pH 5.5) and finally diluted to 500ml 
with trituration buffer. After a further incubation on ice for 45 minutes, the cells were 
recentrifuged at 1800g for 10 minutes at 4°C and the supernatant removed. The pellet was then 
resuspended in 50ml ice cold trituration buffer and sufficient 80% (v/v) glycerol added
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dropwise with swirling to give a final concentration of 15% (v/v) glycerol. The cells were then 
aliquoted into 1.5ml Eppendorf tubes and stored at '80°C until required.
2.6.2 Transformation of Host Bacteria with Recombinant Plasmids
For each transformation, a 200pl aliquot of competent cells was defrosted on ice and 3|il 
DMSO added. The suspensions were mixed briefly and 10-20ng plasmid DNA added prior to 
incubation on ice for 30 minutes. Cells were then heat-shocked by incubation at 42°C for 90 
seconds in order to increase transformation efficiency. The tubes were cooled on ice for one 
minute and the cells then allowed to recover by addition of 2ml LB medium and incubation at 
30°C for a minimum of one hour, with gentle shaking.
2.6.3 Selection of Transformed Cells
(i) Blue/White Colour Screening
Transformed JM1090 cells were plated out onto LB plates (15g agar added to 1 litre LB
medium, pH7.5) containing 50|Xg/ml ampicillin, 0.5mM IPTG and 40mg/ml X-gal. The plates
were then incubated overnight at 37°C. The following day, recombinant clones (white colonies)
could be clearly distinguished from non-recombinant clones (blue colonies).
The white colonies were selected for fiirther processing.
(ii) Ampicillin Selection
For plasmids which did not contain the p-galactosidase gene, ampicillin selection was used to 
identify transformants. Transformed cells were plated onto LB plates containing 50pg/ml 
ampicillin and incubated overnight at 37°C. The ampicillin-selected colonies were then screened 
for colonies using the rapid cracking procedure outlined below.
2.6.4 Cracking of Selected Colonies.
Individual bacterial colonies were picked from plates using sterile toothpicks and smeared near 
the bottom of a 0.5ml Eppendorf tube containing 50pl of lOmM EDTA, pH 8.0. 50|il of 
freshly prepared 2 x cracking buffer (200mM NaOH, 0.5% (w/v) SDS, 200g/l sucrose) was 
added and the cells resuspended by vortexing. The sample was then incubated at 70°C for 5
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minutes, allowed to cool to room temperature and then 1.5|il of 4M KCl and 0.5|xl of 0.4% 
(w/v) bromophenol blue were added and mixed. The sample was placed on ice for 5 minutes, 
microfuged for 3 minutes at 4°C and 30pl of the supernatant was run on a 0.7% (w/v) agarose 
gel alongside a sample of the supercoiled plasmid as a marker. Recombinant plasmid DNA 
migrated more slowly in the gel and could be identified by comparison to the supercoiled 
plasmid DNA.
2.6.5 Preparation of Bacterial Glycerol Stocks
Bacterial cultures were maintained on LB plates and restreaked every 6 - 8  weeks. For long term 
storage, transformed bacteria were frozen at -80°C in LB broth containing 15% (v/v) glycerol.
2.6.6 Plasmid Preparation
Two methods were used routinely for the preparation of large amounts of purified plasmid 
DNA, the Qiagen Column purification method (Hybaid Ltd, U.K) and the Promega Maxi 
Preparation system (Promega, Madison, U.S.A). Both methods were based upon the alkaline 
lysis method originally described by Bimboim (1983).
2.6.6.1 Qiagen Column DNA Purification.
A 150ml bacterial culture was routinely grown overnight in LB media containing 50|ig/ml 
ampicillin, at 37°C. The cells were harvested at 4000g and the bacterial pellet resuspended in 4 
ml of buffer PI (lOOmg/ml RNase A, 50mM Tris-HCl, lOmM EDTA, pH8.0). 4ml buffer P2 
(200mM NaOH, 1% (w/v) SDS) was added and the suspension mixed gently and incubated at 
room temperature for 5 minutes. After this time, 4ml buffer P3 (2.55M potasium acetate) was 
added, mixed and the cell lysate centrifuged at 15,000g at 4°C for 30 minutes to remove the 
bulk of chromosomal DNA and cell debris. The supernatant was removed immediately and 
recentrifuged (as above) to produce a particle-free clear lysate. A Qiagen Tip-100 (anion 
exchange silica gel column) was equilibrated with 3ml buffer QBT (750mM NaCl, 50mM 
MOPS, 15% (v/v) ethanol, pH 7.0, 0.15% (v/v) Triton X-100) and allowed to empty by 
gravity flow. The lysate was then applied to the column and again, the column allowed to empty 
by gravity flow. The column was then washed with 10ml buffer QC (l.OM NaCl, 50mM
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MOPS, 15% (v/v) ethanol, pH 7.0) and the DNA eluted with 5ml buffer QF (1.25M NaCl, 
50mM MOPS, 15% (v/v) ethanol, pH 8.2).
The DNA was precipitated from the eluate with 0.7 volumes isopropanol, incubated at room 
temperature for 30 minutes and centrifuged at 12,000g for 30 minutes. The purified plasmid 
DNA pellet was finally washed in 70% (v/v) ethanol, dried and resuspended in lOOpl sterile 
distilled water. The DNA was stored at -20°C until use.
2.6.6.2 Promega Maxi preps
Bacterial cultures (100-500ml) were grown and pelleted as described in section 2.6.2.1. The 
bacterial pellet was then resuspended in 15ml cell resuspension solution (lOOpg/ml RNase A, 
50mM Tris-HCl pH 7.5, lOmM EDTA) and 15ml cell lysis solution (0.2M NaOH, 1%SDS) 
was added. The lysate was then mixed thoroughly and 15ml neutralisation solution (2.55M 
potassium acetate, pH4.8) added. The sample was then centrifuged for 15 minutes at 14,000g 
and the supernatant decanted immediately avoiding the white protein interface. The DNA was 
then precipitated by addition of 0.6 volumes of isopropanol and mixed. The precipitated DNA 
was then pelleted by centrifugation at 14,000g for 15 minutes. The resulting pellet was then 
resuspended in 2ml TE buffer (lOmM Tris-HCl pH 7.5, ImM EDTA).
Promega's Purification Resin (10ml) was added to the DNA solution and the resin/DNA mix 
placed in a Maxiprep purification column. The column was then attached to a vacuum source 
and the resin/DNA mix pulled into the column. The preparation was then washed with 25ml 
column wash solution (200mM NaCl, 20mM Tris-HCl pH7.5, 5mM EDTA, diluted 1:1 with 
95% (v/v) ethanol). Vacuum was applied to draw the wash solution through the column. The 
resin was then rinsed with 5ml, 80% (v/v) ethanol and the resin dried by continuing to draw the 
vacuum for a further 10 minutes. 1.5ml preheated (65-70°C) water was added to the column 
and DNA eluted by centrifugation of the column in a 50ml polypropylene tube at 2,500rpm for 
5 minutes.The resulting plasmid DNA solution was then stored at -20°C until use.
2.6.7 Restriction Enzyme Digestion of DNA
Appropriate restriction endonucleases were chosen to isolate the cDNA sequences from their 
respective host plasmids, (see Table 2.1). The digestion mix routinely contained 30|ig plasmid
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DNA, 30 units of restriction enzyme, 60pl of 10 x reaction buffer (appropriate to the enzyme), 
60|il 40mM spermidine and sterile distilled water to a final volume of bOOpl. The digestion 
mixture was then incubated overnight in a 37°C water bath.
2.6.8 Agarose Gel Electrophoresis of DNA
The standard protocol for preparation and electrophoresis of 1% (w/v) agarose gels was 
performed as described by Sambrook et al (1989). The agarose was dissolved in 1 x TAB 
buffer (40mM Tris-HCl, 20mM sodium acetate, lOmM EDTA, pH 8.0) by heating in a 
microwave, and poured into an appropriate sized gel former. Once set, the gel was transferred 
to an appropriately sized gel electrophoresis tank and submerged in Ix TAB electrophoresis 
buffer. DNA was prepared for electrophoresis by addition of loading buffer (30% (w/v) Ficoll, 
0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanole, 0.2M EDTA, pH 8.0 in 10 x 
TAB) such that the loading buffer made up 10% by volume of the final DNA mix.
Gels were run at 150mA constant current at room temperature until the indicator dye reached 
2/3rds of the length of the gel. Hindlll-digested Lambda DNA was corun with the DNA 
samples in order to determine the size of the DNA fragments of interest.
2.6.8.1 Visualisation of DNA Gels using Ethidium Bromide
Once run, gels were immersed with shaking in distilled water containing 0.5|ig/ml ethidium 
bromide for 20 minutes. The gels were then destained in distilled water alone for 20 minutes 
prior to visualisation under UV illumination and photography (see section 2.6.4).
2.6.9 Photography
RNA & DNA agarose gels were visualised using UV illumination. This is possible since the 
fluorescent ethidium bromide dye intercalates with the nucleic acids and irradiation by ultraviolet 
light at 300nm is then re-emitted at 590nm in the red/orange region of the visible spectrum. The 
irradiated gels were photographed using a polaroid land speed MP-4 camera and type 665 
positive/negative film. The film was exposed for approximately 13 seconds with an aperture of 
f4.5 and an orange filter.
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2.6.10 Purification of DNA from Agarose Gels
Agarose gel electrophoresis was performed on restriction enzyme-digested DNA and the gel 
stained with ethidium bromide (section 2.6.3.1 ). The fragment(s) of interest were recovered 
from the gel using the method outlined below.
2.6.10.1 GenecIeanTM method
The method is based upon that of Vogelstein and Gillespie (1979). The cDNA band was 
excised from the gel using a sterile scalpel, weighed and placed in a 15ml poypropylene tube. 
Sodium iodide (2-3 volumes) was added and the gel dissolved by incubation at 55°C for 5 
minutes. G la s s m ilk ™  was then added (l|il per Ipg DNA using a minimum volume of 5pl), 
mixed thoroughly and incubated on ice for 5 minutes to allow binding of the DNA to the silica 
matrix. The silica matrix was then pelleted by centrifugation at 10,000g for 5 seconds and the 
sodium iodide supernatant discarded. The pellet was washed by resuspension in 500|il of ice 
cold 'NEW solution (a sodium chloride/ethanol wash) and the silica matrix sedimented by 
recentrifugation (10,000g, 5 seconds). The supernatant was discarded and the washing 
procedure repeated twice more before resuspending the pellet in lOjil sterile distilled water. The 
mixture was then incubated at 55°C for 5 minutes to elute the DNA from the silica matrix, then 
centrifuged (10,000g, 10 seconds). The supernatant containing the pure cDNA was transferred 
to a 1.5ml Eppendorf tube and stored at "20°C until required.
2.6.11 Quantitation of DNA in solution.
For assessment of DNA concentrations in solution, DNA aliquots were diluted 1:500 in DEPC- 
treated distilled water in 0.5ml quartz cuvettes. The samples were scanned between 200 and 
320nm using a Kontron-Uvikon 860 dual-beam spectrophotometer. Nucleic acids and proteins 
have absorbance maxima at 260 and 280nm respectively. An absorbance ratio (A26o/A280nm) of
1.8 was indicative of pure DNA. The concentration of DNA was determined using the A260nm 
value, as one absorbance unit at this wavelength corresponds to a DNA concentration of 
50mg/ml (Sambrook et al, 1989)
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2.7 Methods Relating to Hybridisations.
2.7.1 Preparation of 32p.iabelled DNA probes
32p-labelling of DNA fragments was performed using the M e g a p r i m e ™  DNA labelling kit 
(Amersham International, U.K.) based on the random priming method of Feinberg & 
Vogelstein (1983,1984).
Single stranded template DNA was prepared by dénaturation at 95°C for 5 minutes followed by 
rapid cooling on ice and was then bound by random sequence nonomers which act as primers 
for DNA synthesis. Incubation of the radioactive label [a-32p]_dCTP, the Klenow fragment of 
DNA polymerase I and dGTP, dATP and dTTP with the template DNA led to DNA synthesis 
incorporating the radiolabelled nucleotide. Unincorporated nucleotides were removed using 
Nick™ columns according to the manufacturer's protocol. Further heat-denaturation released 
the radiolabelled cDNA probe ready for hybridisation to RNA bound to nylon filters.
2.7.1.1 Specific Activity Determination
The percentage incorporation of [a-32p]-dCTP and specific activity of the labelled probe was 
determined by using absorption of the probe to DE-81 filters. DE-81 filters are positively 
charged and strongly adsorb and retain nucleic acids. Unincorporated nucleotides stick less 
tightly to the filters and can be removed by washing the filter in sodium phosphate.
A 3pl sample of probe was diluted to 15jil in distilled water and 5pl of this spotted onto each of 
two labelled DE-81 filters. After air-drying the filters for 15 minutes, one filter was washed six 
times for 5 minutes in 0.5M Na2 HP0 4 . The filter was then washed twice for one minute in 
distilled water and twice for one minute in 95% (v/v) ethanol. The washed filters were then 
dried and counted in a scintillation counter in an aqueous scintillation fluid ('Optiphase', 
Fisons, Loughborough, U.K). The unwashed filter measured the total radioactivity in the 
sample and the washed filter measured only the radioactivity incorporated into the nucleic acid.
Calculation of the specific activity of radiolabelled DNA :
i) Megaprime labelling leads to a net DNA synthesis so the amount of DNA at the end of 
the reaction must be calculated.
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Total amount DNA (A) ng = Total pCi added x * 13.2 x % incorporation
 --------------  +25
Total dNTP's added x average sp.act. of dNTP's
assuming 25% content of any one dNTP in the newly synthesized DNA and 25ng
template DNA.
* 13.2 represents four times the average molecular weight of the four dNMP's divided by 100 i.e. (330 x 
4 )/ 100 = 13.2
ii) The amount of radioactivity incorporated in the reaction (B) dpm =
pCi added x 2.2 x 10  ^x % incorporation
iii) Specific activity of the labelled DNA = B/A x 10  ^dpm/pg
2.7.2 Hybridisation Protocols
Prehybridisations and hybridisations were carried out at 42°C in Hybaid™ bottles in a rotary 
hybridisation oven (Hybaid, U.K.). Blots were prehybridised (50% deionised formamide, 5 x 
Denhardt's, 1% (w/v) SDS, 5 x SSC, 0.25mg/ml sonicated denatured salmon sperm DNA and 
lOmg/ml Poly A & Poly C DNA) at 42°C for 18 hours, followed by hybridisation in the same 
solution with the addition of 1 0 % (v/v) dextran sulphate and the 32p_iabelled probe for 24 
hours. After hybridisation, the filters were washed under stringent conditions ( 2 x SSC, 0.1% 
SDS at room temperature for 2 x 20 minutes; 0.5 x SSC, 0.1% SDS, 2 x 20 minutes). The 
temperature of the final wash was dictated by the homology of the probe to the message being 
detected, but ranged from 42-65°C. After washing the membrane was wrapped in Saran-wrap 
and autoradiographed as described in section 2 .7 .3 .
2.7.2.1 Stripping of Probes from Filters
Radiolabelled probes were removed from filters by agitation of the filters in a boiling solution of 
0.1% (w/v) SDS for 2 X 20 minutes and then rinsing in 5 x SSC at room temperature. The 
filters were then autoradiographed to ensure complete removal of the hybridised probe, prior to 
rehybridisation.
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2.7.3 Autoradiography
After washing the nylon membranes, the extent of hybridisation was visualised by 
autoradiography. Filters wrapped in Saran wrap were placed in a cassette containing an 
intensifying screen. Kodak X-Omat AR5 high speed film was preflashed to increase sensitivity 
and placed over the membranes. The film was exposed at -80°C for a period of 1-7 days judged 
by the monitoring the radioactive counts emitted by the filters with a Geiger counter prior to 
autoradiography. After an appropriate exposure time, films were developed in a Fuji RGII 
Medical Film Processor.
2.7.4 Densitometry
The relative abundance of mRNA transcripts on Northern and slot blot autoradiographs was 
assessed by densitometric analysis using a CS-9001 Dual Wavelength Flying-Spot Scanner 
(Shimadzu Europa, Germany). Scanning was performed using parameters and procedures 
recommended in the instruction manual. The data were generated graphically as absorbance 
peaks corresponding to individual bands. Areas under the peaks (arbitrary units) corresponded 
to band intensities and hence were used in quantitation of relative mRNA transcript 
abundancies.
2.8 Mammalian Cell Culture Techniques
2.8.1 Routine Culture of the H4IIEC3 Cell Line
H4IIEC3 cells were grown as monolayers in 80cm^ tissue culture flasks (Nunclon) in two 
different growth media:
(i) Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) foetal calf 
serum, gentamycin (0.1 mg/ml), L-glutamine (2mM)
(ii) Nutrient Mixture F-10 (Ham's) supplemented with 10% (v/v) foetal calf serum, 
gentamycin (0.1 mg/ml), L-glutamine (2mM)
Cells were subcultured when the monolayer growth was seen to become contact inhibited. 
Growth media was aspirated off the monolayer and the cells incubated with 1 x trypsin-EDTA 
(0.5g trypsin, 0.2g EDTA/litre modified Pucks saline A) at 37°C until the cells were seen to 
detach from the base of the flask. After subsequent dilution of the cells in prewarmed growth
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medium, the cells were counted using a Hawksley cristalite neubauer haemocytometer and then 
reseeded at appropriate density into SOcm  ^tissue culture flasks ( to be grown as stock) or 
90mm petri dishes (for transfection).
2.8.2 Frozen Cell Stocks
Cell monolayers were trypsinised, centrifuged at SOg for 5 minutes and resuspended in growth 
medium containing 20% (v/v) FCS and 10% (v/v) DMSO to a final concentration of 1 x 1 0  ^
cells/ml. The cells were then dispensed into 1ml aliquots and frozen overnight at(^0°C prior to 
removal to liquid nitrogen for storage. When recovered from liquid nitrogen, an appropriate 
number of aliquots were thawed quickly at 37°C and cells diluted in 10ml growth medium. 
Residual DMSO was removed by centrifugation of this solution at SOg for 5 minutes, 
discarding the supernatant and resuspension of the cell pellet in 1 0 ml fresh growth medium 
(containing 10% (v/v) FCS). This suspension was then transferred to a SOcm^ tissue culture 
flask and incubated at 37°C in 5% CO2 , 95% air.
2.8.3 Estimation of Plating Efficiency.
Plating efficiency was assessed as a measure of how well individual H4TTFC3 cells were able to 
colonise under different culture conditions. Cells which had previously been grown in the 
media under test for a minimum of 2  weeks, were seeded at a density of 2 0 0  cells per 90mm 
plate. The plates were then incubated at 37°C in 5% CO2 , 9 5 % air for 10 days, without 
renewing the growth medium. After this time, medium was removed from each plate and the 
colonies washed thoroughly with 1 x PBS. The cells were then fixed in methanol;acetic acid 
(3:1 by volume) for 20 minutes at room temperature and the fixative then washed off using 
three PBS washes. A Grunwald-Giemsa stock stain (0.25% (w/v) May Grunwald stain in 
methanol : 0.03% (w/v) Giemsa stain in 1:1 methanol :glycerol, 1:9 by volume) was diluted 1:9 
in O.IM KPO4  pH 6 . 8  and was used to stain the colonies for a minimum of one hour. Stain 
was removed by copious washing in distilled water and the plates then dried by inversion on 
tissue paper. Examination of the plates on a light box allowed counting of colonies and viewing 
under a microscope allowed estimation of fold divisions of each single cell.
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2.9 Transient Cotransfection Assay
H4IffiC3 cells were seeded at 2 x 1 Q6  cells per 90mm plate (see section 2.8.1) in Ham's FIG 
medium supplemented with 10% (v/v) FCS three days prior to transfection. Cells were then 
washed in serum-free medium and transfected by mixing lOpg plasmid DNA with lOOpg N-[l- 
(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and 5ml serum-free 
medium which was applied to the cells. Unless otherwise stated, each plate was transfected 
with Ipg CAT reporter plasmid, Ipg expression vector (pSG5, pSG5.PPAR, pSGS.RXR), 
3|ig P-galactosidase expression vector (pCHllO) , and 5pg pBluscript as carrier. Each 
transfection was performed in triplicate. After 5 hours, 5ml Ham's FIO containing 20% (w/v) 
dextran-coated charcoal (DCC)-treated FCS was added with DMSO or ligand (Wy-14,643 
and/or 9-cis retinoic acid) prepared in DMSO. After 20 hours, the medium was replaced with 
fresh Ham's FIO containing 10% (w/v) DCC-FCS and appropriate ligands. After 48 hours, the 
cells were harvested and cytosol extracts (300pl in 0.25M Tris-HCl pH7.8) prepared by three 
cycles of freeze-thawing and used for estimation of p-galactosidase activity (see section 2 .9 .1 ), 
as an assessment of transfection efficiency.
2.9.1 P-Galactosidase Assay
A p-galactosidase assay was performed on the cell extract from each plate. lOOjxl of cell extract 
was incubated with 0.28mg o-nitrophenyl-P-D-galactosidase (ONPG) in 50mM phosphate 
buffer pH 7.0, ImM MgCl2  for 3 hours at 37°C. The reaction was stopped by addition of 
400pl, IM Na2 C0 3 . The absorbance of each sample was then read at 420nm using a Kontron 
Uvikon 860 spectrophotometer and the following equation used to determine p-galactosidase 
activity:
lU /pl.h = 1000xA420nm
|Ltl cytosol extract x hrs of incubation at 37°C
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2.9.2 Chloramphenicol Acetyl Transferase Assay
Chloramphenicol acetyl transferase activity was measured using the Quan-T-CAT assay system 
(Amersham International, U.K) according to the manufacturer's protocol. Briefly, samples of 
cytosol extract (40ml) were incubated with 500pCi [^Hj-acetyl coenzyme A and 20mM 
biotinylated chloramphenicol in 0.12M Tris buffer pH 7.8 & incubated for 30 minutes at 37°C. 
Streptavidin-coated fluomicrospheres (10ml) were then added to each reaction tube and the 
tubes scintillation counted for 30 seconds each using a fully open counting window. CAT 
activity was then interpolated from a standard curve of known amounts of CAT enzyme and 
results expressed as CAT activity per unit beta-galactosidase in order to normalise for 
differential transfection efficiencies.
2.9.3 KCN-Insensitive Palmitoyl Co A Oxidation Assay
Cell extracts for KCN-insensitive Palmitoyl Co A oxidation estimation were prepared by 
harvesting one 90mm plate into 6ml 50mM Tris-HCl pH7.4, 0.154M KCl, 0.25% Triton X- 
100. Cell suspensions were then sonicated for two times 10 seconds at an amplitude of 2-3. 
The samples were then centrifuged at 8000g for 2 minutes and the supernatants removed and 
stored at -80°C until use. The KCN-insensitive Palmitoyl CoA oxidation assay was then 
performed as described in section 2.4.5 using lOOpl of cell extract per reaction.
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CHAPTER 3
TEMPORAL RESPONSE OF RAT LIVER TO CLOFIBRIC ACID
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3.1 Summary
The effect of 1-14 day administration of the hypolipidaemic drug, clofibric acid on rat liver was 
investigated with particular reference to the ability of this compound to cause hepatomegaly and 
to induce cytochrome P450 4A1 and enzymes of the peroxisomal p-oxidation spiral. A 
significant hepatomegaly was observed from 24 hours onwards concomitant with an elevation 
of the ©-hydroxylation of lauric acid - the marker substrate for CYP4A1 activity, reaching a 
maximum of 10-fold of control values at 14 days. A very significant (7-fold) increase was also 
seen in palmitoyl CoA oxidation catalysed by acyl CoA oxidase, the rate limiting step in 
peroxisomal p-oxidation.
The establishment of a bank of microsomal oxidase and protoonocogene DNA probes and 
optimisation of hybridisation conditions for these probes allowed further investigation of the 
effects seen, at the mRNA level. Examination of the transcriptional activation of a series of 
hepatic protooncogenes showed significant induction of the nuclear transcriptional factors c- 
myc and c-fos and of CYP4A1. The other protooncogenes investigated, Ha-ras, Ki-ras, mos 
& ErbAl showed no discernible transcriptional activation in response to this protocol.
The role of CYP4A1 and peroxisomal P-oxidation in the metabolism of clofibric acid is 
discussed and related to possible mechanisms of peroxisome proliferation. Further, the role of 
the protooncogenes in tissue growth and the relationship between cell proliferation and 
carcinogenesis is examined.
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3.2 Introduction
It is now well-documented that the peroxisome proliferator and hypolipidaemic drug, clofibric 
acid causes a marked induction of CYP4A1 and of peroxisomal p-oxidation in rodent species. 
In addition, this compound causes a marked increase in the incidence of hepatocellular 
carcinoma in susceptible species. A key characteristic of the pleiotropic effect of clofibric acid is 
a marked hepatomegaly associated with both hyperplasia and hypertrophy.
The actual mechanism by which peroxisome proliferators induce liver growth is unclear. 
Thompson et al (1986) showed that restorative cell proliferation after partial hepatectomy is 
controlled by the sequential expression of hepatic cellular protooncogenes and, associated with 
this phase are stimulation of tyrosine kinases, activation of protein kinase C and calcium 
mobilisation (Berridge, 1987). In addition, nafenopin treatment of rats appeared to stimulate the 
expression of some of the cellular protooncogenes (Bentley et al, 1987). These findings suggest 
that the mechanisms which control normal cell growth and growth induced by peroxisome 
proliferators may be the same.
The objective of the present study was to investigate whether peroxisome proliferators such as 
clofibric acid could cause a triggering of the type of stimulus outlined above and thereby disturb 
the normally very tightly controlled process of cell proliferation. If so, it would be interesting to 
speculate as to the role of the protooncogenes and cell proliferation in non-genotoxic 
carcinogenesis.
72
The main objectives of the study presented in this chapter are summarised below :
1. To confirm that administration of the peroxisome proliferator clofibric acid to rats 
produces significant hepatomegaly, an induction of CYP4A1 protein and catalytic 
activity and an induction of the peroxisomal P-oxidation system in accordance with the 
observations of Sharma et al ( 1988a,b) and Kozuka et a l{ \9 9 \) .lo  define the time 
course of the effects seen up to 14 days.
2. To establish a DNA 'probe bank' of protooncogene and microsomal oxidase 
complementary and genomic DNA's and define experimental conditions for their use in 
examination of the role of protooncogenes in non-genotoxin-mediated events.
3. To examine the effect of clofibric acid on protooncogene messenger RNA levels in rat 
liver and relate these effects to possible mechanisms of xenobiotic-induced liver growth.
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3.3 Experimental
Male Wistar albino rats (100-130g initial body weight, University of Surrey strain) were 
housed as described in Materials and Methods, and allowed to acclimatise for three days with 
free access to control powdered diet and tap water. During the dosing periods five animals per 
group were administered diets containing 0.2% (w/w) clofibric acid or control diet for 1,4,7 or 
14 days ad libitum , and the dietary intake recorded daily during this time. At appropriate time 
points, the livers were removed and subcellular fractions prepared as described in Materials and 
Methods (section 2.3). Liver sections were snap frozen for RNA isolation. Subcellular 
fractionation of the remaining tissue provided homogenate and microsomal fractions used for 
peroxisomal P-oxidation and P450 isozyme determinations respectively.
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3 .4  Effect of clofibric acid on food intake and body weight gain
Clofibric acid was administered in the diet for 1 ,4 ,7  and 14 days. Initially the presence of this 
compound caused a marked decrease in food intake in the test group (statistically significant at 
the 0.01% level) likely to be due to palatability of the diet mix. This is evidenced by a decrease 
in body weight gain in the Day 1 group in comparison to control levels (Table 3.1). 
Consequently, the dose received by the Day 1 group was accordingly reduced, this group 
receiving a calculated daily dose of 67.3mg/kg.
Table 3.1 : Effect of clofibric acid on Body Weight Gain and Calculated Mean Daily Dose
Treatment Group Body weight gain 
(g/day)
Food intake 
(g/Kg/day)
Mean Daily Dose 
(mg/Kg/day)
DAY 1 Control 6.00 ± 1.34 113.461 1.37 N/A
Test 4.60 ± 1.36 LOSS ** 33.68 1 0.57 67.3 1  1.16
DAY 4 Control 7.25 ±0.31 70.75 1  0.6 N/A
Test 5.30 ± 0.68 64.51 1 1.46 127.413.12
DAY 7 Control 8.0010.15 87.67 1 1.00 N /A l
Test 6.40 ± 0.48 80.22 1  5.29 173.7 1  4.94
DAY 14 Control 7.02 ± 0.26 82.021 1.20 N/A
Test 6.67 ± 0.39 80.861 1.81 162.2 1  3.60
Body weight gain is the mean weight gain over the corresponding dosing period.
Food intake and daily dose are means of the daily intake over the corresponding dosing period. 
Statistical analysis was carried out using Student's t-test.
** significantly different from corresponding time point control p < 0.01 
N/A : Not applicable
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Due to animals being caged in groups, no statistical evaluation of food intake and mean daily 
dose is possible.
For subsequent time points, body weight gain and food intake in treatment groups did not differ 
significantly from the respective control groups. It should be noted, however that test groups 
showed consistently (although not statistically significantly) lower food intake than control 
groups which is reflected in the body weight gain profiles. This could again be attributed to 
palatability of the diet mix.
Examination of historical data from our laboratory (Sharma et al, 1988 a,b) revealed that the 
mean daily dose of clofibric acid received after day 1 would be sufficient to produce maximal 
induction at 14 days.
3 .5 .  Effect of clofibric acid on relative liver size
Hepatomegaly is defined as an enlargement of the liver due to either (or both) hyperplasia and 
hypertrophy and is associated with a large increase in phospholipid and total protein levels 
(Azamoff et al, 1976). This condition is a common adaptive response to treatment with 
peroxisome proliferators such as clofibric acid (Reddy et al, 1980, Lake et al, 1975). 
Hepatomegaly is expressed as an increase in the liver/body weight ratio relative to control 
(Beckett et al, 1972).
Treated animals at the 4 ,7  and 14 day time points showed a significant increase in relative liver 
weight in response to clofibric acid treatment, reaching a maximum of 156% of control at 14 
days (see Figure 3.2). No increase in relative liver weight above control was observed after a 1 
day treatment period and this lack of effect could be attributed to the palatability of the diet mix 
(see section 3.1).
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Figure 3.2 : The effect of clofibric acid on liver/body weight ratio in rats
Data points represent means ± standard error of the mean (s.e.m) for 5 observations 
Statistical analysis of data by Student's t-test :
** significantly different from corresponding time point control p<0.1%
* * * significantly different from corresponding time point control p<0.01 %
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3 .6 .  Effect of clofibric acid on hepatic microsomal cytochrome P450 
monooxygenase enzymes
One of the major biochemical markers of adaptive xenobiotic-induced hepatomegaly is induction 
of drug-metabolising enzymes, in particular, cytochromes P450. To examine these effects, 
microsomal fractions were prepared from control and treated animals as described in Materials 
and Methods (section 2.3.1) and microsomal enzymes measured as described in sections 2.4.2 
and 2.4.3. The total microsomal CO-discemible P450 specific content was significantly 
increased in the 4 ,7  and 14 days treatment groups above respective time point controls (Figure 
3.3).
3.6.1 CYP4A1 lauric acid hydroxylase activity
The cytochrome CYP4A1 isoenzyme was characterised by its marker substrate. The
relatively
hydroxylation of lauric acid at the O) position is ajspecific activity of the CYP4A
subfamily (Sharma et al, 1988a). Clofibric acid significantly increased the activity of the 11- 
hydroxylase at all time points to a maximum of 152% of control activity (Figure 3.4). The most 
marked induction however, was of the 12-hydroxylase activity which showed a 10-fold 
increase above control at 14 days of treatment.
3.6.2 CYP4A1 apoprotein level measured hy western blotting
SDS-PAGE analysis of microsomal protein and subsequent Coomassie Blue staining of the gel 
(section 2.4.7) revealed an equivalent protein loading of samples (see Figure 3.5) and serves to 
add confidence to quantitative evaluation of the western blot. The only slight variation seemed 
to be in the 14 day time point lane which appears to contain fractionally less protein than other 
lanes. Western blot analysis of a duplicate gel to confirm induction of the CYP4A apoprotein 
was performed using an antibody which exhibits specificity for at least two rat CYP4A 
isozymes.
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Figure 3.3 Total cytochrome P450 specific content of liver microsomes from rats 
treated with clofibric acid.
Data points shown represent means ± sem for 5 observations 
Statistical analysis of data by Student's t-test
significantly different from corresponding time point control 
significantly different from corresponding time point control***
p<0.1
p<0.01
Control absolute values (nmoles P450/mg) protein! s.e.m
Day 1 
Day 4 
Day 7 
Day 14
0.80 ±0.13 
0.83 ± 0.21 
0.74 ± 0.07 
0.91 ±0.11
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Figure 3.4 Lauric acid ll-(o )-l) and 12-(œ) hydroxylase activities of liver 
microsomes from rats treated with clofibric acid.
Data points shown represent means ± s.e.m for 5 observations.
Statistical analysis by Student's t-test
* significantly different from time point control p<0.05
** significantly different from time point control p<0.01
*** significantly different from time point control p<0.001
Control activities at zero time point :
11-hydroxylase activity = 0.78 ± 0.26 nmol/min/mg protein
12-hydroxylase activity = 1.38 ± 0.45 nmol/min/mg protein
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(Tamburini éta l, 1984). The western blot shown in Figure 3.6 shows two bands : a lower 
(major) band (molecular weight 51.5 kD) corresponding to CYP4A1 increasing in intensity 
with duration of treatment with clofibric acid. Sundseth and Waxman (1992) reported that the 
CYP4A2 isozyme comigrates with CYP4A1 and thus estimation of the differential induction of 
the two isoforms is difficult using this form of analysis. The upper (minor) band (molecular 
weight 52kD) corresponding to CYP4A3 (Sundseth and Waxman, 1992; Aoyama et at, 1990) 
also shows induction in all treatment groups.
The induction in CYP4A1 apoprotein therefore closely parallels the induction in lauric acid 12- 
hydroxylase - a marker activity for this enzyme. This indicates that increased translation of the 
apoprotein results in an increase in enzyme activity. Again, the 14 day sample appears to be less 
induced, however than the 7 day treatment group. The reason for this is unclear as rats do not 
usually demonstrate an adaptive response to clofibric acid at 14 days. The reduced protein levels 
in this lane detected by Coomassie Blue staining could imply that this effect is simply due to a 
reduced amount of protein loaded in this well.
Figure 3.7 shows densitometric analysis of the western blot as detailed in section 2.7.4. Due to 
the similarity of migration distance of the three isoforms described, each peak represents the 
cumulative optical density of the three bands. The quantitative evaluation of CYP4A apoprotein 
by densitometry revealed a very similar trend of induction over the 14 day period to that seen 
for the lauric acid co-hydroxylation marker activity of this isozyme (Figure 3.4). The lower 
induction than expected in the 14 day time point is again attributable to under-loading of this 
lane. The response of the densitometer to increasing band intensity has been shown to be linear 
(S. Gamble, personal communication).
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Figure 3.5 SDS-polyacrylamide gel electrophoresis of rat liver microsome samples.
Liver samples from five separate animals were pooled on an equiprotein basis, diluted
to O.lfi^p-l in sample solubilisation buffer and Ipg protein loaded in each well. The gel 
was stained using a Coomassie Blue stain (see Materials and Methods).
C l, 4 ,7 ,14  Control animals at 1 ,4 ,7 ,14  day time points
T l, 4 ,7 ,14  Test animals treated with 0.2% (w/w) clofibric acid in diet for 1,4, 7,14 
days
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Figure 3.6 Western blot analysis of effect of clofibric acid on hepatic CYP4A1 
apoprotein.
SDS-PAGE gel was run as in Figure 3.5. An antibody to rat CYP4A1 isozymes 
was used and visualisation performed using diaminobenzidine (see Materials and 
Methods).
N.B the western blot shown is in reverse orientation to the Coomassie Blue-stained gel 
shown in Figure 3.5 due to the loading method used.
C l, 4, 7,14 Control animals at 1,4, 7, 14 day time points
T l, 4,7, 14 Test animals treated with 0.2% (w/w) clofibric acid in diet for 1 ,4 ,7 ,14  
days
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Figure 3.7 Densitometric analysis of relative levels of hepatic CYP4A in Western blot 
shown in Figure 3.6.
Each value represents cumulative optical density of CYP4A isozymes (CYP4A1,4A2 and 
4A3). The use of composite group samples limits the quantitative expression of the bands 
such that statistical analysis of group data is not possible.
C l, 4, 7, 14 Control animals at 1,4, 7,14 day time points
T l, 4 ,7 ,1 4  Test animals treated with 0.2% (w/w) clofibric acid in diet for 1, 4 ,7 , 14 
days
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3.7 Effect of clofibric acid on peroxisomal P-oxidation enzymes
3.7.1 KCN-insensitive palmitoyl CoA oxidation
Peroxisomal p-oxidation was measured as palmitoyl CoA oxidation that was insensitive to 
potassium cyanide in liver homogenates as described in Materials and Methods (section 2.4.5). 
This gives an indication of the activity of the rate-limiting step in the peroxisomal p-oxidation 
spiral, the acyl CoA oxidase enzyme, and is distinguished from its mitochondrial counterpart by 
its insensitivity to potassium cyanide.
The palmitoyl CoA oxidation activity was increased significantly by clofibric acid treatment at 
all time points reaching a maximum of 7.8 fold above control by day 14, as shown in Table
3.8. Day one values for treated animals were however, lower than expected (Lazarow & De 
Duve 1976) and, once again, this is attributable to the reduced compound intake on this day.
Table 3.8 : Peroxisomal P-oxidation activities on liver homogenates of rats treated with 
clofibric acid
Sample Palmitoyl CoA oxidation activity (nmol/min/mg protein)
Treatment (Days) 1 4 7 14
Control 5.0 ± 0.23 5.7 ± 1.1 6.3 ± 0.97 6.0 ± 0.80
Test 8.0 ±1.24* 20.8 ± 2.56**^ 36.1 ±3.72*** 47.2 ± 4.90 ***
Determinations were described as in Materials and Methods. 
Values are means ± s.e.m from 5 animals per group.
Statistical analysis was carried out using Student's t-test.
* p < 0.05 compared to corresponding time point control
*** p < 0.01 compared to corresponding time point control
85
3.8 Establishm ent of DNA probe bank
In order to examine the molecular role of both microsomal oxidases and cellular protooncogenes 
in chemical toxicity, it was necessary to establish a bank of DNA probes within our laboratory. 
The plasmids containing DNA fragments of interest were supplied by the Human Genome 
Mapping Project (HGMP) Probe Bank, although some of the microsomal oxidase DNA probes 
had either originally been cloned within our laboratory or supplied by other sources (see section 
2.1.5).
Spg of plasmid containing the DNA fragments of interest were supplied by HGMP and 
processed as shown in Figure 3.9. This cloning strategy served to (i) provide E.Coli host cells 
transformed with plasmids containing the DNA fragments of interest allowing bulk preparations 
of these DNA's (ii) provide glycerol stocks of these cells for long term storage (iii) allow 
isolation of probe fragments and confirmation of their size, integrity and identity. The 3|ig of 
the original plasmid sample was then restriction digested for Southern blotting as described 
below.
After transformation of the E.Coli (JM1090) host cell with 10-20ng plasmid DNA, 
transformants were selected by plating out onto LB plates overnight and use of either IPTG (an 
inducer of the lacZ gene) and X-gal (a substrate which is broken down to a blue dye by the lacZ 
gene product) if the plasmid contained a p-galactosidase gene, or ampicillin resistance. The 
result of this process was that three categories of cells were found :
a) Cells lacking plasmid did not grow as they lacked an ampicillin resistance gene
b) Cells containing a plasmid with no insert had a functioning lac Z gene which was 
induced by IPTG to produce p-galactosidase to break down the X-gal causing the 
colonies to appear blue.
c) Cells containing a plasmid with an insert had a defective lac Z gene and therefore did not 
metabolise X-gal, causing the colonies to remain white.
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This process therefore ensured that the colonies selected contained plasmids with inserts rather 
than artefacts of the cloning process. The resultant colonies were 'cracked' to confirm the 
presence and size of insert. Cracking is a high throughput lysis method to screen for plasmids 
with inserts and is described in section 2.6.4. Lysed cells were analysed using agarose gel 
electrophoresis and plasmid without insert was run as a marker. Any plasmid containing insert 
was identifiable as this would run slower than the plasmid without insert. In this secondary 
screening procedure, approximately 60% of colonies would contain insert.
These colonies were then prepared in bulk to produce sufficient DNA for restriction digestion 
and a sample of the plasmid preparation retained for Southern blotting. The method of choice 
for plasmid preparation was Promega Maxi-preps. This method offered two distinct advantages 
over the Qiagen preparations namely (i) with the aid of the vacuum manifold, clean plasmid 
DNA could be prepared from culture in 30 minutes compared with 3-4 hours for Qiagen 
preparations, (ii) there is no salt in the elution buffer producing a clean, more easily 
quantitatable sample. An example of restriction digestion of plasmid followed by 1% agarose 
gel electrophoresis is shown in Figure 3.10. Figure 3.11 illustrates how the insert size could be 
confirmed by interpolation of migration distances with those of a ^Hindlll marker. This gave 
confidence that the insert isolated was of the same size as the original insert supplied and by 
inference, the insert had been isolated correctly and was not a cloning artefact.
After Genecleaning of the insert (section 2.6.10.1), a sample of the insert could then be used 
for southern blotting. The purpose of the southern blot (section 2.6.8) was to confirm the 
identity of the isolated fragment by examining its homology to insert restriction digested from 
the original plasmid sample. An example of this process is shown in Figure 3.12. The newly 
isolated cDNA was labelled with ^^P using a random priming method (section 2.7.1) and 
hybridised to itself and a digest of the original plasmid sample. Washing of the filter at very 
high stringency allowed confirmation of the identity of the newly isolated insert.
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For short term storage of the transformed cells, a loop of the 150ml liquid culture was streaked 
onto LB Amp. plates, grown up overnight and stored at 4°C. Cells stored in this fashion were 
viable for up to 6 months. For longer term storage and archiving, cells were stored as glycerol 
stocks (to prevent rupture by ice crystals) at -80°C. The cells were viable in this form for 2-3 
years.
For later generation of the DNA fragment of interest, these cells could be retrieved at any point, 
bulk prepared, plasmid isolated and restrictrion digested and the fragment isolated similarly to 
the process in Figure 3.9.
The probe bank established as a result of this work is shown in Appendix I.
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Overnight incubation at 37°C
Overnight incubation at 3VC
Glycerol
Stocks
SOUTHERN BLOT 
CONFIRMATION
Plasmid containing DNA insert
TRANSFORMATION 
DMSO, heat shock
Geneclean of DNA insert 
[DNA] measurement
Plasmid preparation 
[DNA] estimation
Plating out of transformants 
& selection
Restriction digestion 
(i) 20pg (ii) lOO^g
Preparation of competent E. Coli 
host cells
1% agarose gel electrophoresis 
Confirmation of size
Bulk preparation of confirmed 
positive clones (150ml culture)
Restriction digestion of original 
sample (for reference)
Cracking of transformants 
to confirm presence/size 
of insert
Figure 3.9 Schematic diagram illustrating the transformation of host E.Coli cells 
with plasmids containing DNA inserts of interest, production of probe DNA and 
confirmation by Southern blotting.
This strategy was used for all DNA probes listed in Appendix I. Details of the 
process for the preparation of PPAR cDNA are shown, as an example, in section
3.8.
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Figure 3.10 : 1% agarose gel electrophoresis 
Lane 1 : 20|ig PPAR.pSGS plasmid DNA
Lane 2 : 3jig PPAR.pSG5 plasmid DNA BamHI digested (from original sample) 
Lane 3 : 5|ig PPAR cDNA (L80kb)
Lane 4 : 10p.g iH indlll DNA marker (fragment sizes are shown)
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Figure 3.11 : Confirmation of transformant insert size
Logarithmic relationship between distance migrated by a marker DNA fragment 
in 1% agarose and the size of the fragment (bp) allows estimation of insert size 
by interpolation
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PPAR cDNA 
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Figure 3.12. Southern blot of PPAR.pSG5, PPAR.pSG5 digest and PPAR 
cDNA hybridised to^^P-labelled PPAR cDNA
Lane 1: 5|ig PPAR cDNA (newly isolated)
Lane 2: 3|J.g PPAR.pSGS, BamHI digested (original sample) 
Lane 3: 20jLig PPAR.pSG5 plasmid DNA 
Lane 4: 10|ig AHindlll DNA marker
Filter washing stringency : 2.0xSSC,0.1%(w/v)SDS 42"C 20 mins x 2 
1.0xSSC,0.1%(w/v)SDS 55'C 20 mins x 2 
0.5xSSC,0.1%(w/v)SDS 65"C 20 mins x 2 
0.1xSSC,0.1%(w/v)SDS 65°C 20 mins x 2
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3.9 Molecular effects of clofibric acid on rat liver
Total RNA was isolated from snap frozen sections of rat liver by the method of Cathala et al 
(1983) outlined in section 2.5.1.1. Due to the low yield of RNA obtained by this method 
(approximately bOOpg of total RNA from 0.5mg tissue) only a single isolation from each 
sample was possible. Technical difficulties in optimising the slot blot procedure for the probes 
used meant that there was only sufficient RNA left for the 14 day time point to be analysed. The 
slot blots were produced as replicates, using the same RNA samples and hybridised against 
CYP4A1, fos, myc, ErbAl, mos, Ha-ras and Ki-ras. To standardise the process, in order to 
compensate for the amount of RNA loaded, the membranes were stripped of previously 
hybridised probe and reprobed with a ^^P-labelled 1.8kb human actin probe. The actin gene is 
one of a number of 'house-keeping' genes which are constitutively expressed in all cell types 
and is routinely used as an RNA 'loading control' since its level is not usually affected by drug 
treatments (Morgan 1991, Morgan & Norman 1990). This assumption was checked by 
hybridisation of a known quantity of control and clofibrate-induced RNA to actin and 
autoradiography. The filter was then stripped and stained using a methylene blue stain which 
visualises the total RNA on the filter (section 2.5.6). Scanning densitometric analysis of the 
autoradiograph and the methylene blue-stained filter revealed no induction of the actin gene in 
response to clofibrate (data not shown). Therefore, actin was seen to be an appropriate loading 
control.
Specific hybridisation of the DNA probe with corresponding mRNA species was detected by 
autoradiography which records the reaction of p-particles emitted from a specifically bound 
32p-labelled probe with silver halide grains in the emulsion layer of the X-ray film. This 
localised reaction forms a latent image which is rendered visible by the action of developing 
agents generating a spectrum of intensities ranging from very faint to intense black depending 
upon the level of p-emission and duration of exposure to the X-ray film.
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3.9.1 Effect on CYP4A1 transcription
The level of hepatic CYP4A1 mRNA in clofibric-acid treated rats at the 14 day time point was 
significantly elevated above control rats (Figure 3.13). The constitutive level of CYP4A1 
transcription was clearly detectable by slot blot analysis.
Hybridisation to an actin cDNA showed even loading of the RNA samples for each of the 
groups. Quantitative analysis of the autoradiographs by scanning densitometry showed the 
response to clofibric acid treatment to be 3.2-fold above control (see section 3.10.1 for 
calculation method). However, the statistical analysis of data generated by the determination of 
specific mRNA levels by slot blotting was hampered by a number of problems encountered 
with experimental technique (see section 3.10.1)
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Figure 3.13 Slot blot analysis of effect of clofibric acid on CYP 4A1 mRNA at 14 day 
time point
Lanes 1-4 : Control total rat liver RNA, animals 1-4
Lanes 5-8 : Clofibric acid- induced total rat liver RNA, animals 1-4
RNA was diluted in 6.15M deionised formaldehyde : 20 x SSC (1:1 mixture) and slot blotting 
performed as detailed in section 2.5.4 of Materids and Methods.
Hybridisations against a rat 2.1kb CYP 4A1 cDNA probe and human 1.80kb actin cDNA 
were carried out as described in sections 2.7.1 and 2.7.2.
Washing stringency : (for both CYP 4A1 and actin)
2 X SSC, 0.1% (w/v) SDS 
1 X SSC, 0.1% (w/v) SDS 
0.5 X SSC, 0.1% (w/v) SDS 
0.1 X SSC, 0.1% (w/v) SDS 
5xSSC
42‘C 20 mins x 2
55“C 20 mins x 2
65*C 20 mins x 2
65'C 20 mins x 2
RT 20 mins
RT : room temperature
Filter exposed to X-ray film  for 72 hours (see section 2.7.3)
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3.9.2 Effect on hepatic protooncogene transcription
Similar slot blots were hybridised to the cellular protooncogene probes outlined above. No 
induction of the mRNA for mos, ErbAl, Ha-ras and Ki-ras was discernible by visual 
inspection or by scanning densitometry (data not shown).
However, both the c-myc and c-fos protooncogene mRNA was significantly induced at the 14 
day timepoint by clofibric acid treatment (see Figures 3.14 and 3.15). Quantitative analysis of 
the autoradiographs by scanning densitometry revealed inductions of 8.8-fold and 11-fold 
above control values for c-myc and c-fos respectively. Subsequent hybridisation to actin 
showed even loading of RNA across all the groups.
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Figure 3.14 Slot blot analysis of effect of clofibric acid on c-myc mRNAat 14 day 
time point
Lanes 1-4 : Control total rat liver RNA, animals 1-4
Lanes 5-8 : Clofibric acid- induced total rat liver RNA, animals 1-4
RNA was diluted in 6.15M deionised formaldehyde : 20 x SSC (1:1 mixture) and slot blotting 
performed as detailed in section 2.5.4 of Materials and Methods.
Hybridisations against a rat 2.0kb c-myc genomic DNA probe and human 1.80kb actin cDNA 
were carried out as described in sections 2.7.1 and 2.7.2.
Washing stringency : (for c-myc only). Actin stringency as shown in Figure 3.13
2 X SSC, 0.1% (w/v) SDS RT 20 mins x 2
1 X SSC, 0.1% (w/v) SDS 30"C 20 mins x 2
0.5 X SSC, 0.1% (w/v) SDS 42°C 20 mins x 2
0.5 X SSC, 0.1% (w/v) SDS 55"C 20 mins x 2
5x SS C RT 20 mins
RT : room temperature
Filter exposed to X-ray film  for 72 hours (see section 2.7.3)
96
jig Total RNA loaded per slot
20 10 2.5 1.25 0.625
1
2
3
4
5
6
7
8
Actin c-fos
Figure 3.15 Slot blot analysis of effect of clofibric acid on transcription of c-fos mRNA 
at 14 day time point
Lanes 1-4 : Control total rat liver RNA, animals 1-4
Lanes 5-8 : Clofibric acid- induced total rat liver RNA, animals 1-4
RNA was diluted in 6.15M deionised formaldehyde : 20 x SSC (1:1 mixture) and slot blotting 
performed as detailed in section 2.5.4 of Materials and Methods.
Hybridisations against a rat 3.0kb c-fos genomic DNA probe and human 1.80kb actin cDNA 
were carried out as described in sections 2.7.1 and 2.7.2.
Washing stringency : (for c-fos only). Actin stringency as shown in Figure 3.13
2 X SSC, 0.1% (w/v) SDS 
1 X SSC, 0.1% (w/v) SDS 
0.5 X SSC, 0.1% (w/v) SDS 
0.5 X SSC, 0.1% (w/v) SDS 
5xS SC
RT : room temperature
Filter exposed to X-ray film  for 96 hours (see section 2.7.3)
RT 20 mins X 2
30°C 20 mins X 2
42°C 20 mins X 2
55"C 20 mins X 2
RT 20 mins
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3.10 Discussion
Hepatomegaly is a common response of laboratory animals, especially rats, to xenobiotic 
challenge and is a result of both hyperplasia (increased cell proliferation) and hypertrophy 
(Beckett et al, 1972, Reddy et al, 1979). The hypertrophy is largely due to a proliferation of 
subcellular organelles, in particular the smooth endoplasmic reticulum and peroxisomes, in 
response to peroxisome proliferators. Hyperplasia is known to occur within 3-4 days of 
administration of a peroxisome proliferator (Mitchell, 1985). In the study described, liver:body 
weight ratio was increased to approximately 130% of control values at 4 days. This 
hepatomegaly was maintained and increased over the 14 day dosing period. The hyperplastic
A
phase of liver growth in respojfee to peroxisome proliferators is usually transient (1-2 days) and 
is indicated by an increase in cells in S-phase. The latter stages of this growth are more likely to 
be hypertrophic in nature (characterised by an increase in intercellular constituents, for example, 
peroxisomes) (Beckett et al, 1972, Reddy et al, 1979).
Hepatomegaly is associated with a variety of biochemical changes depending upon the chemical 
administered (Schulte-Hermann, 1979). One of the major biochemical markers of adaptive 
xenobiotic-induced hepatomegaly is induction of drug-metabolising enzymes especially 
cytochromes P450. This has long been recognised as a mechanism for increasing the efficiency 
of xenobiotic elimination (Conney, 1967). Total cytochrome P450 content was increased in 
response to clofibric acid treatment, however the most striking induction was of the CYP4A 
family lauric acid (o-hydroxylases (Orton and Parker, 1982) responsible for the co- 
hydroxylation of fatty acids (Hardwick et al, 1987).
In addition, the western blot prepared with the anti-CYP4A antibody showed a clear increase in 
CYP4A apoproteins reflecting the induction pattern of catalytic activity. Furthermore, slot blot 
analysis of total RNA from control and clofibric acid-treated animals using a 2.1kb CYP4A1 
cDNA probe, revealed a 3.2-fold increase in abundance of CYP4A1 mRNA in response to 
clofibric acid for 14 days. The regulation of the CYP4A subfamily has been shown to occur at 
the transcriptional level (Hardwick et al, 1987) implying that the fold induction of mRNA 
should
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correspond to that of the catalytic activity. Whereas transcriptional activation of CYP genes is a
common regulatory mechanism, it should be noted that, by contrast, induction of the ethanol-
for some, but not all inducers 
inducible isozyme, CYP2E1 is controlled at the level of protein stabilisatioijh(Song et al, 1986).
Results from this study, however do not support regulation of CYP4A1 at a transcriptional level
- the induction of catalytic activity at 14 days being > 10-fold, the mRNA induction 3.2-fold.
This is very likely to be due to a number of problems associated with the slot blotting technique
and described in detail in section 3.10.1, or for biological reasons related to the translation process./ - - - — .. . ' - — - — _    ....................
Induction of CYP4A1 and the associated lauric acid hydroxylase activity occurs in response to a 
variety of stimuli in addition to clofibric acid treatment. High fat diets (Capdevila, 1992) and 
malnutrition or diabetes (Wada et al, 1971, Orellana et al, 1990) may also induce this activity. 
Administration of clofibric acid resulted in a slight reduction in rate of body weight gain over 
the 14 days with respect to control however, it is likely that the effect on body weight gain is 
not significant and the enzyme induction seen is a direct effect of clofibric acid administration.
Induction of CYP4A1 also indicates that the compound is a peroxisome proliferator as all 
peroxisome proliferators to date also induce CYP4A1 (Sharma et al, 1988a, Kozuka et al, 
1991). Sharma et al (1988a,b> suggested that peroxisome proliferators induce CYP4A1 directly 
or via lipid accumulation, and this causes an increase in the levels of (U-hydroxylated fatty acids 
and subsequently of dicarboxylic acids (the preferred substrates of peroxisomal P-oxidation). It 
was further hypothesised that due to this increase in substrate, the enzymes of peroxisomal p- 
oxidation are induced to deal with the increased flux. Indeed, clofibric acid treatment for 14 
days resulted in a 8-fold induction in the rate of peroxisomal p-oxidation. This is in accordance 
with the results of Lazarow and DeDuve,1976.
Recently there has been a considerable amount of attention paid to the role of cell proliferation in 
carcinogenesis, and it is clear that cancer is characterised by a subversion of normal growth 
control in the cell. This process of normal, constitutive growth control involves the action of the 
cellular protooncogenes although the control of cell proliferation by these genes remains a
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poorly understood part of cell biology. It is known, however that growth factors e.g. 
hepatocyte growth factor, epidermal growth factor and insulin-like growth factor stimulate 
protein phosphorylation, phosphatidyl inositol turnover, plasma membrane ion flux and 
changes in cytosolic calcium concentration within minutes of addition to cells (Whitman and 
Cantley, 1988). An increase in cytosolic free calcium results in activation of protein kinases and 
other calcium dependent processes including the subsequent stimulation of nuclear 
transcriptional activators, for example, the fos/jun complex AP-1. It is not clear, however, 
which of these event(s) is/are critical in stimulating cell division and what sequence of events is 
required. Certainly, there may be other factors such as vasopressin & angiotensin II acting via 
GTP proteins and phopholipase C which could contribute to this effect and steroid hormones 
are known to trigger cell proliferation in their target cells (Landers and Spelsberg, 1992).
In order to begin to define the possible role of the protooncogenes in non-genotoxic 
hepatocarcinogenesis the protooncogene probe bank described in section 3.8 was established 
and from this, six protooncogenes selected from specific functional categories. Table 3.16 
details the protooncogenes examined in this study.
Figure 3.16 : Protooncogenes and corresponding oncoproteins and function
Protooncogene Oncoprotein Function
Ha-ras
Ki-ras
p21 GTP-binding proteins signal transduction from extracellular to 
intracellular effector systems
mos cytosolic serine/threonine 
receptor kinase
Intracellular signal transduction 
?in vivo substrate
fo s p55-p62
comprises subunit of AP-1
AP-1 = nuclear transcriptional activator 
stimulation of cell growth/differentiation
myc p64/p67 nuclear transcriptional activator 
induction of cell proliferation
ErhAl T3 thyroid hormone receptor(?) steroid hormone receptor
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The mechanism which converts the normal gene or 'protooncogene' to its transforming 
counterpart, the oncogene is thought to be a critical event in initiation and maintenence of 
neoplastic transformation. Proposed mechanisms for this conversion include chromosomal 
translocation, point mutations, retroviral insertion and gene amplification. Due to technical ease 
and feasibility the mechanism examined was that of gene amplification to examine xenobiotic- 
induced overproduction of the oncoprotein.
No apparent induction was observed for Ha-ras, Ki-ras, mos and ErbAl after 14 days of 
treatment with clofibric acid. The constitutive expression of both Ha-ras and Ki-ras seen is 
likely to serve a regulatory role in signal transduction, possibly acting to mediate the hormonal 
regulation of protein kinase C (Majerus et al, \9^6). Ha-ras and Ki-ras have been shown to be 
activated by both point mutation and overexpression mechanisms. Ha-ras mutations have been 
reported in human bladder and urinary tract carcinomas (Reddy et al, 1982) while mutant I^ras 
genes are more common in lung and colon carcinomas (McCoy et al, 1983).
The evidence for transcriptional induction of Ha-ras is, however, equivocal. A number of 
reports have implicated a link between overexpression of the normal ras gene and neoplastic 
transformation (Gerosa et al, 1989, Fujita et al, 1987). A greater than 10-fold induction of the 
p21 protein was detected by Gallick et al (1985) in colorectal tumours. In addition, Bentley et al 
(1987) demonstrated induced expression of Ha-ras in rat liver after 24 hours exposure to the 
peroxisome proliferator, nafenopin and Cherkaoui-Malki et al (1990) showed a marked 
induction of Ha-ras in response to ciprofibrate at 2 and 52 weeks exposure. In the study 
described here, however, clofibric acid treatment did not produce any transcriptional activation 
of either Ha-ras or Ki-ras. It is possible that this is due to clofibric acid being a weaker 
peroxisome proliferator and weaker carcinogen than those used in the studies of Bentley and 
Cherkaoui-Malki.
The mechanism of activation of the mos oncogene is largely unclear, however, the closely 
related serine kinases, mil/rafarc activated by truncation of the 5'-coding region (Schultz et al.
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1988). Clofibric acid treatment for 14 days produced no transcriptional activation of this 
protooncogene indicating that at 14 days the cytoplasmic serine kinase encoded by mos is 
unaffected at the transcriptional level. The relevance of this to the non-genotoxic carcinogenic 
process will become clearer when the substrate for this enzyme is defined.
The localisation of several oncogene-encoded proteins to the cell nucleus implies these proteins 
may play a regulatory role in either DNA replication or in the control of gene transcription. 
ErbAl has been shown to correspond to the constitutively activated form of the thyroid 
hormone receptor (Weinberger et al, 1986), a member of the steroid hormone receptor 
superfamily (section 1.6.1).This family act by binding to specific target DNA sequences 
thereby regulating the transcription of specific genes. Experiments conducted here show no 
induction of this gene by clofibric acid treatment indicating that either ErbAl is not involved in 
the non-genotoxic carcinogenic process at the 14 day time point, or that the constitutive level of 
expression is sufficient to mediate this response.
The final two oncogenes examined, fos  and myc, are further examples of oncogene-encoded 
proteins which have been localised to the cell nucleus. A role for normal fos protein has been 
suggested in the control of both cell growth and differentiation and expression of the fo s  
protooncogene is rapidly transcriptionally activated by agents such as PDGF and TPA that 
stimulate cell division (Kruijer et al, 1984). Clofibric acid is shown here to increase the 
constitutive expression of the fos protooncogene 11-fold at the 14 day time point. The results of 
Bentley et al (1987) indicate that c-fos is induced within 24 hours of administration of the 
peroxisome proliferator, nafenopin. Indeed,the induction of c-fos has been shown to occur in 
the presence of the protein synthesis inhibitor, cycloheximide (Ledwith et al, 1993) and as such 
can be seen as an 'early-immediate' response.
This induction was maintained throughout the treatment. Interestingly, this response is much 
more prolonged than following partial hepatectomy and this finding may therefore be consistent 
with a continuing stimulation of cell growth during prolonged treatment with a peroxisome 
proliferator.
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Ledwith et al (1993) proposed that the effects on the fos  oncogene seen are independent of the 
effects of clofibric acid on peroxisome proliferation zsfos  induction has also been identified in 
cell lines which do not undergo peroxisome proliferation, in response to the peroxisome 
proliferators, Wy-14.643 and DEHP. Also, the induction of immediate-early gene expression 
would procédé peroxisome proliferation (which requires protein synthesis) in cells that do 
undergo peroxisome proliferation.
A marked increase in c-myc mRNA was also observed after 14 days of treatment with clofibric 
acid which is consistent with an association of c-myc mRNA with cellular proliferation. Sobcak 
et al (1989) and Thompson et al (1986) showed a marked increase in the level of c-myc mRNA 
proceeding DNA synthesis during rat liver regeneration after partial hepatectomy. These 
findings suggest a role for c-myc in regulating the entry of hepatocytes into the cell cycle (GO- 
G1 transition). In liver regeneration, this increase in c-myc expression is transient, however in 
the study detailed in this chapter, c-myc appears to remain elevated long after liver growth, and 
by inference, DNA synthesis has begun. Indeed, similarly to c-fos, c-myc mRNA remains 
elevated for the duration of the treatment, up to 14 days.
It is important to note in analysis of the results of this study, that the protooncogene effects seen 
at 14 days represent a 'snapshot' of effects over the time course. Milton (1989) showed that 
CYP4A and peroxisomal P-oxidation enzymes respond to peroxisome proliferator 
administration with an immediate peak at 24 hours, falling back to control levels and then a 
more sustained induction over 14 days. It follows therefore that any protooncogene changes 
associated with these inductions would not be evident in the results of this study.
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3.10.1 The limitations of slot blotting for the quantitative analysis of mRNA
The application of densitometry to the molecular results presented in this chapter has highlighted 
some weaknesses in the slot blotting experimental technique which was, until now, assumed to 
produce consistent and reliable results. Previous work performed in our laboratory has relied 
upon observation of relative intensities and inductions described based upon judgement of 
relative intensities of the bands.
The introduction of densitometric scanning has offered the possibility of accurate measurement 
of intensities of bands and quantitation of the response. However certain weaknesses in the 
technique have been highlighted by the work performed in this study.
Slot blots produced as described in section 2.5.4 rely upon accurate serial dilution of the RNA 
sample. Assuming linearity of this serial dilution of RNA and assuming uniform hybridisation 
with actin across the filter, it follows that the autoradiograph band intensity should be directly 
proportional to the amount of total RNA loaded. Visualisation by the human eye has always 
supported this, however initial attempts to quantify the response by scanning densitometry did 
not support this assumption.
Figure 3.17 (a and b) shows an example of the non-linear response defined by scanning 
densitometry. The results shown are of the relative intensity of signal produced by hybridisation 
of a slot blot to CYP4A1 and the relative intensities of the same bands hybridised to actin. The 
non-linearity of the response is clear - CYP4A1 : actin ratios should be constant if the response 
was linear (Figure 3.17b).
Two main issues resulted from this finding : (i) analysis of the data obtained, and (ii) 
improvement/alteration of the experimental protocol to provide a linear response by 
densitometric scanning. Each of these issues will now be discussed.
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Figure 3.17a. Quantitation of intensity of hybridisation signal by scanning 
densitometry. Plot shows the relationshipn between hybridisation signal (to
CYP4A1 and actin) and |ig total RNA (control or test) loaded per slot. Each 
sample is representative of the treatment group.
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Figure 3.17b. Relationship between ratio of CYP4A1 to actin signal intensity and
[ig total RNA (control or test) loaded per slot. Normalization of CYP4A1 
intensity to actin should produce a constant ratio if the slot blotting technique is 
linear.
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Currently, there is no published model for the statistical analysis of data generated from 
densitometric analysis of slot blots. However, attempts have been made in our laboratory to 
analyse this data (Dr D. Bulsara, personal communication).In summary, analysis of probe:actin 
ratios from one group of animals by Komolgorov-Smimov goodness of fit test revealed that the 
data generated was not normally distributed. Bulsara went on to assess statistical significance of 
variation by one way Anova and Duncan's multiple range t-test (enabling pair-wise comparison 
of group means). However this approach was seen as invalid due to non-normal distribution of 
the data.
A second approach was to use only the 20|Xg slot data (as these showed the greatest degree of 
difference between control and test animals). The statistical approach detailed above was then 
used, homoscedasity (equal variances) being obtained by linear transformation. However, the 
use of 20|Xg data only was seen only to reduce non-linearity rather than produce a linear 
response. The essential problem was therefore defined as the intrinsic non-linearity of the 
response and Bulsara concluded that statistical approaches would remain questionable until 
linearity of response could be achieved.
Linearity can only be improved by increasing understanding of the current experimental 
technique, its limitations and modifications to the protocol. Possible areas of the slot blotting 
techniques which may be reponsible for the observed non-linearity will now be discussed.
i) Quality of RNA : The quality of RNA isolated will affect the linearity of the slot blot for 
two reasons (i) if the RNA isolated is of poor quality, the results of spectrophotometric 
quantitation of the RNA samples will be less reliable and therefore, preparation of serial 
dilutions for slot blotting will be correspondingly inaccurate. This would account for inter­
animal variations in hybridisation signal, (ii) The extent of degradation of the total RNA prior 
to loading on the filter will affect the hybridisation signal. Although specific hybridisation may 
occur even if some sequences are degraded, variation in this degradation would also affect inter-
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animal variations. A discussion of RNA isolation and quantitation problems can be found in 
Chapter 4. Confidence in specific hybridisation was gained from including a yeast tRNA 
negative control and 0.5)Lig probe cDNA as positive control on each filter. No binding to the 
negative control and specific clear hybridisation to the positive control supported specific 
hybridisation to target sequences of interest
ii) Masking of mRNA species of interest : The slot blotting technique involves the 
application of total RNA samples directly to a nylon filter within a limited area. It is possible 
therefore, that access of a labelled probe to the small percentage of mRNA species of interest 
could be inhibited by other ribosomal and messenger RNA species or salt. This would also 
account for a marked difference in apparent induction of a paticular mRNA when assessed by 
slot blotting as compared to Northern blotting - the Northern blotting technique allowing 
electrophoretic separation of the mRNA's of interest from other RNA's and contaminating 
salts/formaldehyde. To resolve this problem with the slot blotting technique, the amount of 
RNA which can be applied to the membrane before overloading needs to be investigated.
iii) Passage of RNA through the filter : It is possible that suction applied to the slot 
blot apparatus to draw the RNA onto the filter may, in fact, draw some of the RNA through the 
filter. This can be demonstrated by placing two filters on the slot blot apparatus and applying 
suction to draw the RNA through. Hybridisation of the lower filter to a ^^P-labelled probe 
results in a signal indicating that some RNA may pass through the upper filter. This could be 
one source of the non-linearity. Removing the suction component of the technique, for 
example, by simply applying the RNA direct to the filter would obviate this problem, although 
sizes of resulting dots may not be uniform.
iv) Response of the X-ray film
At low and high levels of p-emission, the response of the X-ray film is not linear. However, 
information from the supplier (Kodak) indicates that between these two levels there is a range
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within which a linear response is expected. Therefore in order to determine the intensities of the 
bands which fall within a linear response of the film, commercially available calibration 
standards should be used.
A short, uniform, low-level pre-exposure of the X-ray film to high-intensity light before 
exposure to the radioactive filter has been shown to enhance the image such that less exposure 
to the signal is required (Kodak literature). This procedure may also increase the linear range of 
the film.
In summary, the non-linearity of response is likely to be due to the compound effect of poor 
RNA quality, inaccuracies in quantitation/loading of RNA, and a lack of understanding of the 
linearity of the film and densitometer settings.
For purposes of this study, therefore there seems little to be gained from extensive statistical 
analysis of data to 'enforce' what may not be valid statistical reasoning. Therefore the approach 
taken here involved taking the limited range of data within the linear range of both the 
densitometer and the X-ray film. Assuming that the errors in-built in the slot blotting technique 
are constant for a particular amount of RNA loaded, hybridisation method etc, we can use peak 
areas to generate probe;actin ratios for each of the animals in a particular group and calculate the 
mean value. From this data, a fold induction of mRNA can be calculated although statistical 
significance of this induction can not be assessed due to reasons described above.
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3.11  Conclusions
The clofibric acid dosing regime used in this study was shown to produce the spectrum of 
enzyme effects characteristic of a peroxisome proliferator namely CYP4A1, peroxisomal p- 
oxidation enzyme induction and hepatomegaly. This effect served as a benchmark or positive 
control for subsequent molecular studies.
Prior to my work, no studies involving oncogenes had taken place in our laboratory therefore 
containment and hybridisation conditions were established. Molecular studies showed initially 
that constitutive expression and induction of oncogene mRNA was detectable by slot blot 
hybridisation.
Results strongly indicated that the peroxisome proliferator, clofibric acid can directly activate 
growth-regulatory signal transduction pathways leading to the expression of the early- 
immediate genes, fos  and myc. Both of these genes have been shown to be involved in cell 
proliferation and, as such may, in part, explain the hepatocellular hyperplasia observed.
It seemed logical at this point to identify whether the protooncogene responses seen are 
indicative of only peroxisome proliferators or of non-genotoxic carcinogens as a whole, or 
more broadly of all carcinogens. Equally, investigation of whether this response is specific to 
tissues undergoing growth or to all tissues exposed to peroxisome proliferators is also 
important. The differential effects of two non-genotoxic carcinogens in responsive and non- 
responsive species and tissues are explored in Chapter 4.
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CHAPTER 4
A COMPARISON OF RAT & GUINEA PIG TISSUE RESPONSES TO 
CLOFIBRATE AND PHENOBARBITONE
1 1 0
4.1 Summary
The preceding chapter provides evidence that the peroxisome proliferator, clofibric acid 
produces, in addition to the classical pleiotropic enzyme induction, an induction of the growth 
control genes c-fos and c-myc. As discussed in Chapter 3, these genes have been associated 
with control of the cell cycle and, as such are putatively linked to the marked hepatomegaly 
observed in response to clofibric acid.
However to define early markers of non-genotoxic carcinogenesis, it was clearly important to 
investigate the specificity of this response. It was necessary to delineate whether the 
protooncogene inductions seen for clofibric acid were characteristic of :
a) Tissues exposed/susceptible to non-genotoxic carcinogens
b) Tissues exposed to peroxisome proliferators/undergoing peroxisome proliferation.
c) Tissues undergoing growth.
The findings detailed in this chapter indicate that induction of c-myc, c-fos and c-jun is a 
common response to both the peroxisome proliferator, clofibrate and the tumour promoter, 
phenobarbitone. Also, the induction of these genes is not specific to those tissues undergoing 
peroxisome proliferation, similar inductions being seen, for example in phenobarbitone- 
exposed rat liver. Further, the effects seem to correlate well with those tissues which exhibit 
tissue growth in response to clofibrate and/or phenobarbitone.
It seems clear, therefore, that the induction of c-myc, c-fos and c-jun is indicative of an increase 
in cell cycling and, hence of mitogenesis. Increase in mRNA abundance of these genes seems to 
be characteristic of mitogenic agents and hence of both tumour promoters and peroxisome 
proliferators. It is concluded that this response alone is insufficient to use an an early marker of 
non-genotoxic hepatocarcinogenesis although, as tissue growth is a common response of the 
liver to all non-genotoxic carcinogens this may be an indicator of the liklihood of hepatic 
epigenetic change.
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4.2 Introduction
In the preceding chapter I defined the hepatic protein and molecular effects of 14 day 
administration of clofibric acid to the rat. At the protein level, clofibric acid displayed the 
pleiotropic effects associated classically with peroxisome proliferators i.e. induction of 
CYP4A1 and palmitoyl Co A oxidation as a marker of induction of peroxisomal p-oxidation. 
These effects of clofibric acid provided the benchmark for molecular studies of the effect of the 
non-genotoxic carcinogen on genes involved in cell cycle growth, c-myc and c-fos. Both of 
these genes were seen to be significantly induced at the 14 day time point. This indicated that 
the cell cycle genes were abnormally and continually expressed after the cessation of liver 
growth.
In the search for clearer characteristic markers of non-genotoxic hepatocarcinogenesis at the 14 
day time point, it was therefore important to define whether the activation of these cell cycle 
genes was specific to (a) tissues responsive to peroxisome proliferation (b) tissues which 
undergo growth in response to xenobiotic challenge, or (c) tissues which on prolonged 
exposure to non-genotoxic carcinogens, will finally progress to carcinoma. This was achieved 
by comparing responsive and non-responsive species and tissues.
The definition of pronounced species and tissue difference in xenobiotic-induced peroxisome 
proliferation has led to the suggestion that the rat liver response to peroxisome proliferators can 
be considered as a unique, atypical phenomenon related to the biology of the peroxisome in this 
species (de la Iglesia, 1981). Rats and mice are extremely sensitive to peroxisome proliferators, 
hamsters show an intermediate response whereas guinea pigs, monkeys and man appear to be 
relatively insensitive or non-responsive at dose levels that produce a marked response in 
rodents. These species differences are reproducible in vitro using primary hepatocytes isolated 
from a variety of species, including man (ECETOC, 1992).
Studies with clofibrate (Oesch et al, 1988), DEHP (Osumi and Hashimoto, 1979), MEHP 
(Mitchell et al, 1985), methylclofenapate (Elcombe, unpublished data) and nafenopin (Lake et
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al, 1989) at doses exceeding the effective dose levels in rats, have consistently failed to elicit 
peroxisome proliferation in guinea pigs. However, small (3-fold or less) increases in 
peroxisomal |3-oxidation were reported following the administration of tiadenol (Oesch et al, 
1988) and bezafibrate (Watanabe et al, 1989) to guinea pigs. By comparison, experiments in 
rats with equivalent doses resulted in a 13-fold and 19-fold stimulation of peroxisomal 13- 
oxidation respectively. The refractoriness of the guinea pig to peroxisome proliferation has led 
to a lack of published data on the carcinogenicity of peroxisome proliferators in this species. 
The lack of responsiveness of the guinea pig is, however, not explicable by variations in liver 
exposure of the compounds. Makowska (1987) administered rabiolabelled ciprofibrate to rats 
and guinea pigs at 2mg/kg. At 4 hours, no significant difference was observed in liver exposure 
(0.28% and 0.25% dose/g liver for rat and guinea pig respectively). The species specificity of 
this response has allowed examination of the reasons for the lack of response mechanisms to 
peroxisome proliferators.
In the rats, the induction of chemical carcinogenesis by non-genotoxic carcinogens displays 
clear tissue specificity. Unlike the liver, no gross kidney enlargement or renal proliferation of 
the endoplasmic reticulum has been observed in the rat treated with hypolipidaemic agents such 
as clofibric acid. However, the kidney does undergo peroxisome proliferation with a 
corresponding increase in peroxisomal p-oxidation enzymes. Indeed, it appears from the work 
of Le Hir and Dubach (1982) that the renal proximal tubule possesses a peroxisomal pathway 
for p-oxidation with a capacity of the same magnitude as in the hepatocytes. The lung and heart 
are largely refractory to peroxisome proliferation although these tissues do show constitutive 
inducible CYP4A activity (Milton, 1989).
The guinea pig was therefore used in this study as a model non-responsive species, and heart 
and lung samples taken as non-responsive tissues. The final comparison was between two non- 
genotoxic carcinogens - the peroxisome proliferator, clofibrate and the tumour promoter, 
phénobarbital.
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A common feature of many tumour promoters (eg. phénobarbital) is their ability to induce 
adaptive responses in normal liver, including increases in drug-metabolising enzymes and organ 
growth by hypertrophy/hyperplasia. Phénobarbital is not a complete carcinogen in the rat but 
will promote the growth of initiated cells giving rise to tumours (Jirtle et al, 1991). 
Considerable evidence suggests that unlike many carcinogens, peroxisome proliferators are not 
DNA reactive and that the hepatocarcinogenicity of peroxisome proliferators may result from 
their promotional activity (Schulte-Hermann etal, 1981,1983). Therefore this study compared 
a peroxisome proliferator with a tumour promoter to identify whether the protooncogene effects 
seen were a common feature of tumour promotion events or specific to a peroxisome 
proliferator-type response.
Therefore, the major objectives of the study outlined in this chapter were:
(i) To confirm the classical responses to clofibrate and phenobarbitone administration in rat 
and guinea pig liver, kidney, heart and lung and delineate the responses at the 
protein/enzyme level.
(ii) To examine the effects of the above compounds on tissue growth and to re-examine the 
cellular protooncogene effects detailed in Chapter 3 in non-responsive species and 
tissues
(iii) To compare the effects produced by treatment with the peroxisome proliferator, 
clofibrate with those produced by the tumour promoter, phenobarbitone.
(iv) To draw conclusions as to the importance of these changes in cell proliferation and non- 
genotoxic carcinogenesis.
1 1 4
4.3 Experimental
Male Wistar University of Surrey strain rats (180-200g initial body weight) and male Duncan 
Hartley guinea pigs (350-400g initial body weight, Porcellus Animal Breeders Ltd., Heathfield) 
were allowed to acclimatise for three days prior to the commencement of treatment, with free 
access to tap water and chow, as described in section 2.2. Dosing solutions were prepared in 
0.25% (w/v) gum tragacanth.
During the 14 day dosing period, rats were administered 250mg/kg/day sodium clofibrate or 
lOOmg/kg/day sodium phenobarbitone and control groups administered vehicle only. Doses 
were administered by gavage at 0.1ml dosing solution per lOOg body weight per day, every day 
for 14 days.
Guinea pigs were administered 250 mg/kg/day clofibrate or lOOmg/kg/day sodium 
phenobarbitone (dose reduced to 50mg/kg/day after day 3) and control animals were given 
vehicle only at 0. Iml/lOOg body weight/day.
At day 14, animals were weighed, killed by cervical dislocation, tissues removed and 
subcellular fractions prepared as described in Methods and Materials (section 2.3)
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4.4 Effect on Body Weight Gain
The body weights of both rats and guinea pigs were monitored for three days prior to the 
commencement of dosing (data not shown) and each day during the dosing period up to 
autopsy. Figure 4.1 shows body weight gain data over the period of the study for control, 
clofibrate and phenobarbitone-treated rats and guinea pigs. Throughout the 14 days, the treated 
and control rats showed similar rate of body weight gain although initially the control group had 
a higher average weight than the treatment groups. However, the rate of body weight gain for 
the three groups was not significantly different (as assessed by one way Anova & Student's t- 
test - data not shown). This indicated that treatment with clofibrate and phenobarbitone 
produced no loss of appetite.
The guinea pig body weight gain , however was less uniform. There is a clear discontinuity in 
the body weight gain of the phenobarbitone-treated group between days 2 and 3. This was due 
to the initial dose of phenobarbitone (lOOmg/kg) producing limited narcotic effects at 6-8 hours 
post dose. This effect was reversed by reducing the dose to 50mg/kg. After the dose of 
phenobarbitone had been reduced, rate of body weight gain for the three groups was similar. 
This indicates that the revised treatment produced no adverse effects on food intake.
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Figure 4.1 Body weight gain over 14 days for control, phenobarbitone- and 
clofibrate-induced (a) rats and (b) guinea pigs.
Data points shown represent mean ± s.e.m for 5 animals per group.
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4.5 Effect on Relative Tissue Weights
Figure 4.2 shows tissue weights taken at autopsy expressed as g/lOOg body weight. At 
autopsy, a highly significant hepatomegaly was observed in the rat in response to both 
clofibrate (134% of control) and phenobarbitone (117% of control). No significant increases in 
rat kidney and heart weights were observed in response to clofibrate and equally, 
phenobarbitone caused no effect in these latter tissues. The guinea pig was refractory to tissue 
growth- no significant increases in tissue weights above control values being observed. There 
were, however, two significant decreases in tissue weight below control levels - the reason for 
this is unclear.
4.6 Effect on Microsomal Cytochrome P450 Monooxygenase Enzymes
Homogenate and microsomal fractions were prepared from tissues of control and treated 
animals as detailed in Materials and Methods (Section 2.3.1) and enzyme levels measured as 
described in section 2.4.
4.6.1 Total CO-discernihle Cytochrome P450 Specific Content
Total CO-discemible cytochrome P450 content was determined as the carbon monoxide-Fe^+ 
complex by the method of Omura and Sato (1965) and the results from liver and kidney 
samples are shown in Figure 4.3.
The significant increases in total cytochrome P450 specific content in clofibrate and 
phenobarbitone-treated liver was likely to be due to the induction of specific isoforms. The 
kidney, however, shows less responsiveness being largely refractory in the guinea pig.
The spectrophotometric technique (section 2.4.2) used to measure total cytochrome P450 
content proved too insensitive to quantitate total P450 content in heart and lung microsomes 
despite the use of large amounts of sample, and was not further pursued.
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Figure 4.2 Relative Tissue Weights (g/lOOg body weight) after 14 days 
exposure of a) rats and b) guinea pigs to clofibrate, phenobarbitone or 
vehicle only (control).
Data points shown are mean ± s.e.m for 5 animals per group 
Statistical analysis by one way Anova and Student's t-test
* significantly different from control p<0.05 
significantly different from control p<0.01 
significantly different from phenobarbitone group p<0.05
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There are two methods which can be used to quantitate the amount of total cytochrome P450 in 
the presence of large amounts of haemoglobin (for example, lung microsomes) or at very low 
levels. Johannesen and DePierre (1978) described the estimation of P450 in the presence of 
large amounts of haemoglobin by reducing the haemoglobin with ascorbate or phenazine 
ethosulphate. The assay technique is then carried out as described in section 2.4.2. 
Alternatively, the use of second derivative spectroscopy involving the mathematical analysis of 
the reduced CO-spectrum was described by Ghersi-Egea et al (1987). Standardisation of both 
of these techniques would require a very large amount of sample to produce quantitative results 
and would also benefit from pure sample. Neither of these techniques were therefore seen as 
feasible for this study.
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Figure 4.3 Total cytochrome P450 specific content in microsomal fractions from rat and 
guinea pig liver and kidney.
Data points shown are the mean ± s.e.m. for 5 animals per group.
Statistical analysis was by one way Anova and Student's t-test. 
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4.6.2 CYP4A1 Laurie Acid Hydroxylase Activity
CYP4A1 was characterised using its marker substrate, lauric acid as described in section 2.4.3. 
Figure 4.4 shows lauric acid 11- and 12-hydroxylase activities of rat and guinea pig liver and 
kidney microsomes. The highest fold induction in all the samples was 12-hydroxylation activity 
in clofibrate-induced rat liver (330% control). Rat kidney CYP4A1 12-hydroxy lation activity 
was equally responsive to clofibrate induction (350% control). However, no significant 
induction of the 12-hydroxylation of lauric acid was seen in response to phenobarbitone.
The highest constitutive level of both 11- and 12-hydroxylation activities was seen in guinea pig 
liver. However, neither activity was inducible by either clofibrate or phenobarbitone in either 
tissue in the guinea pig. Further, no significant control or induced CYP4A1 activity was 
detected in heart or lung microsomes of either species (data not shown).
4.6.3 CYP4A1 Apoprotein as Assessed by Western Blotting
SDS-PAGE analysis of microsomal liver samples and subsequent Coomassie Blue staining of 
the gel (section 2.4.7) revealed an approximately equivalent protein loading of samples (see 
Figure 4.5). Western blot analysis of a duplicate gel to confirm induction of the CYP4A 
apoprotein was performed using an antibody which exhibits specificity for at least two rat 
CYP4A isozymes (Tamburini et al, 1984).
The Western blot shown in Figure 4.6 shows a very pronounced induction of an approximately 
50kd protein in clofibrate-induced rat liver. Close examination of the blot revealed that this 
signal consisted of two poorly resolved bands. These correspond to the CYP4A1/2 and 
CYP4A3 isozymes, as discussed in section 3.6.2. Induction of CYP4A apoprotein by clofibrate 
in rat liver can therefore be seen to parallel the induction of lauric acid 12-hydroxylase.
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Figure 4.4 Lauric acid 1 l-(co-l) hydroxylase and 12-(co) hydroxylase activities of 
liver and kidney microsomes from rats and guinea pigs treated with clofibrate and 
phenobarbitone.
Data points shown are mean ± s.e.m for 5 animals per group.
Statistical analysis by one way Anova and Student's t-test
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Figure 4.5 SDS-PAGE gel of hepatic microsomal proteins from rats and guinea pigs
treated with clofibrate and phenobarbitone (Ijig protein/lane). The gel was stained using 
Coomassie Blue (see Materials and Methods)
RC Control rat 
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Figure 4.6 Western blot analysis of the effect of clofibrate and phenobarbitone- 
treatment on rat and guinea pig hepatic CYP4A. SDS-PAGE gel was run as in Figure
4.5, Ijig protein loaded per well. An antibody specific to rat CYP4A isozymes was 
used and visualisation performed using diamino-benzidine (see Materials and Methods).
N.B. the Western blot shown is in reverse orientation to the Coomassie Blue stained gel 
shown in Figure 4.5 due to the transfer method used.
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4.6.4 Pentoxyresorufin O-Depentylase Activity
Pentoxyresomfin 0-depentylase is a specific activity of CYP2B1 (Lubet etal, 1985) and was 
measured as described in section 2.4.2, Dosing with clofibrate produced no response above 
control values apart from ' rat and guinea pig liver (280 and 300% control respectively). 
Treatment with phenobarbitone however produced highly significant induction in both rat and 
guinea pig liver. Rat kidney and lung were also seen to be inducible (418 and 320% control 
respectively). Guinea pig extrahepatic tissues were refractory. No CYP2B1 activity was 
detectable in rat or guinea pig heart microsomes.
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Figure 4.7 Pentoxyresorufin 0-depentylase activities of tissue microsomes from 
clofibrate and phenobarbitone-treated rats and guinea pigs.
Data points shown are mean ± s.e.m for 5 animais per group
* significantly different from control p<0.05 
** significantly different from control p<0.01 
*** significantly different from control p<0.001 
t  significantly different from phenbarbitone group p<0.05 
t t  significantly different from phenobarbitone group pcO.Ol 
t t t  significantly different from phenobarbitone group p<0.001
ND : Not determined
Control values (pmol/min/mg protein) :
Rat Liver 
Rat Kidney 
Rat Heart 
Rat Lung
2.49 ± 0.06 
21.93 ±2.02 
ND
7.34 ± 0.67
Guinea Pig Liver 
Guinea Pig Kidney 
Guinea Pig Heart 
Guinea Pig Lung
5.42 ± 0.37 
73.9 ± 8.21 
ND
9.1 ±0.63
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4.7 RNA Methodology Development
Chapter 3 described in some detail the limitations of slot blotting for the quantitative analysis of 
RNA. It was suggested therefore that the molecular analysis of the study outlined in this chapter 
should be performed by Northern blotting. However, at the time this work was started the 
Northern blotting technique was proving non-reproducible and unreliable in our laboratory. The 
aim of this section of work was therefore to look at the technique in detail and to identify and 
correct any methodological errors.
4.7.1 RNA Isolation and Quantitation
The Cathala method (Cathala et al, 1983) used routinely to isolate total RNA from snap-frozen 
whole tissue was compared to a new method using the RNAzol B™ isolation reagent 
(Biogenesis, Bournemouth). The results of this analysis are presented in Table 4.9. Figure 4.10 
shows the 1% agarose gel electrophoresis of total RNA samples isolated using the two 
methods. The Cathala method clearly provides substantially increased opportunity for 
contamination of the extract and resulting lower quality RNA. It was clear that RNAzol B was 
the RNA extraction method of choice for this and subsequent studies.
RNA had been quantitated routinely by spectrophotometric determination (Kontron Uvikon 860 
dual beam spectrophotometer) at 260nm, and using the A 260/ 280n m  ratio as a measure of sample 
purity (see section 2.5.2). It is clear that any error in measurement of the concentration of an 
RNA sample will introduce error into the quantitation of specific mRNA abundance. The 
precision of the P20 Gilson pipettes used and the UVkon spectrophotometer were assessed by 
15 repeat measurements of Ijxl aliqots of the same total RNA sample (data not shown). Using a 
P20 Gilson pipette, the absorbance reading at 260nm varied by ± 13% - this would clearly have 
significant impact on any quantitative assessment of mRNA abundance. Replacement of the P20 
with a P2 Gilson reduced the error to ± 5% thereby reducing the possible error introduced into 
RNA analysis techniques.
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(a) Lithium chloride/guanidinium isothiocyanate extraction method 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Lane
18S -
5S —^----
(b) RNAzol B extraction method
1 2 3 4 5  6 Lane
Figure 4.10 : Comparison of (a) poor quality RNA isolated from snap frozen 
whole liver using the method of Cathala et al (1987) (section 2.5.1.1) with 
(b) high quality RNA isolated using RNAzol B (Biogenesis) (section 2.5.1.2)
Both gels were loaded with lOpg total liver RNA per well.
129
4.7.2 Northern blotting.
An analysis of the effectiveness of overnight capillary transfer using 20 x SSC was conducted 
and results are shown in Figure 4.11.
Photograph (i) shows 1% agarose gel electrophoresis of six lOfig total RNA samples stained 
with ethidium bromide. The total RNA was transferred onto Hybond N nylon filter as described 
in section 2.5.5. Photograph (ii) shows the filter after approximately 15 hours of transfer and 
photograph (iii) shows the remainder of each RNA sample left in the gel. Overall, the smaller 
RNA fragments have transferred more efficiently than the larger fragments. It is clear from 
photographs (ii) and (iii) that the transferred RNA pattern is interrupted by 'fluid movement' 
lines inhibiting the transfer in areas. Also, the two samples on the left have transferred less 
efficiently than the other four. This uneven transfer will clearly introduce error into any 
quantitative assessment of mRNA abundance on the filter.
Work by Thomas (1983) suggested that the poor transfer observed with the original capillary 
method could in part have been due to the intercalated ethidium bromide retarding the transfer 
by retaining the RNA in the agarose matrix. The failure to observe any signal on Northern blots 
in the laboratory at the time could also have been partially attributed to the 0.05M sodium 
hydroxide soak. This was designed to facilitate transfer of the larger molecular weight RNA's 
but perhaps could be degrading the RNA prior to transfer. The impact of both ethidium bromide 
intercalation and sodium hydroxide soaking was therefore investigated and the results shown in 
Figure 4.12.
It was clear from hybridisation of RNA transferred to filters to a human actin cDNA probe, that 
the effect of both ethidium bromide and sodium hydroxide was significant. The combined effect 
of these treatments, shown in autoradiograph (a), was no signal at all. Eliminating the sodium 
hydroxide step produced sample (b) - some indication of intact RNA is visible on the 
autoradiograph, but transfer is clearly not complete. This could be due to retention of the RNA
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(i)
Origin
28S
Total RNA gel pre-transfer, 
18S ethidium bromide stained
(ii)
(iii)
— Origin
— 28S
188
Total RNA transferred to 
Hybond-bP’^ filter
58
Origin
288
Total RNA remaining on 
gel after transfer
Figure 4.11 Illustration of effectiveness of RNA capillary transfer from agarose gel to 
Hybond N™ nylon filter using 20 x 88C as transfer buffer.
Gel was transferred overnight (approximately 15 hours)
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(a) + 0.05M NaOH, + 0.5|Xg/ml EtBr (b) - 0.05M NaOH, + 0.5^g/ml EtBr
(c) + 0.05M NaOH, - 0.5jig/ml EtBr (d) - 0.05M NaOH, - 0.5 |Lig/ml EtBr
Figure 4.12 Northern Blot Conditions : Illustration of the effect of (a) presoaking the RNA 
gel in 0.05M sodium hydroxide solution prior to transfer and (b) intercalation of RNA molecules
with (0.5}ig/ml) ethidium bromide (EtBr) to visualise RNA in gel prior to transfer.
Effects of the above processes have been assessed by hybridisation of four similar control 
RNA filters to l.SOkb human actin cDNA (see section 2.7)
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in the gel by ethidium bromide intercalation. Autoradiograph (c) shows the effect of elimination 
of ethidium bromide intercalation. Again, a signal can be seen on the film, but is entirely non­
specific and probably represents the transfer of degraded RNA species. The most promising 
result came from eliminating both steps. Autoradiograph (d) shows a much more successful 
Northern blot with specific hybridisation to the actin mRNA. The transfer has been successful 
and the signal indicates intact non-degraded RNA species. Therefore, the removal of both the 
ethidium bromide staining and sodium hydroxide soak prior to transfer, coupled with the use of 
a Pharmacia Vacuum blotter (VacuGene XL^^) which allowed complete transfer in 20 minutes, 
gave very significant improvements in the Northern blotting technique.
4.7.3 Hybridisation.
Once transfer had taken place, the RNA was routinely fixed to the nylon membrane in our 
laboratory by exposure to UV light. This procedure had not, however, been standardised. The 
procedure was examined by using a time-course of exposure to UV (20 seconds to 10 minutes) 
on a series of identical filters. The filters were then hybridised to a human actin cDNA probe 
and the exposure time giving the optimum hybridisation signal identified (data not shown). The 
protocol necessary for this calibration was optimised for routine use (3 monthly) in the 
laboratory. Originally, the optimum UV exposure time was 3 minutes. Filters were stored after 
fixation at 4°C until use.
Non-optimised hybridisation methodology was thought to be having a significant effect on the 
lack of signal encountered in the laboratory. Key influences on rate and extent of hybridisation 
were identified as probe concentration and probe specific activity.
(Ï) Probe concentration
The initial rate of filter hybridisation depends upon the concentration of target RNA on the filter 
and probe in the solution. It is generally accepted that increasing the probe concentration will 
increase the rate of hybridisation but this will also favour reassociation of the probe in solution.
1 3 3
The addition of formamide to the solution however slows this rate of reassociation. In order to 
provide a compromise between quantity of probe and that which is practical to produce using 
Megaprime random-labelling (Section 2.7.1) and optimum hybridisation rate, a level of 5ng 
probe DNA/ml hybridisation solution was decided upon.
riil Probe Specific Activity
At the time this work was started, probe specific activity was not measured routinely in the 
laboratory. Initially the effect of mass of template DNA on percentage incorporation of the 32p- 
dCTP was assessed - Table 4.13. It was clear that the mass of DNA used as template in the 
Megaprime random priming reaction (see Section 2.7.1) was critical. The protocol recommends 
the use of 25ng DNA and the results presented in Table 4.12 support this. The error seemed to 
be in accurate measurement of DNA concentration. The cDNA probes were extracted from 
agarose gels using the Geneclean method (Section 2.6.10.1). This method however produces 
DNA contaminated with sodium iodide and ethanol which shifts the cDNA absorbance peak 
from 260nm to 215nm. The concentration of the DNA cannot therefore be quantitated exactly 
without reprecipitation. Removal of contaminants by reprecipitation also gave a higher 
percentage incorporation of radioactive nucleotide and a resulting higher specific activity, (see 
Table 4.12).
Standardisation of the amount of RNA loaded per well had been carried out using the human 
'house-keeping' gene, actin. However, there was a possibility that this gene could itself be 
inducible by treatment compounds. Therefore alternative methods were explored including 
photography of an ethidium bromide-stained duplicate gel and the methylene blue staining 
method described by Wilkinson et al (1990) (see Section 2.5.6). As a method for assessment of 
the integrity and amount of RNA loaded per well (by scanning densitometry) and the 
localisation of the major RNA species to be used as RNA markers, the methylene blue stain 
proved excellent (see Figure 4.13). The methylene blue stain also proved 3 fold more sensitive 
than the ethidium bromide stain (data not shown).
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Table 4.13 Analysis of the effect of mass of template DNA and reprecipitation on % 
incorporation of ^^P-dCTP and specific activity of labelled probe.
Sample Original 'Genecleaned' cDNA Reprecipitated cDNA
% incorporation specific activity 
(dpm/|ig)
% incorporation specific activity 
(dpm/|Lig)
200ng 23.0 2.28 X 108 72.2 4.35 X 108
25ng 32.4 1.32 X 109 90.6 2.09 X 109
5ng 18.6 1.49 X 109 64.4 2.30 X 109
jor—
r  1
..-S.'S:
— 28S
— 18S
-  5S
Figure 4.14 Total RNA Hybond N™ filter stained for one minute with 
0.03% (w/v) methylene blue in 0.3M sodium acetate pH 5.2 and destained in
distilled water. 10p,g total rat liver RNA loaded in lanes 1-6.
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4.8 Molecular Effects of Clofibrate and Phenobarbitone Treatment
Total RNA was isolated from snap-frozen samples of liver, kidney, heart and lung using the 
revised methodology described in section 4.8.1. Quantitation, Northern blotting and 
hybridisation were also carried out using the revised procedures outlined in Section 4.8. The 
species, tissue and inducer comparison involved analysis of 24 separate samples (plus negative 
and positive controls). For reasons described in Chapter 3, slot blotting was not seen as 
appropriate for quantitative assessment, therefore eight Northern blots were run (see Figures 
4.15, 4.17, 4.19 etc.), each using RNA from a different tissue. The rat liver Northern blots 
only are shown here. The graphical data given in Figures 4.16,4.18, 4.20 etc., were generated 
using scanning densitometry to measure relative intensity of bands and standardised to the 
relative intensities of the methylene blue-stained filters (prior to hybridisation). This effectively 
standardises for variation in amount of RNA loaded per well and thereby improves accuracy of 
quantitation. Each data point shown represents the average of the sample band intensities. The 
specificity of hybridisation (and washing stringency) for each blot was determined using a 
positive (0.5|ig unlabelled probe cDNA) and a negative (5pg yeast tRNA) control on the comer 
of each filter (data not shown).
4.8.1 Effect on microsomal mixed function oxidase transcription
4.8.1.1 CYP4A1 transcription
Figure 4.15 shows a Northern blot of total control, clofibrate-induced and phenobarbitone- 
induced rat liver RNA hybridised to a 2.1 kb rat CYP4A1 cDNA probe (four RNA samples per 
group). Although the 'streaking' effect seen does indicate some degradation of the RNA, it is 
still clear that the clofibrate-induced samples show a marked increase in CYP4A1 abundance 
over control and phenobarbitone-induced groups.
Figure 4.16 shows a graphical representation of this data with similar data for rat kidney, heart 
and lung samples. Corresponding data is shown for the guinea pig samples. It is clear that the
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Figure 4.15 Northern blot analysis of total rat liver RNA from conti'ol, clofibrate 
and phenobarbitone-treated rats. Hybridisation to^^P-labelled 2.1kb rat CYP 4A1
cDNA probe. lOpg total RNA loaded per well.
Northern blotting of isolated RNA was canied out as described in sections 2.5.5 and 
4.8.2.
Cl-C4
F1-F4
P1-P4
Control animal 
Clofibrate-treated animals 
Phenobarbitone-treated animals
Washing stringency :
2xSSC, 0.1% (w/v) SDS 
1 X SSC, 0.1% (w/v) SDS 
0.5 X SSC, 0.1% (w/v) SDS 
0.1 X SSC, 0.1% (w/v) SDS 
5xSSC
42°C 20 mins x 2
42"C 20 mins x 2
5 5 T 20 mins x 2
6 5 T 20 mins x 2
RT 20 mins
RT : room temperature
Filter exposed to preflashed X-ray film  for 72 hours (see Section 2.7.3)
137
I
pq
I
t l
S i
II 
II
Î Î
§
a) RAT
I
pq
12-,
Control
10- Clofibrate
Phenobarbitone8 -
6 -
4 -
2 -
NPD
LIVER KIDNEY HEART LUNG
b) GUINEA PIG
pq
3.5-,
i  I  2.5
I I , :
>>
0.5
NPD
LIVER KIDNEY HEART LUNG
Figure 4.16 : Relative abundance of CYP4A1 mRNA standardised for errors in 
RNA loading, as assessed by densitometric analysis of Northern blots.
NPD : No Peak Detected by scanning densitometry
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most significant induction is in the clofibrate-treated rat liver and kidney samples. 
Phenobarbitone treatment of these same samples failed to induce CYP4A1 and the data 
correlated well with the enzyme data shown in Figure 4.4. The only anomalous result is in the 
guinea pig lung. Clofibrate appears to significantly induce CYP4A1 in guinea pig lung. This 
result does not reflect the refractoriness of the guinea pig to clofibric acid and therefore this 
result should be treated with caution.
4.8.1.2 CYP2B  transcription
Figure 4.17 shows a Northern blot of total control, clofibrate-induced and phenobarbitone- 
induced rat liver RNA hybridised to a 1.8kb rat CYP2B cDNA probe (four RNA samples per 
group). Again, there is a streaking effect due to some degradation of RNA species but a clear 
induction of CYP2B mRNA can be seen in response to phenobarbitone treatment. Lanes C l-4 
show some variation in band or 'smear' intensity. Lane C4 in particular shows an increased 
band intensity over lanes C l-3. Methylene blue staining of this filter prior to hybridisation 
revealed an uneven loading of the control lane samples, C4 containing significantly more RNA 
(and hence more intense methylene blue staining) than the other control lanes. However, 
standardisation of the autoradiograph densitometry readings to methylene blue stain intensity 
produced a true representation of CYP2B induction.
Figure 4.18 shows a graphical representation of this data and similar data for rat kidney, heart 
and lung. Corresponding data for the guinea pig is shown on the lower graph. The mRNA 
abundance data can again be seen to correlate closely with the enzyme data shown in Figure 
4.7. There were marked differences in the constitutive level of expression of CYP2B in both 
species. Significant induction above control level were seen in response to phenobarbitone in rat 
liver and kidney and guinea pig liver. No signal was detected in guinea pig heart samples.
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Figure 4.17 Northern blot analysis of total rat liver RNA from control, phenobarbitone
and clofibrate-treated animals. 10|ig total RNA was loaded per lane and hybridised to 
32p-labelled 1.8kb rat CYP 2B cDNA probe.
Northern blotting was carried out as described in sections 2.5.5 and 4.8.2
C1-C4 : Control animals
P1-P4 : Phenobarbitone-treated animals
F1-F4 : Clofibrate-treated animals
Washing stringency :
2 X SSC, 0.1% (w/v) SDS 42"C 20 mins x 2
1 X SSC, 0.1% (w/v) SDS 42"C 20 mins x 2
0.5 X SSC, 0.1% (w/v) SDS 55"C 20 mins x 2
0.1 X SSC, 0.1% (w/v) SDS 65“C 20 mins x 2
5xSSC RT 20 mins
RT : room temperature
Filter exposed to X-ray film  for 72 hours (see section 2.7.3)
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Figure 4.18 Relative abundance of CYP2B mRNA standardised for errors in 
RNA loading, as assessed by densitometric analysis of Northern blots.
NPD : No Peak Detected by scanning densitometry
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4.8.2 Effect of Clofibrate and Phenobarbitone on Cellular Protooncogenes
Figures 4.19 to 4.21 show Northern blots of control, clofibrate-induced and phenobarbitone- 
induced total rat liver RNA hybridised to c-myc, c-fos and c-jun protooncogene DNA probes 
respectively. Figure 4.22 shows a summary of all the scanning densitometry data for each of 
the three protooncogenes examined in both rat and guinea pig tissues.
The nuclear transcription factor, c-myc had been shown to be induced at 14 days by treatment 
with clofibric acid, in Chapter 3. The basal level of the l.SOkb c-myc mRNA in this series of 
experiments proved barely discernible by eye although scanning densitometry allowed 
quantitation of this response. The induction of this gene in response to clofibrate was confirmed 
in rat liver, and in addition, was also seen in response to phenobarbitone treatment. These, 
however represented the only marked inductions of this gene, as shown in Figure 4.22. Rat 
kidney showed a marginal increase in c-myc expression in response to clofibrate treatment but 
all other tissues were non-responsive. No signal could be detected for the rat lung sample - 
either due to methodological error or due to insufficient constitutive levels of any of the three 
protooncogenes examined.
The protooncogenes c-fos and c-jun showed patterns of expression which were very similar to 
that of c-myc. Both c-fos and c-jun showed significant increases in mRNA abundance above 
control in response to clofibrate and phenobarbitone treatment, in rat liver. The remaining 
tissues were largely non-responsive showing no other clear inductions of these messenger RNA 
species. Again, no results are reported for c-fos and c-jun mRNA abundance in rat lung for the 
reasons described above.
1 4 2
c-myc — 
2.30kb mRNA
,  '.Y
28S
18S
5S
Figure 4.19 Northern blot analysis of total rat liver RNA from control, 
phenobarbitone and clofibrate-treated animals. 10|ig RNA was loaded per lane 
and hybridised to a^^P-labelled 2.00kb c-myc cDNA probe.
Northern blotting was carried out as described in sections 2.5.5 and 4.8.2
Lane 1 : Clofibrate-induced total rat liver RNA
Lane 2 : Control total rat liver RNA
Lane 3 : Phenobarbitone-induced total rat liver RNA
(The blot shown is representative of two duplicate c-myc Northern blots).
Washing stringency :
2 X SSC, 0.1% (w/v) SDS 30"C
1 X SSC, 0.1% (w/v) SDS 42°C
0.5 X SSC, 0.1% (w/v) SDS 55"C
5 XSSC RT
2 X 20 minutes 
2 X 20 minutes 
2 X 20 minutes 
20 minutes
RT : room temperature
Filter exposed to X-ray film  for 72 hours (see section 2.7.3)
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Figure 4.20 Northern blot analysis of total rat liver RNA from control, 
phenobarbitone and clofibrate-treated rats. lOjig RNA was loaded per lane 
and hybridised to a^^P-labelled 3.0kb c-fos genomic DNA probe.
Northern blotting was carried out as described in sections 2.5.5 and 4.8.2.
Lanes 1 & 2 
Lanes 3 & 4 
Lanes 5 & 6
Control total rat liver RNA 
Clofibrate-induced total rat liver RNA 
Phenobarbitone-induced total rat liver RNA
Washing stringency :
2 X SSC, 0.1% (w/v) SDS 
1 X SSC, 0.1% (w/v) SDS 
0.5 X SSC, 0.1% (w/v) SDS 
5xSSC
30'C 2 X 20 minutes
42° C 2 X 20 minutes
55°C 2 X 20 minutes
RT 20 minutes
RT : room temperature
Filter exposed to X-ray film for 72 hours (see section 2.7.3)
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Figure 4.21 Northern blot analysis of total rat liver RNA from control, 
phenobarbitone and clofibrate-treated animals. lOpg RNA was loaded per lane 
and hybridised to a^^P-labelled 2.6kb c-jun cDNA probe.
Northern blotting was carried out as described in sections 2.5.5 and 4.8.2
Lanes 1 & 2 : Control total rat liver RNA
Lanes 3 & 4 : Clofibrate-induced total rat liver RNA
Lanes 5 & 6 : Phenobarbitone-induced total rat liver RNA
Washing stringency :
2 X SSC, 0.1% (w/v) SDS 30°C 2 X 20 minutes
1 X SSC, 0.1% (w/v) SDS 42°C 2 X 20 minutes
0.5 X SSC, 0.1% (w/v) SDS 55°C 2 X 20 minutes
5xSSC RT 20 minutes
RT : room temperature
Filter exposed to X-ray film  for 72 hours (see section 2.7.3)
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Figure 4.22. Relative abundance of cellular protooncogene mRNA expressed as band intensity 
standardised to methylene blue stain intensity.
NPD : No Peak Detected by scanning densitometry 
R : Rat, GP : Guinea Pig, L : Liver, K : Kidney, H: Heart, Lg: Lung
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4.9 Discussion
The work detailed in this chapter was based upon the definition of the specificity of the hepatic 
protooncogene response to clofibric acid described in Chapter 3. The experimental strategy used 
was to look at these effects in species and tissues which were known to be non-responsive to 
peroxisome proliferators and compare these to responsive species and tissues. A comparison of 
a peroxisome proliferator, clofibrate with a tumour promoter (and hepatomegalic), 
phenobarbitone was also undertaken. The mechanistic role of these induction phenomena and 
their potential use as early markers of the non-genotoxic carcinogenic response could then 
hopefully be defined.
Hepatomegaly was observed in response to both clofibrate and phenobarbitone in the rat but 
neither compound had any effect on liver mass in the guinea pig. As discussed in Chapter 3, an 
effect normally associated with adaptive xenobiotic-induced hepatomegaly is induction of 
cytochrome(s) P450. Indeed total cytochrome P450 specific content was induced in rat liver but 
also in guinea pig liver in response to clofibrate and phenobarbitone. There was also a less 
significant induction of total P450 in rat kidney in response to clofibrate. The increases in total 
P450 on clofibrate administration could be seen to be due to an induction of the CYP4A1 
specific isoform (and in particular the œ-hydroxylation activity of this isozyme). This enzyme 
activity correlated well with CYP4A mRNA level in rat liver (as assessed by Northern blotting) 
indicating that the enzyme is under tight transcriptional control in this species and tissue.
Phenobarbitone is the prototypical hepatomegalic in rodents. Associated with the administration 
of phenobarbitone to rats is induction of CYP2B1 and CYP2B2 (Ryan et al, 1979) and, to a 
much lesser extent, CYP2C6 and CYP3A1 (Guengerich et at, 1992). Pentoxyresorufin O- 
depentylation is considered to be a good marker for CYP2B1 (Lubet et al, 1985) and can be 
induced by over 160-fold (Close et al, 1992) by phenobarbitone. The work detailed in this 
chapter showed CYP2B1 activity to be induced in rat liver, kidney and lung and also in guinea 
pig liver. The inductions of the CYP2B family were not associated exclusively with tissues 
undergoing growth in response to phenobarbitone induction.
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Therefore it seems there is an imperfect correlation between tissue growth and mixed function 
oxidase induction associated with clofibrate and phenobarbitone administration in these species. 
Indeed, Price et al (1982) showed that peroxisome proliferation and liver growth but not cell 
proliferation can be observed in the Syrian hamster. This may suggest that cell proliferation and 
cytochrome P450 induction are mediated via separate signalling pathways.
Since the limitations of using slot blots in the quantitative analysis of mRNA had been defined 
previously (see section 3.10.1), it was decided to use Northern blotting for the molecular 
analysis of gene expression in this study. Each Northern blot only allows a small number of 
samples to be analysed at one time, although the high degree of RNA species separation attained 
by electrophoresis of the sample allowed specific hybridisation. At the time this work was 
started, the Northern blotting technique was proving non-reproducible, little or no signal being 
detected on resulting autoradiographs. The molecular work detailed in this chapter was therefore 
made possible by a thorough review of the existing techniques and a series of alterations and 
standardisations. RNase protection assays offer an alternative to Northern blotting which would 
have given increased sensitivity over the latter technique. Had time permitted, it would have 
been useful to develop this methodology in our laboratory.
It was necessary to focus in this study on the protooncogenes which showed a response in 
Chapter 3 rather than looking at non-responsive genes. Using the revised Northern blot 
hybridisation technique to analyse the effects of clofibrate and phenobarbitone on 
protooncogene expression, I have shown a marked increase in myc, fos  & jun  mRNA 
abundance in tissues which exhibit an increase in cell mass.
Two factors should be considered at this time. Firstly, the lack of oncogene and mixed function
oxidase response seen in some tissues may be due to variations in tissue exposure to the
and kidney
compound(s). Makowska (198%) compared the rat and guinea pig liverjjexposure after a single 
dose of radiolabelled ciprofibrate and showed no significant difference at 4 hours. However, no 
equivalent data has been produced for extrahepatic tissues in the rat and guinea pig. Therefore,
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variation in compound distribution between tissues can not be discounted as a reason for the 
refractoriness of certain tissues.
Secondly, the use of a single time point (14 days) produced a limited view of the cell biology 
changes associated with these compounds. It should be noted that changes in protooncogene 
and mixed function oxidase transcription occurring before and/or after 14 days would not be 
observed using this protocol.
The ability of peroxisome proliferators to induce sustained enhancement of liver cell 
proliferation correlates with the degree of carcinogenicity (Marsman et al 1988, Bieri et al 
1986). In a study of acute hyperplasia induced by methylclofenapate (a peroxisome 
proliferator), Styles et al (1988) observed a marked increase in replicative DNA synthesis in 
mouse and rat liver but no effect in guinea pig hepatocytes. Equally, Price et al (1982) showed a 
marked stimulation of replicative DNA synthesis in rat liver after 7 days of treatment with 
nafenopin and anincrease in cell replication up to 54 days of treatment. This group argued that 
the contradictory evidence that the replicative DNA synthesis in response to a peroxisome 
proliferator is transient only (Eacho et al, 1991), may be due to both the relative potency of the 
compound administered and the dose level.
Hsieh et al reported that BR931 (a derivative of Wy-14,643) gives increase in levels of c-myc 
up to 56 days after commencement of administration. In previous work (Hsieh et al, 1991), the 
same group showed that during liver regeneration (subsequent to partial hepatectomy), there 
was a marked increase in the level of c-myc RNA which preceded the peak of DNA synthesis 
indicating that c-myc plays a role in regulating the entry of hepatocytes into the cell cycle.
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4.11 Conclusions
In conclusion, I have replicated the protooncogene effects shown to be associated with the 
administration of the peroxisome proliferator, clofibrate in rat liver. Further, this work has been 
extended to include the tumour promoter phenobarbitone which also has been shown to produce 
induction of hepatic cell cycle control genes upon 14 days of administration to the rat. These 
gene inductions closely correlate with the incidence of tissue growth, the guinea pig and extra- 
hepatic tissues being refractory. On the balance of available evidence however, it seems that 
these early proliferative responses in the rat are not exclusively predictive of non-genotoxic 
carcinogenesis but are also observed for compounds such as phenobarbitone which, in the rat, 
acts as a tumour promoter and not a complete carcinogen.
Having associated these changes with tissue growth, it was important to define whether these 
gene inductions are epigenetic in nature or would also be seen in response to genotoxic 
carcinogens. This is explored further in Chapter 5.2
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CHAPTER 5
CELL BIOLOGY OF GENOTOXIN AND NON-GENOTOXIN-INDUCED
RESPONSES IN RAT LIVER
1 5 3
5 .1  Summary
The results presented in the preceding chapters have shown that the protooncogene activations 
seen in response to the peroxisome proliferator, clofibrate and the tumour promoter, 
phenobarbitone are indicative of an early proliferative response of the liver to these compounds. 
However, in order to ascertain whether these responses are epigenetic or 'non-genotoxic' in 
nature or would also be seen in response to a 'genotoxic' initiation-promotion protocol, a 
comparison of phenobarbitone treatment with and without diethylnitrosamine initiation was 
carried out. The effect of withdrawing the treatment after 12 and 4 weeks (respectively) was 
also examined.
Both with and without prior initiation with DEN, phenobarbitone produced a significant 
hepatomegaly which returned to normal pre-dosing levels after withdrawal of treatment. 
Equally, all groups exposed to phenobarbitone showed induction of both total cytochrome P450 
specific content and pentoxyresorufin 0-depentylase activity (a marker activity of CYP2B). 
Interestingly, none of these three effects occurred in response to DEN initiation alone but only 
appeared after commencement of phenobarbitone administration. Further, withdrawal of 
treatment resulted in a return of all measured enzyme inductions to control levels - all responses 
therefore being adaptive. Examination at the subcellular level revealed strong pericentral 
enhancement of immunostaining using a specific CYP2B antibody. This finding was in 
accordance with the work of Bars & Elcombe (1991).
The observed increase in CYP2B protein abundance was reflected at the molecular level by 
marked induction of CYP2B mRNA as assessed by Northern blotting (indicating tight 
transcriptional control of the gene). Further examination of total RNA from treated and control 
rat livers by Northern blot analysis revealed modifications in the expression of the 
protooncogenes c-myc, c-fos and c-jun. The mixed function oxidase and protooncogene 
inductions seen in response to each treatment regime and their possible role as early markers of 
carcinogenesis, are discussed.
1 5 4
5 .2  Introduction
The preceding chapters have addressed the impact of non-genotoxic carcinogen treatment on 
microsomal mixed function oxidases and protooncogene activations at the protein and molecular 
(messenger RNA) level. These studies have placed particular emphasis on the effects of 
clofibrate and phenobarbitone treatment on rat liver. In Chapter 3 it was established that 
clofibric acid caused CYP4A1 induction (associated with a marked increase in hydroxylation of 
lauric acid) and an induction of the peroxisomal ^-oxidation spiral. Further it was postulated 
that these effects may be associated with transient or sustained induction of the protooncogenes 
c-fos and c-myc each of which have classically been associated with the cell cycle and tissue 
growth.
In Chapter 4, results are presented which show that the induction of CYP4A1 «s
associated with those tissues which undergo peroxisome 
proliferation whereas, induction of the nuclear protooncogenes, c-fos, c-jun and c-myc, is 
associated with tissues undergoing growth. As such, it seems that the induction of these 
protooncogenes are not specific to tissues undergoing peroxisome proliferation, but are clearly 
associated with the process of tissue growth.
The aim of the study outlined in this chapter was to define whether these protooncogene and 
mixed function oxidase changes are characteristic of non-genotoxic carcinogens, all 
carcinogens, tumour promoters or simply of tissues undergoing growth. The experimental 
strategy used was to compare the cell biology of responses to the tumour promoter 
phenobarbitone (an epigenetic protocol), to those associated with phenobarbitone promotion of 
diethylnitrosamine (DEN) initiation, in rat liver (a 'genotoxic' protocol).
The nitrosamines are 'versatile' carcinogens, inducing tumours in a wide variety of tissues and 
most species are susceptible to their action (Tannock & Hill, 1987). A single injection of DEN 
followed by partial hepatectomy can cause hepatocellular carcinoma at high frequency in rats
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(Solt-Farber procedure) (Soit & Farber, 1976), acting via an oxidative mechanism. DEN is 
oxidised by cytochrome P450 and ultimately is cleaved to produce an electrophilic alkylating 
species. This latter species is highly DNA-reactive and will interact with DNA in target tissues 
to produce covalent adducts. The initiation process then requires one cycle of cell proliferation 
so that repairable DNA lesions become permanent (Farber, 1982). Unlike initiation which is a 
rapid and reversible process, promotion of the initiated cell usually takes place over a prolonged 
period of time and is only reversible up to the development of the first tumour cell with 
autonomy of growth (Tannock & Hill, 1987).
The objectives of the study outlined in this chapter are summarised below:
(i) To compare the effects of an epigenetic and a genotoxic protocol on liver growth and 
induction of mixed function oxidase enzymes.
(ii) To examine the effect of these two protocols on the hepatic cellular protooncogenes c- 
myc, c-fos and c-jun
(iii) To draw conclusions as to the specificity of the observed cell biology changes to non- 
genotoxic carcinogenesis/tissue growth.
1 5 6
5 .3  Experimental
Male Charles River Wistar rats (145-155g) were housed in polypropylene cages with access ad 
libitum to tap water and basic ESL modified AIN-76A diet consisting of (%) maize starch (65), 
casein (20), solkafloc (5), maize oil (5), MOD AIN-76 mineral mix (3.5), AIN-76A vitamin 
mix (1), DL-methionine (0.3), choline bitartrate (0.2). Animals were kept at 21+ 2°C with a 
relative humidity of 55±10% and a day/night cycle of 12 hours.
(0 Diethvlnitrosamine Initiation. Sodium Phenobarbitone Promotion Studv
The study used a dosing regime based on that employed by Ledda-Columbano et a/(1992). Beer 
et al, (1988), and, more recently. Neveu et a/(1994). Diethylnitrosamine was administered as a 
single non-necrogenic dose (150mg/kg in 0.9% (w/v) saline) by intraperitoneal injection. 
Sodium phenobarbitone was administered in the diet at 0.05% (w/v) at the expense of the maize 
starch. The treatment groups and sizes are detailed in Table 5.1. All test animals received a 
single dose of DEN 14 days before the start of PB dosing (where appropriate). All animals 
were killed at the end of the appropriate treatment period by cervical dislocation.
fiB Sodium Phenobarbitone Study
Exposure to the non-genotoxic carcinogen without prior initiation was achieved using a protocol 
based on the work of Mesnil et al, 1988. Sodium phenobarbitone was administered at 0.1% 
(w/v) in the drinking water. Table 5.2 gives details of the treatment groups.
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Table 5.1 Treatment Groups and Dosing Regimen for Diethylnitrosamine Initiation/Sodium 
Phenobarbitone Promotion Study
Group Treatment (duration of treatment)
A l-3 Control
A4-6 Test (DEN)
B l - 3 Control
B4-6 Test (DEN + PB 4 weeks)
Cl-3 Control
C4-6 Test (DEN + PB 8 weeks)
D l-3 Control
D4-6 Test (DEN + PB 12 weeks)
E l-3 Control
E4-6 Test (DEN + PB 12 weeks + 4 weeks recovery)
Table 5.2 Treatment Groups and Dosing Regimen for Sodium Phenobarbitone Promotion 
Only
Group Treatment (duration of treatment)
F l -3 Control
F4-6 Test (PB 1 week)
G l-3 Control
G4-6 Test (PB 2 weeks)
H l-3 Control
H4-6 Test (PB 4 weeks)
11-3 Control
14-6 Test (PB 4 weeks + 2 weeks recovery)
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The two protocols are not quantitatively comparable due to the following differences
P aram eter DEN/PB study PB only study
Route of administration Diet Drinking Water
Dose level of phenobarbitone 0.05% (w/v) 0.1% (w/v)
Duration of exposure 12 weeks 4 weeks
Recovery period 4 weeks 2 weeks
The tissues in question were made available from two previous studies which were conducted at
Unilever Research and, as such, were not designed specifically for the study detailed in this 
chapter.
5.4  Effects on Relative Liver Weight
The effect of phenobarbitone and DEN initiation/phenobarbitone promotion on relative liver 
weight is shown in Figure 5.3. Administration of 0.05% (w/v) phenobarbitone in the diet after 
DEN initiation resulted in a statistically significant hepatomegaly at 12 weeks of phenobarbitone 
treatment (reaching a maximum of 119% of control value). This effect was seen to be adaptive, 
the liver returning to pre-dosing weight two weeks after withdrawal of the compound. 
Treatment with 0.1% (w/v) phenobarbitone in drinking water with no prior DEN initiation 
resulted in very significant hepatomegaly after 2 weeks reaching a maximum of 152% control at 
4 weeks of treatment. Once again, withdrawal of the treatment and subsequent recovery on 
control diet allowed the liver to return to its pre-dosing weight.
It should be noted that due to error in setting up the experiment, the two protocols are not 
quantitatively comparable. The DEN/PB study entailed treatment with 0.05% (w/v) 
phenobarbitone in the diet for 12 weeks whereas the PB only study entailed treatment with 
0.1% (w/v) phenobarbitone in the drinking water for 4 weeks. The results are therefore only 
comparable on a qualitative not a quantitative basis.
5 .5  Effects on Microsomal Cytochrome P450 Monooxygenase Enzymes
5 .5 .1  Total CO-discernihle Cytochrome P450 Specific Content
The total CO-discemible cytochrome P450 specific content of liver microsomes was assessed 
according to the method of Omura and Sato (1965) (Figure 5.4). Initiation with 
diethylnitrosamine produced no discernible effect on total cytochrome P450 specific content, 
but promotion of this initiation with phenobarbitone produced a induction of 167, 153 and 
182% on control values at 4, 8 and 12 weeks exposure respectively. This induction was, 
however, seen to be reversed to pre-promotion levels upon withdrawal of the phenobarbitone. 
The effect on total cytochrome P450 induction in response to sodium phenobarbitone alone was 
more marked. Four weeks of administration of phenobarbitone alone resulted in an induction of
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Figure 5.3. Relative Liver Weights (g/lOOg body weight) expressed as % control values 
after exposure to sodium phenobarbitone or sodium phenobarbitone promotion of DEN 
initiation.
Data points shown are mean ± s.e.m for 3 animals per group. Statistical analysis by 
Student's t-test and One-way Anova.
* significantly different from control p<0.05 
** significantly different from control p<0.01
Control values (g/lOOg body weight) :
A 4.53 ± 0.11 F 5.32 ± 0.13
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D 3.69 ± 0.10 I 3.81 0.12
E . 3.51 ± 0.15
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Figure 5.4 : Total cytochrome P450 specific content of liver microsomes from rats 
treated with (a) DEN initiation/PB promotion (b) PB promotion only, protocols.
Data points shown represent means ± s.e.m for 3 observations 
Statistical analysis by Student's t-test.
* significantly different from control value p < 0.05 
significantly different from control value p < 0.01
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280% of control in comparison to 167% of control values after DEN initiation. This maximal 
induction in response to phenobarbitone was again, shown to be adaptive in nature, reverting to 
pre-dosing levels after the compound was withdrawn. It is interesting to note that the induction 
seen in response to 14 days of phenobarbitone treatment in this study is comparable to that 
observed after treatment of Wistar rat liver with phenobarbitone (lOOmg/kg/day) by gavage for 
14 days (see Chapter 4).
5 .5 .2  CYP2B Pentoxyresorufin O-Depentylase Activity
Pentoxyresorufin O-depentylase was used as a marker of CYP2B1 activity in rat (Lubet et al, 
1985). Dosing with diethylnitrosamine produced no significant change in constitutive levels of 
CYP2B1 activity (Figure 5.5) (consistent with no significant increase in total cytochrome P450 
content). However, commencement of dosing with phenobarbitone after DEN initiation resulted 
in a maximal induction of CYP2B1 activity within 4 weeks , sustained as long as 
phenobarbitone dosing was continued and regressing to constitutive levels upon cessation of 
dosing.
CYP2B1 activity was induced significantly above control levels at all time points, increasing to 
a maximum at 4 weeks administration and, again adapting to removal of the compound by 
returning to constitutive levels.
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Data points shown represent means ± s.e.m for 3 observations 
Statistical analysis by Student's t-test.
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5 .5 .3  Immunolocalisation of CYP2B induction
Figures 5.8 and 5.9 show immunohistochemical localisation of CYP2B in paraffin wax- 
embedded sections of rat liver treated as described in section 5.3. Tissue processing for 
immunocytochemistry and subsequent immunochemical staining were carried out as described 
in sections 2.3.2 and 2.4.8 respectively.
Each figure shows a staining control in photograph 'A'. These sections were processed in 
exactly the same way as the remaining sections but no antibody was added to the incubations in 
order to provide a 'benchmark' for comparison to labelled sections. The remaining photographs 
show representative sections of tissue from each of the treatment groups indicated. Photograph 
'D' in each figure shows tissue sections after 2 weeks recovery (withdrawal of treatment).
In Figure 5.8 (DEN & phenobarbitone) the liver of control animals stained up uniformly and 
moderately with some minor localisation in the pericentral region. After treatment, however, the 
pericentral hepatocytes showed a greater degree of staining whilst the periportal cells remained 
similar to control. In Figure 5.9, the response is more marked, pericentral cells staining very 
positively for CYP2B and periportal cells remaining unstained. The zonal distribution of 
CYP2B which is thought to reflect the differences in microenvironment generated by the hepatic 
circulation across the liver (Bars and Elcombe, 1991), showed no discernible difference in 
response to the two treatment protocols. The adaptation of the liver to withdrawal of each of the 
two treatments is clear with a reversal of the increased intensity of staining in pericentral areas.
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5 .5 .4  CYP2B mRNA Induction as Assessed by Northern Blotting
Total RNA was isolated from snap-frozen samples of liver using the revised methodology 
described in section 4.8.1. Quantitation, Northern blotting and hybridisation were also carried 
out using the revised procedures outlined in section 4.8.
Figure 5.7 shows Northern blot of total rat liver RNA (lOpg per well) hybridised to a 1.8kb 
^^P-labelled CYP2B1 cDNA. The specificity of hybridisation and washing stringency for the 
blot was determined using a positive control (0.5|Lig unlabelled probe cDNA) and a negative 
control (5|ig yeast tRNA) on the comer of the filter (data not shown).
No signal was detected in any of the control groups or in either of the 'reversal' groups 
therefore quantitation of the induction seen was not possible. The blot does however reveal a 
marked induction of CYP2B mRNA in all treatment groups which corresponds to the induction 
in pentoxyresomfm O-depentylase activity and CYP2B protein abundance defined in sections
5.5.2 and 5.5.3.
5 .6  Effect on Hepatic Protooncogenes
Total RNA was isolated from snap-frozen samples of liver using the revised methodology 
described in section 4.8.1. Quantitation, Northern blotting and hybridisation were also carried 
out using the revised procedures outlined in section 4.8.
lil Effect on c-mvc
Figure 5.10 shows Northern blot analysis of representative samples of total RNA from each of 
the treatment groups (10|Xg total RNA per well). The wells were loaded with a control sample 
from one time point followed by the corresponding test sample. In order to ensure that all bands 
produced fell within the linear range of the film (see section 3.10.1) the film was exposed for 
36 hours only, therefore the resulting bands appear to be faint.
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After hybridisation to a 2.0kb c-myc cDNA probe, there appeared to be some uneven loading of 
total RNA in some of the wells. The filter was therefore stripped and stained using the 
methylene blue technique described in section 2.5.6. The intensity of methylene blue-stained 
bands was then measured by scanning densitometry and the c-myc band intensities divided by 
the corresponding methylene blue values to standardise for uneven loading of wells. The results 
of this analysis are shown in Figure 5.11.
As can be seen in Figure 5.11, there appears to be a significant induction above control values 
in groups B, C and D in response to treatment with DEN/PB and reaching a maximal induction 
of 2.5 fold at 8 weeks exposure to phenobarbitone. Treatment with phenobarbitone only (but at 
double the dose level and by a different route of administration) produced induction of c-myc in 
groups F and H, reaching a maximum of 3.5 fold at 4 weeks exposure to PB. In both cases, the 
c-myc induction seen reverts to approximately control levels upon withdrawal of the compound.
Group G in the phenobarbitone only study produced an anomalous result. Quantitation gave a 
c-myc:methylene blue ratio of less than 50% - this is unlikely to represent a true biological 
response as time points immediately before and after group G give 2.5 and 3.5-fold induction 
of c-myc respectively. The reason for this anomalous result is unclear although likely to be due 
to either inaccuracy in quantitation of bands or poor quality of the total RNA sample from this 
group. However, overall it is clear that the DEN initiated/PB promoted liver transcribes 
significantly increased levels of c-myc over control untreated liver.
riil Effect on c-fos
Figure 5.12 shows quantitation of a duplicate Northern blot to that shown in Figure 5.10 but 
hybridised to a ^^P-labelled c-fos cDNA probe. As previously, intensities of autoradiograph 
bands were standardised for uneven loading of wells using the methylene blue staining 
procedure outlined in section 2.5.6. The results shown are the ratios of band intensity to 
methylene blue stain intensity.
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Figure 5.11. Quantitation of the c-myc Northern blot shown in Figure 5.10 
by scanning densitometry.
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It is clear from the histogram that c-fos expression is increased in all treatment groups exposed 
to phenobarbitone. The increased expression of c-fos mirrors that of c-myc and drops back to 
approximately control levels after withdrawal of treatment (groups E and I). The rapid reversal 
of significant induction of both c-myc and c-fos indicates that these genes must be tightly 
transcriptionally controlled and therefore highly responsive to changes in the cellular 
environment.
liiil Effect on c-iun
Figure 5.13 shows quantitation of a duplicate Northern blot to that shown in Figure 5.10 but 
hybridised to a ^^P-labelled c-jun cDNA probe. Analysis of the data was performed in the same 
way as that described above.
The induction of c-jun mirrors the pattern of induction of c-fos - induction in all groups 
exposed to phenobarbitone and adaptation of this response back to approximately control levels 
upon withdrawal of the compound. The fold inductions of c-jun are, however, higher than 
corresponding inductions of c-fos {c-jun reaches a maximal induction of approximately 5-fold 
control levels in group D). Group G provides an anomalous result appearing much lower than 
would be expected at 2 weeks exposure to phenobarbitone alone. The reason for this is unclear 
but again could be due to inaccuracy in densitometry/quantitation of bands or poor quality of 
RNA in this group.
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5 .8  Discussion
The objective defined at the outset of this study was to compare the cell biology of responses to 
phenobarbitone treatment with and without prior diethylnitrosamine initiation, thereby providing 
a comparison (at early time points) of a genotoxic and a non-genotoxic protocol. It was hoped 
that the degree of specificity of the responses seen in Chapters 3 and 4 to non-genotoxic 
carcinogens could then be defined. The qualitative comparison of effects detailed in the chapter 
could not, however be supported by a quantitative comparison due to the two treatment regimes 
with phenobarbitone being administered at different doses and by different routes.
As described in section 1.3.2.2, phenobarbitone is a prototypical hepatomegalic and produced a 
significant increase in liver:body weight ratio in response to each of the treatment regimes. The 
extent and timing of the hepatomegaly reflected the dose level given - the 'phenobarbitone-only' 
groups displaying a more significant hepatomegaly at earlier time points than the DEN/PB 
groups.
Examination of the effect of the two dosing protocols on mixed function oxidases revealed 
significant inductions of total cytochrome P450 specific content in all treatment groups exposed 
to phenobarbitone. This increase is likely to have been driven by a parallel increase in pentoxy­
resorufin O-deoentvlase activity (the marker activity of CYP2B1). Equally, DEN induces 
(Suzuki a/, 1994)
CYPlAjuna, naa time permitted, confirmation of this using ethoxyresorufin 0-deethylase assay 
would have been worthwhile. With respect to CYP2B, the localisation of the induction in the 
liver was shown to be the same in response to both protocols. It seems, therefore that the early 
changes in mixed function oxidase activity in response to the two protocols are not sufficiently 
different to be 'diagnostic' of non-genotoxic carcinogen activity and the responses are not 
specific to non-genotoxic carcinogens. Analysis of samples at the molecular level revealed that 
the CYP2B enzyme and protein induction seen was underpinned by an induction of the CYP2B 
mRNA in all treatment groups (although quantitation of this response was not possible).
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The three protooncogenes examined at the molecular level {c-myc, c-fos and c-jun) all showed 
marked induction in response to both treatment protocols and this inductions seem from the data 
presented to be independent of prior initiation by DEN. However, as in the time course 
experiment detailed in Chapter 3, each time point group only represents a snap-shot of events 
and it is possible that some very early transient events (perhaps in response to DEN alone) may 
have been missed. Further work focussing on the very early time points may give a clearer 
distinction between genotoxic and non-genotoxic potential.
The induction of c-myc in all treatment groups is consistent with tissues undergoing growth, c- 
myc has been shown to be required to maintain proliferation and may deregulate control of exit 
from the cell cycle when over-expressed (Kelly et al, 1983). The findings shown here are 
supported by the results of Lafarge-Frayssinet (1990) who reported an overexpression of c-fos, 
c-myc and c-Ki-ras in response to phenobarbitone and a Solt-Farber protocol in male Wistar 
rats. Further, Richmond et a/(1988) reported that the volume of liver expressing c-myc protein 
was increased by 60% in animals initiated with DEN and promoted by phénobarbital. It is clear 
from the relative liver weight data reported that treatment groups were all undergoing liver 
growth and therefore activation of genes involved in cell cycle control would be expected. 
Increased expression of c-myc is observed in genotoxin-induced preneoplastic lesions in the rat 
and also in whole liver following carcinogen exposure and after partial hepatectomy indicating 
that c-myc induction is a common and possibly obligatory event in hepatocarcinogenesis. 
Strom and Faust (1990) proposed that the activation of the expression of the c-myc gene in 
hepatocellular tumours is crucial to the neoplastic process, and that cells which contain the 
'activated' c-myc gene are at a selective growth advantage, possibly through their enhanced 
sensitivity to endogenous or exogenously supplied growth factors and through fundamental 
alterations to their growth factor requirements (Stem et at, 1986). The induction of c-myc by 
phenobarbitone may therefore play a role in conferring a growth advantage on certain cells and 
thus tumour promotion activity.
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There is very little published data on the early effects of DEN initiation and phenobarbitone 
promotion. However, one recent study by Suzuki et a/(1994) showed acute differential 
expression of a number of genes within 24 hours of a single dose of DEN. A 4.6-fold increase 
in c-jun expression at 2 hours post-dose suggests that the AP-1 transcriptional factor is involved 
in the response to DEN. The induction of c-jun was accompanied by a parallel induction in 
glutathione-S-transferase which contains two AP-1 binding sites located -2.5kb upstream from 
the GST transcription start site. It is possible therefore that the c-jun induction seen at early time 
points could be responsible for activation of the GST gene in response to the oxidative stress 
produced by DEN.
Pinkus et a/(1993) showed that genes such as GST which are induced by phénobarbital are 
mediated by regulatory elements containing AP-1-like binding sites. Indeed this group showed 
that phénobarbital induced an increase in AP-1 binding activity in nuclear extracts of cultured 
hepatoma cells. It follows therefore that, in view of the AP-1 in the control of cell proliferation 
and tissue growth, the induction by phenobarbitone of AP-1 binding activity may provide a 
mechanism for the tumour-promoting activity of this compound.
The induction of c-fos seen in this study correlates well with the c-jun induction adding weight 
to the involvement of the AP-1 transcriptional activator in either/or protection against oxidative 
stress and cell proliferation. Evidence suggests that c-fos may also play a role in later stages of 
neoplasia. Corcos et û/(1984) and Corral et a/(1985) reported that c-fos transcripts were 
elevated in hepatomas and perinodular hepatocytes in comparison to control liver from animals 
17 months after initiation with DEN.
In conclusion, the work outlined in this chapter suggests that mixed function oxidase activity 
and induction of the protooncogenes c-myc, c-fos and c-jun at the time points investigated, do 
not provide characteristic early markers of non-genotoxic carcinogenesis. Very similar changes 
in these activities are seen in response to phenobarbitone with and without prior initiation with
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the genotoxic carcinogen, diethylnitrosamine. It seems that the effects observed are adaptive 
responses to increased metabolic load and induction of genes involved in cellular growth control 
in response to chemical mitogenic stimulus.
It would certainly be of interest to extend this study to look at other oncogenes, for example, 
Ha-ras which iB thought to act cooperatively with c-myc and also some earlier time points to 
better define the initial and possibly transient response to the compound. It could be postulated 
that the oncogenes examined (in particular c-myc and c-fos) may show a transient immediate 
induction as a protective measure against oxidative stress followed by a further prolonged 
induction driving cell proliferation associated with tumour promotion.
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CHAPTER 6
THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR 
GENE TRANSFECTION STUDIES
1 7 8
6.1 Summary
The multitude and apparently coordinated activation of peroxisomal ^-oxidation genes and 
CYP4A1 in addition to the protooncogene activations detailed in the preceeding chapters 
suggests a common mechanism of activation. Recent work has indicated that a member of the 
steroid hormone receptor superfamily, the peroxisome proliferator-activated receptor (PPAR) 
(Issemann & Green, 1990) may play a key role in regulation of these events. The details of the 
mechanism of activation of the PPAR, however, remain to be elucidated.
An in vitro model of peroxisome proliferator-associated effects was established in our 
laboratory. The culture conditions of the peroxisome proliferator-responsive cell line, H4IIEC3 
were optimised and the original methodologies used by Tugwood et al (1992) used to transfect 
the PPAR and its response element in the acyl CoA oxidase gene into the hepatoma cell line. 
(Tugwood's model used the rat hepatoma cell line, Hepa 1). The results detailed in this chapter 
accurately reproduce and thereby further validate the work of Tugwood et al (1992). In the 
studies outlined in this chapter, PPAR was shown to play a regulatory role in mediation of the 
response of H4IIEC3 cells to peroxisome proliferators.
Detailed examination of the above H4IIEC3 model showed that the retinoid X receptor (RXR) 
acts cooperatively with PPAR in my in vitro system and dramatically increases the ability of 
PPAR to cause transcription of specific target genes (for example, acyl CoA oxidase). The 
cooperation seen in the H4IIEC3 cell line between PPAR and RXR strongly mimics that seen in 
the Hepa 1 line by Tugwood et al (1992). Further, I examined the endogenous effect of receptor 
transfection by analysing constitutive palmitoyl CoA oxidation and showed that PCoA activity 
is induced concurrently with CAT activity. In light of these findings, the role of the PPAR/RXR 
in peroxisome proliferation and its possible role in peroxisome proliferator-induced 
carcinogenesis is discussed.
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6.2 Introduction
The preceeding chapters have examined the effect of non-genotoxic carcinogens on mixed 
function oxidases and genes involved in the control of cell growth in both susceptible and non- 
susceptible tissues and species. In Chapters 3 and 4 it was established that the process of 
peroxisome proliferation is related to induction of CYP4A and enzymes of the p-oxidation 
spiral. Further evidence was presented of nuclear protooncogene activations occu^ng within the 
same time frame i.e. within 14 days of commencement of treatment with the peroxisome 
proliferator sodium clofibrate. It could therefore be postulated that these inductions are 
coordinate in nature and may possibly be mediated through the same mechanism(s).
A novel member of the steroid hormone receptor superfamily termed the peroxisome 
proliferator activated receptor (PPAR) (section 1.6.2) has been strongly implicated in the 
mediation of the induction of peroxisomal p-oxidation and CYP4A (Issemann & Green, 1990). 
These latter studies showed that a chimaeric receptor constructed using the DNA binding 
domain of the estrogen receptor and the putative ligand binding domain of the PPAR was able 
to activate an estrogen-responsive gene in the presence of peroxisome proliferators. A 
comparison of primary amino acid sequences within the steroid hormone receptor family 
revealed considerable identity between the DNA recognition helix of the DNA binding domain 
of the PPAR and the other nuclear hormone receptors that bind to the sequence TGACCT 
(Umesono and Evans, 1989, Smith et al, 1991). Issemann and Green (1990) therefore 
predicted that PPAR would recognise a similar motif.
The enzyme acyl CoA oxidase (AGO) is widely used as a marker of peroxisome proliferator 
action and represents the rate-limiting step in peroxisomal p-oxidation. Measurement of this 
enzyme has taken on particular importance since its tentative link with the tumourigenic process. 
The oxidative stress hypothesis (Reddy and Lalwani, 1984, Kasai et al, 1986) supposes that the 
elevated level of hydrogen peroxide produced by AGO results in the formation of DNA-reactive 
oxygen molecules which can initiate carcinogenesis.
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Examination of the promoter region of the rat acyl CoA oxidase gene (Osumi et al, 1987) 
revealed several DNA binding motifs characteristic of nuclear hormone receptors. Construction 
of 5’ and 3' deletions in the acyl CoA oxidase regulatory sequence and testing of these in co­
transfection assays with the PPAR located the PPRE between -570 and -549 (Tugwood et al, 
1992). It is clear therefore that the ability of peroxisome proliferators to stimulate transcription 
of the acyl CoA oxidase gene is mediated by PPAR.
Subsequent work has shown the peroxisomal trifunctional protein and CYP4A6, the major 
rabbit lauric acid 12-hydroxylase, to contain peroxisome proliferator response elements 
(palindromic repeat sequences) within the 5'-flanking regions of their genes and are activated by 
PPAR (Tugwood et al, 1992, Muerhoff et al, 1992, Bardot et al, 1993).
More recently, it has also been demonstrated that PPAR activates these genes through 
heterodimer formation with the retinoid X receptor RXR (Kliewer et al, 1992, Issemann et al, 
1993, Gearing et al, 1993, Keller et al, 1993, Bardot et al, 1993) and that the RXR ligand, 9- 
cis retinoic acid enhances this action.
The rat Reuber hepatoma cell line, H4IIEC3 which has been shown to be responsive to 
peroxisome proliferators (Osumi et al, 1990) unlike the Hepal cell line, was used as a model 
cell line for PPAR/RXR transfections using the acyl CoA oxidase promoter region (-1273/-470) 
linked to a CAT reporter gene (Tugwood et al, 1992). The response of this system to Wy- 
14,643 and/or 9-cis retinoic acid is reported in this chapter.
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The objectives of the study outlined in this chapter were :
(i) To establish an in vitro model for examination of regulation of the peroxisome 
proliferator-associated gene activations (detailed in Chapters 3 and 4).
(ii) To repeat the PPAR transfection experiments in the responsive H4IIEC3 cell line and 
validate the results of Issemann et al (1993) in my in vitro system.
(iii) To further examine the effect of transfection of the PPAR with and without RXR on the 
constitutive peroxisome proliferative response of this cell line.
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6.3 Experimental
In order to investigate the effect of the pSG5.PPAR and pSG5.RXR expression vectors on 
stimulation of the pACO(-1273/-471)G.CAT reporter plasmid in the presence and absence of 
Wy-14,643 and 9-cis retinoic acid, it was first necessary to set up cell culture facilites within the 
laboratory and then to define suitable culture conditions for the H4IIEC3 cell line (section 6.4). 
Transient cotransfection assays were then carried out as described in section 2.9. A schematic 
diagram of the transfection methodology is shown in Figure 6.1.
Promega Maxi Plasmid preparations were performed on the carrier plasmid pBluscript, 
expression vector pSG5, the PPAR and RXR expression vectors pSGS.PPAR and 
pSGS.RXR, the P-galactosidase expression plasmid pCHl 10, and the reporter vector pACO (- 
12737-471)G.CAT. All plasmids were then diluted to Ipg/pl.
A number of methods have been devised to introduce foreign DNA into eukaryotic cells, the 
most commonly used being DNA/calcium phosphate coprecipitation or methods based on the 
use of high molecular weight polycations such as DEAE-Dextran. These methods however, 
produce a high variability in transfection efficiency and cell survival and the methodology 
requires optimisation for each particular cell line. The transfection method used in this work is 
based on compacted lipid-coated plasmid DNA (Feigner et al, 1987). The reagent used, DOTAP 
(N-[l-(2,3-Dioleoyloxy)propyl)-N,N,N-trimethyl-ammonium methylsulphate, Boehringer 
Mannheim) forms positively-charged liposomes which complex with nucleic acids. The lipid- 
nucleic acid complex, when applied to cells in culture, fuses with the cellular plasma 
membranes and releases the nucleic acid into the cell. This technique gives advantages of 
increased efficiency and cell survival.
The transfection level measured within the cell is highly dependent upon the transfection 
efficiency obtained within the target cell and therefore is was necessary to include an internal
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control in each transfection reaction in order to standardise differential transfection efficiencies. 
The plasmid pCHllO (Stratagene) contains a functional lac Z  gene which, when expressed 
under the control of the SV40 early promoter, produces p-galactosidase which can then be 
assayed colorimetrically at 595nm using ONPG as substrate.
The transfection detailed in this chapter, was performed as triplicate plates in a 'Latin Square'
(Figure 6.2). The reporter plasmid pACO(-l2737-471)G.CAT was transfected into H4IIEC3
cells in the presence or absence of the pSG5.PPAR and pSGS.RXR expression vectors. Each
of these transfections was performed in the presence or absence of the potent peroxisome 
Oo'^M)
proliferator Wy-14,643jand the retinoid X receptor ligand, 9-cis retinoic acidj[ After dosing for 
40 hours, cells were harvested from each plate and the cytosol extracted by three rounds of 
freeze-thaw cycles.
The reporter gene system used was the CAT (chloramphenicol acetyl transferase) gene. Since 
CAT is a bacterial gene, levels of CAT enzyme can be easily assayed with little or no 
background constitutive cellular gene activity. CAT activity was measured using a Quan-T- 
CAT™ assay system (Amersham) (Figure 6.3). In this system, chloramphenicol acetyl 
transferase enzyme in cell extracts acetylates biotinylated chloramphenicol with tritiated 
[3H]acetyl coenzyme A. Biotinylated chloramphenicol binds to streptavidin-coated polystyrene 
beads which are centrifuged to form a pellet. The supernatant, containing unreacted acetyl 
coenzyme A is removed and liquid scintillation cocktail added to the pellet and counted. The 
scintillation signal generated is a measure of CAT activity.
Investigation of the constitutive response of the cells to the transfection was analysed by 
measurement of palmitoyl CoA p-oxidation activity in cell homogenates (section 2.4.5).
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PLATE PLASMID (|ig) LIGAND
pBluscript pSG5 pSGS.PPAR PSG5.RXR pCHllO pACOG.CAT
1 a-c 5 1 . 3 1
2 a-c 5 1 3 1 Wy
3 a-c 5 1 3 1 9-cis
4 a-c 5 3 1 Wy + 9-cis
5 a-c 4 1 1 3 1
6 a-c 4 1 1 3 1 Wy
7 a-c 4 1 1 3 1 9-cis
8 a-c 4 1 1 3 1 Wy + 9-cis
9 a-c 4 1 1 3
10 a-c 4 1 1 3 1 Wy
11 a-c 4 1 1 3 1 9-cis
12 a-c 4 1 3 1 Wy + 9-cis
13 a-c 4 1 1 3 1
14 a-c 4 1 3 1 Wy
15 a-c 4 1 1 3 1 9-cis
16 a-c 4 - 1 1 3 Wy + 9-cis
Figure 6.2 Transfection protocol to investigate the effect of PPAR and RXR transfection and 
administration of the peroxisome proliferator, Wy 14,643 and 9-cis retinoic acid on the 
transcription of an acyl CoA oxidase reporter plasmid.
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6.4 Optimisation of Culture Conditions
Figure 6.4 shows a light micrograph of the H4IIEC3 cells growing in monolayer culture in 
supplemented Dulbecco's Modified Eagle Medium (section 2.8.1). The cells were originally 
derived from an H-35 Reuber rat hepatoma (Sutherland, 1961) and display epithelial 
morphology in monolayer culture. When sufficient cell division had taken place, the monolayer 
reached a maximum of 80-85% confluence. After this time, newly divided cells exhibited 
properties of the transformed phenotype by growing on top of the existing monolayer indicating 
a lack of contact inhibition. The maximum confluence achievable was taken into account when 
seeding for transfection studies - ensuring that the monolayer exhibited approximately 50% 
confluence prior to transfection and dosing.
Initially, it was important to establish the optimum culture medium for H4IIEC3 cell growth. 
The two most likely candidate media were Hams' Nutrient Mixture (FIO) and Dulbecco's 
Modified Eagle Medium (DMEM) each supplemented with 10% (v/v) foetal calf serum, 
gentamycin (O.lmg/ml) and L-glutamine (2mM). DMEM was the medium recommended in the 
ATTC catalogue and FIO suggested by Peter Goldfarb, University of Surrey (personal 
communication) as a medium high in nutrients to support the cells during routine subculture and 
transfection (a process which could result in reduced cell viability). The response of the cell line 
to each medium was analysed by examining plating efficiencies and growth curves.
6.4.1 P lating  Efficiencies
Cell cultures were set up as described in section 2.8.3 and maintained for 10 days at 37“C in 
5% CO2 , 95% air without renewing the growth medium. After 10 days, cell colonies were 
stained with Grunwald-Giemsa stain (section 2.8.3) and plates examined on a light box for cell 
colonies. The results of the plating efficiencies are shown in Figure 6.5. It is clear that the cells 
responded better to the highly stringent conditions when grown in DMEM than FIO, showing 
plating efficiencies of 21.4% ± 1.4% and 0% respectively.
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Figure 6.4 Light photomicrograph of rat Reuber H4IIEC3 cells in monolayer culture.
Growth medium : Dulbecco's Modified Eagle Medium supplemented with 10% (v/v) PCS 
gentamycin (O.lmg/ml), L-glutamine (2mM)
Magnification : x 320
189
1 X FIO supplemented with 10%(v/v) FCS 1 x DMEM supplemented with 10% (v/v) FCS
gentamycin (O.lmg/ml), L-glutamine (2mM) gentamycin (O.lmg/ml), L-glutamine (2mM)
200 H4IIEC3 cell s/100mm plate, 8 days incubation in culture medium as described 
Colonies visualised using Grunwald-Giemsa stain (section 2.8.3)
Growth Medium No. cells seeded/ 
100mm plate
No. colonies 
visualised (8 days)
% plating efficiency
Ix F lO 200 0 0
no colonies visualised on any p] ate after 8 days
1 X DMEM 200 33 16.5
200 44 22.0
200 50 25.0
200 42 21.0
200 25 22.5
Mean ± sem 
IxD M EM 200 38.8 ±4.4 21.4+1.4
Figure 6.5 : Comparison of plating efficiencies of H4IIEC3 cells in Ham's 
Nutrient Mixture (F-10) and Dulbecco's Modified Eagle Medium (DMEM)
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6.4.2 Growth Curves
Initially, 3 x 10  ^H4IIEC3 cells were seeded in each of 12 x 25cm^ culture flasks. Six of these 
flasks contained DMEM and six with Ham's FIO Nutrient Mix; both of these media were 
supplemented with 10% (v/v) foetal calf serum, gentamycin (O.lmg/ml) and L-glutamine 
(2mM). One flask from each group was harvested at time periods up to 110 hours and cells 
counted using a Neubauer haemocytometer.
Figure 6.6 shows a graphical representation of cell growth over 110 hours post-seeding. The 
data points shown are the average of 8 haemocytometer readings. An exponential curve fit has 
been applied to the calculated data points as doubling time for cells in culture should be 
constant.
The doubling time calculated by extrapolation from the curve for DMEM was 24.5 hours 
compared to a doubling time in FIO of 38 hours. This clearly indicates that over 110 hours (the 
time period of the transfection experiments) the H4 cells divide more rapidly in DMEM than 
FIO medium.
It was concluded on the basis of both plating efficiencies and growth curves, that DMEM was 
the medium of choice for culture of H4IIEC3 cells and this medium was therefore used in all 
subsequent work.
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Calculation of doubling time:
i) FIO Doubling time =
ii) DMEM Doubling time =
F2 time point - FI time point 
108.5-70.5 = 38 hours
D2 time point - D1 time point
73.5 - 49.0 = 24.5 hours
Figure 6.6: Graphical comparison of H4IIEC3 cell growth in Ham's Nutrient 
Mixture (FIO) and Dulbecco's Modified Eagle Medium (DMEM)
Data points shown are averages for 8 determinations per group
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6.5 Effect of Cotransfection of PPAR and Retinoid X Receptor on Activation 
of the Acyl CoA Oxidase Reporter Plasmid
6.5.1 Chloramphenicol Acetyl Transferase Assay
Figure 6.7 shows a histogram of CAT activities from each transfection group standardised to 
their respective transfection efficiencies (units of p-galactosidase activity).
The constitutive level of expression in the absence of either receptor or ligand (first column 
from the left) is likely to indicate the presence of endogenous PPAR in the H4IIEC3 cell line. 
Alternatively this may be due to the rabbit globin promoter driving some CAT production. 
Addition of W y-14,643 to the same samples gave a three fold increase in receptor activation, 
supporting Osumi's findings that H4IIEC3 cells are indeed responsive to peroxisome 
proliferators (Osumi et al, 1990). The apparent receptor activation seen with transfected PPAR 
but with no ligand strongly suggests the presence of a yet unidentified endogenous ligand for 
the PPAR either in this cell line or present in the culture medium and/or serum. In addition, the 
H4 cells show constitutive expression of both endogenous RXR and 9-cis retinoic acid.
Cotransfection of the PPAR and RXR with Wy-14,643 and 9-cis retinoic acid produced a 
seven-fold increase in CAT activity relative to samples without receptor or ligand (standardised 
to p-galactosidase to correct for transfection efficiency). These findings indicate that the PPAR 
and RXR can cooperate at a functional level to maximise the standardised CAT response within 
the H4IIEC3 cell line (in agreement with Issemann et al, 1992).
The Quan-T-CAT system I used in generation of these data offered advantages of increased 
simultaneous sample processing capacity and speed over conventional l^C-chloramphenical 
techniques. In addition, the technique markedly improved sensitivity over conventional 
techniques - this was critical in using a cell line of poor transfection efficiency such as H4IIEC3 
cells.
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6.5.2 Influence of Receptor Transfection on KCN-Insensitive Palmitoyi CoA 
p-oxidation
Figure 6.8 shows a histogram of Palmitoyi CoA oxidase activities from each transfection group 
standardised to their respective transfection efficiencies ( p-galactosidase activity in U.pl/hr). 
The protocol used in this experiment is outlined in section 2.9.3 and was largely non-optimised 
for H4 cell homogenates. This may acount for the high standard errors of the mean shown. 
However, it seems clear from the results that the H4IIEC3 cells are responsive to the 
peroxisome proliferator Wy-14,643 showing a 6-fold induction in standardised palmitoyi CoA 
oxidation activity without transfection. Further, the results indicate an increase in constitutive 
activity across the groups, reaching a maximum in response to transfection of both receptors 
and administration of both ligands. Therefore, it can be inferred that increasing the constitutive 
production of PPAR by transfection of the pSGS.PPAR expression vector results in increased 
receptor binding to both the PPRE in the ACO.G.CAT reporter gene and in endogenous acyl 
CoA oxidase.
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* Note :
'Cooperativity' in this context describes the observation that the receptor activation observed in 
the presence of both receptors and both ligands is greater than that seen in the the presence of 
one receptor (and its ligand) alone. The significance of the cooperativity has however, not been 
analysed statistically as n=3 for each observation. Statistical analysis with this low number of 
repeat observations would therefore not add much to the analysis.
In future transfection experiments of this nature the use of more specific controls should 
perhaps be considered. The work reported here uses the pBluscript plasmid to control for mass 
of DNA transfected, and as such is a valid control. However, further confirmation of the 
specificity of the response could be gained from using mutant RXR cDNA sequences in the 
pSG5 expression plasmid to further control for the presence of RXR sequences. This would 
further exclude any non-specific effects on receptor activation - this would be especially 
important if either the absolute level of receptor activation or the increase in activation in 
response to cotransfection with RXR.pSG5 was small.
6.6 Discussion
Tugwood et al (1992) demonstrated that the PPRE contained within the 5' flanking sequence of 
the rat AGO gene is located 570bp upstream from the transcription start site. The reporter 
plasmid used in this work (kindly donated by Stephen Green, Zeneca) pACO(-581/+20)CAT, 
contained the 5' flanking sequence of the rat AGO gene from -581bp to +20bp placed upstream 
of the GAT coding sequence. This was transfected into H4IIEG3 cells in the absence or 
presence of the PPARa and RXRa expression plasmids and their ligands (Figure 6.2). The 
highest stimulation of the AGO.G.GAT reporter plasmid was observed in the presence of both 
PPAR and RXR and both their cognate ligands, indicating that maximum cooperation between 
the two signalling pathways was dependent upon simultaneous activation of both receptors.
The constitutive level of expression of the GAT enzyme in the absence of both receptors and 
ligands indicates the presence of endogenous PPAR in the H4IIEG3 cell line. Equally, 
stimulation of PPAR was observed with 9-cis-retinoic acid indicating involvement of the H4 
endogenous RXR activity. Addition of the peroxisome proliferator W y-14,643 to the 
transfected cells resulted in a three-fold increase in receptor activation, supporting Osumi's 
findings that these cells are indeed responsive to peroxisome proliferators. Taken together, 
these results show that the PPAR and RXR signalling pathways converge in the regulation of 
the acyl GoA oxidase promoter. It is important to note, however, that the cooperativity seen 
may not have been maximal and that altering the amounts or ratio of amounts of PPAR to RXR 
may have resulted in even more cooperativity. As such, these results represent only a 'window' 
in the concentration-response curve.
Furthermore, the apparent activation seen with transfected PPAR but without ligand strongly 
suggests the presence of an as yet unidentified endogenous ligand for PPAR. This ligand could
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either be present constitutively in the cell line or could have originated in the cuture medium 
and/or supplements applied to the cells.
A natural ligand for the PPAR remains unidentified. Evidence that natural factors such as high 
fat diets (Flatmark et al, 1988), starvation, possibly diabetes and the hypolipidaemic steroid 
dehydroepiandrosterone (DFIEA) (Schwartz et al, 1988, Frenkel et al, 1990) can induce 
peroxisome proliferation suggests that the response is a physiological adaptation to some 
biological stimulus; as such, it is reasonable to assume that a natural ligand exists. It is possible 
that accumulation of a lipid product resulting from a perturbation of lipid homeostasis within the 
ce ll, could provide a natural ligand for the PPAR . Potentially such a ligand would play a role 
in the control of fatty acid or cholesterol metabolism (for example the co-hydroxy metabolite of a 
fatty acid such as arachidonic acid). Alternatively, from an examination of the peroxisome 
proliferators which have been shown to activate the PPAR, it is possible that some of these may 
bind directly to the receptor, although the marked structural diversity contra-indicates a unifying 
mechanism of receptor activation for all these compounds. Experiments using radiolabelled 
nafenopin have, so far, shown no binding (Issemann & Green, 1992) although this could be 
due to the low affinity of nafenopin for PPAR, the low level of PPAR expression in the 
transfected model or due to competitive binding of the peroxisome proliferator by other 
molecules, for example, PPBP (Alvares et al, 1991). Although binding of peroxisome 
proliferators to the PPAR has not been demonstrated, displacement of linoleic acid binding to 
vaccina virus-generated PPAR by peroxisome proliferators has been demonstrated (Cliff 
Elcombe, personal communication). It is possible also, that peroxisome proliferators exert their 
effects by the induction of endogenous ligands (Lock et al, 1989, O'Malley, 1989,1990). 
Keller et al (1993) reported that natural fatty acids and especially polyunsaturated fatty acids 
activate the PPAR as potently as Wy-14,643. Additionally, work by Gottlicher et al (1992) 
tested a series of compounds related to lipid metabolism and showed that 150jiM concentrations 
of arachidonic and linoleic acid and saturated fatty acids activated a PPAR-glucocorticoid 
receptor chimera.
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The PPAR response element (PPRE) identified in the 5'-flanking region of the rat peroxisomal 
acyl CoA oxidase gene is an almost perfect direct repeat with the sequence 
5'TGACCTTTGTCCT 3' (Tugwood et al, 1992). Nuclear hormone receptors for retinoic acid 
(RAR), vitamin D3 (VDR) thyroid hormones (TR) and estrogens (ER) all recognise a TGACCT 
half-site (Umesono et al, 1991, Mader et al, 1989). It is of particular interest that a direct repeat 
of the TGACCT half-site separated by one base pair is also a response element for the Retinoid 
X receptor (RXR) (Kleiwer et al, 1992). The relative spacing of the half-sites is an important 
feature that determines the specificity of response elements for receptors that recognise a direct 
repeat of the TGACCT half-site (Umesono et al, 1991). RXR forms heterodimers with and 
enhances the binding of other nuclear hormones that bind to direct repeat of the TGACCT half­
site.
The work presented in this chapter illustrates that, in common with RAR, VDR, TR and 
COUP-TF, the activation of PPARa is dramatically enhanced by addition of RXR. The ability 
of peroxisome proliferators to enhance the activity of RXR is interesting and may indicate that 
part of the action of these compounds is to perturb or enhance pathways that are regulated by 9- 
cis retinoic acid Furthermore Issemann et al (1993) speculated that since fatty acids activate the 
PPAR, then fatty acids and 9-cis retinoic acid may cooperate to regulate genes containing 
upstream RDR-1 motifs such as those important for gluconeogenesis (eg PEPCK) or lipid 
homeostasis (eg. apolipoprotein).
PPAR is a peroxisome proliferator-mediated transcription factor and therefore may well mediate 
the transcription of other genes. It is therefore conceivable that the PPAR may also mediate 
peroxisome proliferator-associated carcinogenesis. It has been proposed that this may be due to 
oxidative damage to DNA resulting from elevated levels of hydrogen peroxide (Reddy and 
Lalwani, 1984). Alternatively, tumour formation could result from important changes in cellular 
growth and differentiation (Gerbacht et al, 1990). In this case, PPAR may be critical in altering 
the expression of key genes relevant to growth and differentiation, for example, the 
protooncogenes. This possibility is discussed further in Chapter 8.
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In conclusion, the H4IIEC3 system established and investigated in this chapter provides a 
coherent model system for analysing the mechanism of the induction response and thereby 
contributing to an understanding of peroxisome-proliferator-mediated hepatocarcinogenesis.
I have demonstrated (in my system) that the PPAR does indeed recognise such a PPRE located 
upstream of the rat AGO gene and that the response of H4IIEC3 cells to the peroxisome 
proliferator Wy-14,643 is receptor-dependent.
PPAR is activated by the peroxisome proliferator Wy-14,643 and controls the peroxisomal 13- 
oxidation of fatty acids through regulation of the gene encoding acyl CoA oxidase. Equally, it 
has been demonstrated that the 9-cis retinoic acid signalling pathway also participates in the 
control of the acyl CoA oxidase gene by heterodimerisation of RXR with PPAR.
Finally, the transfection of PPAR in an expression vector into H4IIEC3 cells has been shown to 
cause an increase in acyl CoA oxidase activity which is enhanced by cotransfection of the 
receptor with RXR.
It is therefore becoming clear that the control of the acyl CoA oxidase gene is maintained by 
both PPAR and RXR signalling pathways. This however raises the question of the next level of 
control - the mechanism of regulation of the PPAR itself - this is explored in the next chapter.
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CHAPTER 7
THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR 
IN VIVO INDUCTION STUDIES
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7.1 Summary
The preceding chapter details the role of the Peroxisome Proliferator Activated Receptor in 
mediation of the response of H4IIEC3 cells to peroxisome proliferators and in the control of the 
peroxisomal |3-oxidation of fatty acids through regulation of the acyl CoA oxidase gene. 
Identification of this regulatory role of the PPAR raises the question - how is the PPAR itself 
regulated?
There is precedence in the literature for autoregulation of steroid hormone receptors - the 
cognate ligand positively influencing the transcription of oestrogen and progesterone receptor 
mRNA (Kaufman et al 1981, Piva et al, 1988). The possibility of this being a regulatory 
mechanism for the PPAR was investigated.
The effect of a series of classical microsomal oxidase inducers (including peroxisome 
proliferators) on the abundance of the mPPAR mRNA was examined. Northern blotting and 
hybridisation analysis of total PFDA-treated rat liver RNA with a PPAR cDNA probe revealed a 
marked induction of the PPAR mRNA in treatment groups. Extension of the number of samples 
analysed (using a dot blotting technique) revealed that the induction of PPAR mRNA by a series 
of inducers correlated to the compound's potency as a peroxisome proliferator, but not to its 
potency as a hepatomegalic.
The regulation of the PPAR by an autoinduction loop (stimulating its own transcription) is 
proposed and the implications of this regulation to our understanding of the mechanism of 
peroxisome proliferation, is discussed.
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7.2 Introduction
Work in the preceding chapter confirmed the role of PPAR in mediation of the p-oxidation of 
fatty acids through regulation of the acyl CoA oxidase gene. In a search for further definition of 
the mechanism of peroxisome proliferation, the regulation of the PPAR itself was investigated. 
Although the mechanism of regulation of the PPAR has not been studied in great detail, two 
publications exist which present contradictory evidence.
Gebel et al (1992) reported induction of PPAR mRNA in response to fenofibrate treatment in 
the male rat, as assessed by Northern blotting. The low constitutive expression of PPAR 
mRNA showed, over a time course investigation, a delayed accumulation in response to 
treatment. The accumulation started on day 2 after a latency period of at least one day and the 
signal then remained enhanced for 12 days. This group however determined the PPAR message 
size to be close to 6kb, when Issemann and Green (1990) reported 1.8 and 2.0kb message 
sizes. (The source of the PPAR cDNA probe used by Gebel et al is not quoted by the authors). 
Secondly, Rumsby et al (1993) reported that dot blot analysis of total rat liver RNA from rats 
treated with nafenopin, methylclofenapate, Wy-14,643 and clofibric acid revealed no effect on 
PPAR mRNA abundance.
The objectives of the study outlined in this chapter were therefore :
1. To investigate the effect of a series of classical microsomal oxidase inducers and 
peroxisome proliferators on the transcription of PPAR mRNA in rat liver.
2. To examine the relationship between PPAR mRNA abundance, lauric acid co­
hydroxylase activity and liver growth.
3. To draw conclusions as to the mechanism of regulation of the PPAR in vivo and the 
possible relationship of this to the process of non-genotoxic carcinogenesis.
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7.3 Experimental
The samples analysed in this chapter were all from male Wistar albino rats (150-200g initial 
body weight, University of Surrey strain) which were housed as described in Materials and 
Methods and allowed to acclimatise for three days with free access to control powdered diet and 
tap water. The samples, however, originated in a number of different studies which took place 
over a period of three months in our laboratory. Each of the studies was designed to produce 
maximal induction of mixed function oxidases over the dose period. Results of enzyme assays 
are therefore expressed as percentage of the corresponding control values. The dosing regimes 
are given in Table 7.1 below and all tissue samples were processed as described in Materials 
and Methods.
Table 7.1. Dosing regimens used in in vivo PPAR induction work.
Group Daily Dose Route Vehicle Days treatment
Clofibrate 250mg/kg gavage Gum Tragacanth 
(0.25% w/v)
0.1 ml/kg
14 days
Phenobarbitone lOOmg/kg gavage Gum Tragacanth 
(0.25% w/v)
0.1 ml/kg
14 days
p-Naphthoflavone 50mg/kg gavage Gum Tragacanth 
(0.25% w/v)
0.1 ml/kg
4 days
Dexamethasone 300mg/kg gavage Gum Tragacanth 
(0.25% w/v)
0.1 ml/kg
4 days
PFDA 20mg/kg i.p Polypropylene 
Glycol : water 
1:1 1 ml/kg
Single dose 
Day 8 kill
PFOA 75mg/kg i.p Polypropylene 
Glycol : water 
1:1 1 ml/kg
Single dose 
Day 8 kill
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For the perfluorodecanoic acid and perfluorooctanoic acid studies, a pair-fed, weight-matched 
group of animals were used as an additional control, in anticipation of a possible inhibition of 
food intake and loss of body weight gain (Olson & Anderson, 1983). These latter animals were 
pair-fed according to the previous day's food consumption in the PFDA and PFOA groups. The 
dose regimen of a single injection of PFDA and PFOA were carefully chosen such as to 
minimise the 'wasting syndrome' associated with these compounds.
At appropriate time points, the livers were removed and subcellular fractions prepared as 
described in Materials and Methods (section 2.3). Liver sections were snap frozen for RNA 
isolation. Subcellular fractions of the remaining tissue provided microsomal fractions for total 
cytochrome P450 specific content and lauric acid hydroxylase activity determinations.
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7.4 Effect on Relative Liver Weight
Food intake. and body weight gain for each study were not affected by any of the treatments 
described (data not shown).
The effect of each of the compounds on relative liver weight is shown in Figure 7.2. As 
discussed in section 3.5, hepatomegaly (which is expressed as an increase in the liverrbody 
weight ratio) is a common adaptive response to non-tissue damaging non-genotoxic carcinogens 
(Hess et al, 1965). Perfluorodecanoic and -octanoic acids showed marked hepatomegaly of 144 
and 141% of control values respectively, and treatment with clofibrate gave an 134% increase in 
liver weight over control. Phenobarbitone treatment produced a lesser growth of 117% and 
dexamethasone and p-naphthoflavone showed no significant hepatomegaly.
7.5 Effect on Microsomal Cytochrome P450 Monooxygenase Enzymes
7.5.1 Cytochrome P450 Specific Content
Figure 7.3 shows the total CO-discemible cytochrome P450 content determined as the carbon 
monoxide-Fe2+ complex by the method of Omura and Sato (1965). All the compounds used 
were chosen as cytochrome P450 inducers and it is therefore not surprising that all compounds 
produced a significant induction in total P450 content over control levels. Phenobarbitone 
shows the most significant increase in P450 content (249% of control) followed by 
perfluorooctanoic acid and dexamethasone at 188% and 178% respectively.
2 0 6
I
I
g
i  
u
145-,
140
135
130
125
120
115
110
105-
100 -
CLOF PB DEX BNF PFDA PFOA
Figure 7.2 Effect on relative liver weight (% control) of treatment with a 
series of microsomal oxidase inducers.
Data points shown are averages ± sem for 6 animals per group
Statistical analysis as described previously (Figure 4.3)
*
**
statistically different from control at p<0.05 level 
statistically different from control at p<0.01 level 
*** statistically different from control at p <0.001 level
Relative liver weight control values :
Clofibrate study (CLOF) 4.98 ± 0.07 g/lOOg body weight
Phenobarbitone study (PB) 4.98 ±0.07
Dexamethasone study (DEX) 3.70 ±0.01
B-Naphthoflavone study (BNF) 3.70 ±0.01
PFDA study (PFDA) 4.81 ±0.1
PFOA study (PFOA) 5.00 ±0.1
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Figure 7.3 Total P450 specific content of liver microsomes from rats treated with 
a series of microsomal oxidase inducers (expressed as % control).
Data points shown are averages ± sem for 6 observations
Statistical analysis as described previously (Figure 4.3)
* statistically different from control at p<0.05 level 
** statistically different from control at p<0.01 level 
*** statistically different from control at p<0.001 level
Total P450 content control values :
Clofibrate study (CLOF)
Phenobarbitone study (PB)
Dexamethasone study (DEX)
B -Naphthofiavone study (BNF)
PFDA study (PFDA)
PFOA study (PFOA)
0.618 ± 0.03 nmol P450/min/mg protein 
0.618 ±0.03 
0.570 ±0.02 
0.570 ±0.02 
1.01 ±0.06
0.73 ±0.03
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7.5.2 CYP4A1 Laurie Acid Hydroxylase Activity
The specific activities of CYP4A1, lauric acid 11- and 12-hydroxylase were measured by the 
method of Parker and Orton (1980). The highly significant increase in 12-hydroxylation of 
lauric acid in response to clofibrate correlated well with that seen in preceeding chapters. 
Interestingly, PFDA, PFOA also produced significant increases in 12-hydroxylation activity 
above respective control values in addition to significant increases in 11-hydroxylation activity. 
The remaining compounds studied (phenobarbitone, dexamethasone and P-naphthoflavone) 
showed no apparent increase in 12-hydroxylation activity above control.
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Figure 7.4 : Lauric acid ll-(o)-l) hydroxylase and 12-(œ) hydroxylase activities 
of liver microsomes from rats treated with a series of microsomal oxidase inducers 
(expressed as % control).
Data points shown are averages ± s.e.m for 6 observations.
Statistical analysis as described previously (Figure 4.3)
* statistically different from control at p< 0.05 level 
** statistically different from control at p<0.01 level 
*** statistically different from control at p<0.001 level
Lauric acid 11- and 12-hydroxylase control values :
Clofibrate study 
Phenobarbitone study 
Dexamethasone study 
B-Naphthoflavone study 
PFDA study 
PFOA study
nmol/min/mg protein
11-OH 12-OH
(CLOF) 2.79 ±0.03 4.50 ±0.58
(PB) 2.79 ±0.03 4.50 ±0.58
(DEX) 0.86 ±0.045 3.52 ±0.46
(BNF) 0.86 ±0.045 3.52 ± 0.46
(PFDA) 1.40 ±0.10 3.74 ± 0.30
(PFOA) 1.40 ±0.10 3.40 ± 0.30
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7.6 Effect on PFDA on CYP4A1 and mPPAR transcription
Figure 7.5 shows duplicate Northern blots of control, pair-fed and PFDA-treated rat liver RNA 
hybridised against (i) a 32p_iabelled 2.10kb CYP4AI cDNA and (ii) a 32p_iabelled l.SOkb 
mPPAR cDNA probe. Four samples of each 'treatment' of rat liver RNA were loaded at lOpg 
per well. After hybridisation, both filters were washed at high stringency (detailed in Figure 
7.5) and exposed to X-ray film for a period of 72 hours.
Autoradiography revealed a degradation of RNA species in all the treatment groups indicated by 
the 'streaking' effect seen. The hybridisation to the RNA 'streaks' at this stringency indicates 
partial degradation of the nucleic acid leaving sufficient CFP4A1 or PPAR sequence fragments 
for recognition by the ^^P-labelled probe.
Assuming an approximately similar level of degradation for each of the three treatment groups, 
it is clear that there is a marked induction of both 2.00kb CTP4A1 mRNA and l.SOkb PPAR 
mRNA in PFDA-treated animals over control. This effect is not observed in the pair-fed 
animals. The very high washing stringency used adds weight to this finding and indeed, 
subsequent attempts to wash the filters to higher stringency did not alter the fold induction 
observed.
Hybridisation of the above filters to a human actin cDNA probe revealed that lanes 5 and 7 
contained significantly less RNA than the other lanes (data not shown). Also, lanes 3 and 12 
were slightly overloaded in comparison to the majority of wells (which showed even loading). 
This slight difference in loading of total RNA between some of the wells, however was not
c
seen as significant enough to account for the very marked induction seen on both 
autoradiographs. The induction represented on the autoradiograph was therefore seen to be 
'real'.
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Figure 7.5 Northern blot analysis of the effect of treatment with perfluorodecanoic acid on 
hepatic transcription of (a) CYP 4A1 (b) mPPAR.
Lanes 1-4 
Lanes 5-8 
Lanes 9-12
Control animals 
Pair-fed animals 
PFDA-treated animals
Washing stringency (for both filters):
RT = room temperature
2xSSC , 0.1%(w/v) SDS 
0.5xSSC, 0.1%(w/v) SDS 
O.lxSSC, 0.1%(w/v) SDS 
5 X SSC, 0.1%(w/v) SDS
42° C 2 X 20 minutes 
• 55°C 2 X 20 minutes 
65°C 2 X 20 minutes 
RT 2 X 20 minutes
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7.7 Effect of Microsomal Oxidase Inducers on mPPAR Transcription
Total RNA was prepared from snap frozen whole liver samples as described in section 2.5.1.2. 
Due to facilities available at the time, the analysis of these samples was carried out using a 
conventional dot blot technique. Briefly, lOpg of each total RNA sample was applied directly 
onto a nylon filter and fixed to the filter using UV-crosslinking. In order to discount the 
possibility of non-specific binding, 5pg yeast tRNA negative control was also applied to the 
filter alongside 0.5|ig of PPAR cDNA as positive control. The filter was then hybridised 
against a 1.8kb PPAR cDNA using the protocol outlined in section 2.7.
The autoradiograph produced after high stringency washing is shown in Figure 7.6. The figure 
also shows a histogram of induction^ relative to control as assessed by scanning densitometry. 
The yeast tRNA negative control showed no hybridisation signal and the positive control 
showed very dense hybridisation of probe to the filter (data not shown) - these two controls 
added confidence in the specificity of hybridisation.
It is clear from the histogram that PPAR mRNA levels are strongly induced by the classical 
peroxisome proliferator, clofibrate. Further, it seems clear that this induction does not correlate 
with hepatomegaly in general as the phenobarbitone-induced samples show no significant 
induction of PPAR mRNA.
The peroxisome proliferators PFOA and PFDA show a lesser induction than clofibrate. The 
CYP4A1 enzyme data does however, indicate that these compounds are stronger inducers of
12-hydroxylase activity than clofibrate. The reason for this apparent discrepancy is unclear. 
Dexamethasone and p-naphthoflavone show slight increases in PPAR message. Although it is 
possible that dexamethasone acts through another member of the steroid hormone receptor 
superfamily, the glucocorticoid receptor, the reason for the induction of the PPAR by this 
compound has not been explored experimentally.
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Figure 7.6 Effect of a series of microsomal oxidase inducers on mPPAR transcription in 
rat liver, as assessed by RNA dot blot analysis. Histogram shows values from only the 
blot shown.
lOjig of total rat liver RNA was loaded per dot and hybridised to a 
mPPAR cDNA.
32 P-labelled l.SOkb
Washing stringency: 2 x SSC, 0.1 % (w/v) SDS 42°C 2 X 20 minutes
1 X SSC, 0.1% (w/v) SDS 55°C 2 X 20 minutes
0.5 X SSC, 0.1% (w/v) SDS 55°C 2 X 20 minutes
0.1 X SSC, 0.1% (w/v) SDS 65'C 2 X 20 minutes
5xSSC RT 20 minutes
RT = room temperature
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7.8 Discussion
The results of the study outlined in this chapter are summarised in Table 7.7. Importantly in this 
study all results have been expressed as percentage of respective control values as samples were 
obtained from different studies. The use of absolute values was seen as invalid, however, the 
comparison of relative fold induction above control was, however, seen as valid.
Table 7.7. Summary of PPAR in vivo induction study results
Percentage control values
Compound Dose/duration Hepatomegaly P450
induction
CYP4A1
induction
PPAR mRNA 
induction
Clofibrate 250mg/kg 
14 days
133.5 142.9 324.4 71
Phenobarbitone lOOmg/kg 
14 days
116.9 249.0 97.8 1
Dexamethasone 300 mg/kg 
4 days
108.0 178.6 126.1 4
p-Naphthoflavone 50mg/kg 
4 days
115.0 134.2 139.8 5
PFOA 75mg/kg 
single dose
138.6 210.4 333.3 2
PFDA 20mg/kg 
single dose
140.6 223.3 335.8 11
The results presented indicate that PPAR mRNA is induced by those cornpounds known to be 
peroxisome proliferators: clofibrate (activity described in Chapter 3), and the perfluorinated 
fatty acids, PFDA and PFOA. Accumulating evidence has classified the perfluorinated fatty 
acids (used in industry as lubricants, plasticisers etc) as peroxisome proliferators. In particular, 
work by Chinje et al (1994) in our laboratory has shown that PFDA is, like other peroxisome
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proliferators, a CYP4A1 inducer and conforms well to the documented species specificity of 
induction for this class of compound. PFOA is a highly potent peroxisome proliferator in rat 
liver, producing a several-fold induction of CYP4A1 in both male and female mice. PFOA 
produces increased peroxisome diameter and number and cytoplasmic volume occupied in adult 
rat hepatocytes (Feller & Intrasuksri, 1993 - New Orleans). PFDA and PFOA also produce 
increases in microsomal laurate 11- and 12- hydroxylase and palmitoyl Co A oxidase 
(PFOA>PFDA) in rat hepatocytes.
The fold induction in response to PFDA derived from the dot blot seems markedly less than that 
derived from the Northern blot. These differences can be explained by differences in the 
technique used. Dot blotting involves the application of total RNA (and any contaminating salts 
etc) to a limited area of the filter. This can result in the masking of some specific mRNA species 
and a resulting weaker hybridisation. Northern blotting involves separation of the mRNA 
species and removal of contaminating salts by gel electrophoresis prior to hybridisation. This 
latter technique will therefore produce a much stronger hybridisation signal than dot blotting due 
to improved access of the probe to mRNA species.
It is clear that the PPAR is both activated (Chapter 6) and induced by peroxisome proliferators. 
Although no ligand binding has been shown to date, it is possible that the peroxisome 
proliferators themselves are ligands for the PPAR suggesting an autoregulatory mechanism of 
PPAR induction. Recent investigations with computer-aided modelling (D. Lewis, personal 
communication) has suggested that, although peroxisome proliferators have diverse chemical 
structures, many share common structural features and functional groups - a putative ligand- 
binding site which can accommodate numerous peroxisome proliferators has been proposed 
(Lewis and Lake, 1993).
There is a precedence for this mode of regulation in the steroid hormone receptor superfamily. 
Autoregulation of the hormone-receptor concentration by the homologous ligand has been
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demonstrated for steroid hormones such as glucocorticoids, androgens and estrogens 
(Cidlowski & Cidlowski, 1981, Kaufman et al 1981, Markavirich & Clark, 1979, Piva et al, 
1988). In the case of glucocorticoid receptors, there is evidence both in vivo and in vitro that 
down-regulation of the mRNA for the receptor also occurs.
The involvement of such an autoregulatory feedback loop would readily explain the magnitude 
of induction of peroxisomal enzymes by peroxisome proliferators. Induction of peroxisomal 13- 
oxidation has been reported to be as much as 30-fold, and carnitine acetyl transferase can be 
induced by 160-fold (Lazarow & DeDuve, 1976, Reddy & Lalwani, 1984).
Heterodimerisation to the retinonid X receptor (RXR) is essential for the action of the thyroid 
hormone receptors, the RAR's and vitamin D receptor (Kleiwer et al, 1992) and has also been 
shown to play a key role in the action of the PPAR (see Chapter 6). This interaction with other 
members of the steroid hormone superfamily (Green, 1993) would serve to increase the number 
of transcription factors, and therefore increase biological sensitivity.
Dexamethasone (the action of which is known to be mediated via the glucocorticoid receptor) 
has been shown to cause induction of peroxisomal p-oxidation (Osmundsen et al, 1991) 
although the mechanism by which this occurs is unclear. It is conceivable, however that the 
PPAR will heterodimerise with other transcription factors (for example, the glucocorticoid 
receptor) to mediate the induction of p-oxidation by substances such as dexamethasone. 
Alternatively, these substances could activate independent signalling pathways working through 
different response elements in the gene promoter regions.
The role of receptor heterodimerisation in subtle control of response to steroid hormone 
receptor-ligand interaction is discussed further in Chapter 8.
The question of the functionality of this autoregulation remains to be defined. However, 
comparison of the lauric acid 12-hydroxylase induction and the mPPAR induction reveals some
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similarities in induction - in both cases the compounds known to have peroxisome proliferative 
activity (clofibrate, PFOA and PFDA) induced both CYP4A1 activity and mPPAR mRNA 
levels. No significant induction of CYP4A1 or mPPAR mRNA levels was observed in 
response to phenobarbitone, dexamethasone or P-napthoflavone administration. Therefore these 
results strongly suggest a correlation between CYP4A1 induction and mPPAR mRNA 
induction.
Assuming that the densitometric quantitation of the dot blot is accurate and further assuming that 
all mPPAR message transcribed is translated into protein, it follows that clofibrate (for example) 
is triggering the production of more PPAR protein within the cell than, for example, P- 
naphthoflavone. Therefore, the fold induction in PPAR-regulated activities should correlate 
with the PPAR mRNA levels. I have shown 12-hydroxylase activity correlates well with 
mPPAR induction and there therefore seems to be a functional correlation between PPAR and 
CYP4A1.
In conclusion, the results presented in this chapter provide evidence in agreement with Gebel et 
al (1992) that the PPAR is regulated by its own ligand (or indirectly, by a biproduct of lipid 
metabolism). These findings add weight to a positive feedback mechanism of steroid hormone 
regulation. Finally, evidence has been presented for a functional correlation between mPPAR 
mRNA transcription and CYP4A1 induction. The implications of these findings will be 
discussed further in Chapter 8.
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CHAPTER 8 
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The aim of the present research was to investigate the early cell biology changes associated with 
administration of non-genotoxic carcinogenesis and with particular reference to the 
protooncogenes. The mechanism of action of the Peroxisome Proliferator Activated Receptor 
was also considered.
The phenomenon of non-genotoxic carcinogenesis has invariably been associated with tissue 
growth. Recently the involvement of the Peroxisome Proliferator Activated Receptor in 
mediation of peroxisome proliferator-induced changes has been identified. However, the 
relationship between non-genotoxic carcinogenesis, tissue growth and the genes which control 
these processes has not been fully studied at the molecular level.
In this thesis I report on the analysis of protooncogene involvement in the early stages of non- 
genotoxic carcinogenesis and establish the specificity of these responses to tissue growth, non- 
genotoxic carcinogenesis and genotoxin-induced carcinogenesis. The PPAR has been shown to 
act cooperatively with retinoid X receptor in the activation of both peroxisomal p-oxidation 
genes and CYP4A6 (Muerhoff et al, 1992) and this work has been substantiated herein in a 
novel transfection system. Further, the endogenous effects of the PPAR transfection on 
H4IIEC3 rat hepatoma cells was investigated. I also examined the mechanism of regulation of 
the PPAR and an autoregulatory mechanism is proposed.
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8 .1  Cell Proliferation & Hepatocarcinogenesis
Administration of clofibrate to species and tissues undergoing peroxisome proliferation and 
tissue growth produced a marked transcriptional induction of the nuclear protooncogenes c- 
myc, c-fos and c-jun. (at 14 days exposure to clofibrate). Due to technical considerations, 
analysis was only performed at the transcriptional level and therefore any of the protooncogenes 
examined which could be activated by mechanisms other than transcriptional over-expression, 
would not have been detected. Equally, Milton (1989) showed that CYP4A and peroxisomal P- 
oxidation enzymes respond to peroxisome proliferator administration with an immediate peak at 
24 hours, falling back to near control levels and then a more sustained induction over 14 days. 
It follows therefore that any protooncogene changes associated with these early inductions 
described by Milton (1989) would not be evident in the results of the study described in Chapter
3.
However, the induction of c-myc, c-fos and c-jun in tissues undergoing growth is of interest. A 
role for normal fos protein has been suggested in the control of both cell growth and 
differentiation and expression of the fos  oncogene is rapidly transcriptionally activated by 
agents such as PDGF and TPA that stimulate cell division (Kruijer, 1984). The c-fos protein 
heterodimerises with the c-jun protein to form the transcriptional activator factor, AP-1 which in 
turn regulates the transcription of several genes involved in normal growth and in the induction 
of neoplasia by tumour promoters (Curran & Franza, 1988).c-myc has been shown to play a 
role in regulating the entry of hepatocytes into the cell cycle (GO-Gl transition).
Each of these genes has been shown to be transcriptionally activated after partial hepatectomy 
(Thompson et al, 1986) but the activation is only transient. In response to clofibrate (and, 
indeed phenobarbitone) the response seems much more prolonged (continuing to 14 days). 
Two d istil^  phases of chemically-induced cell proliferation have been identified in the liver - 
that occui^g during the first few days of administration of the chemical followed by a lower 
level sustained proliferation. It seems likely therefore that the protooncogene induction seen at
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14 days is a residual induction driving a low level proliferation in response to the inducer. 
Clarification could be obtained using a detailed time course experiment at intervals from 1 hour 
to 14 days post dose.
The guinea pig which is refractory to all peroxisome proliferators had detectable constitutive 
levels of each of the protooncogenes examined in both control and test animals, suggesting a 
certain level of mRNA is transcribed in the normal cell. The function of these proteins in 
tissues such as the liver which has a low mitotic index is unclear although it seems reasonable 
that a low basal level of cell division controlled by these protooncogenes would be part of 
normal cell turnover. The protooncogenes were, however, not inducible when exposed to 
peroxisome proliferators and no significant tissue growth was observed.
A recent review by Ashby et a/ (1994) of available data relating cell proliferation to chemically- 
induced hepatocarcinogenesis revealed a qualitatively good correlation between the two, 
particularly when DNA synthesis was determined over a time course of less than two weeks. 
The mechanism by which non-genotoxic carcinogens induce cell proliferation is unclear 
although induction of the cell cycle genes c-myc, c-fos and c-jun implies that these compounds 
may well be mimicking the effect of growth hormones.
Ames and Gold (1990) have proposed that the increased mitogenesis associated with 
administration of non-genotoxic carcinogens may produce increased mutagenesis since the 
increased rate of cell cycling allows naturally occurring adducts to be fixed as mutations. In 
addition the increased cell division allows less time for DNA repair mechanisms to act 
effectively and therefore the conversion of more adducts to mutations.
A second hypothesis concerning the role of cell proliferation in non-genotoxin-induced 
carcinogenesis involves the promotion of spontaneous lesions (Schulte-Hermann, 1983). This 
is thought to be due to a combination of clonal expansion of selected preneoplastic cells, a
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mitoinhibitoiy effect on the surrounding normal cells and inhibition of programmed cell death in 
the foci. The overall progression of the liver to hepatocellular carcinoma is illustrated in Figure 
8 . 1.
It is possible, however that both of these mechanisms may play a role in the progression to 
neoplasia. The initial mitogenic burst could produce an increase in initiated cells (Ames and 
Gold, 1990) and once the initiating events have taken place, a low sustained level of cell 
division amplifying the initiated cells - promotion.
It seems likely that different degrees and time periods of cell proliferation and different 
involvement of other cellular factors are required to produce tumours in different target organs 
and species. The additional cell response which may be essential to produce neoplasia could be 
inhibition of apoptosis, inactivation of tumour suppressor genes, modulation of growth factor 
production etc.
It is interesting to note that the tissues seen here as most responsive to cell cycle control gene 
induction are those with very low mitotic indices (ie. liver and kidney) but are capable of 
undergoing very marked proliferative growth when stimulated. It follows therefore that in these 
tissues, inappropriate stimulation of cell division would be a major factor in carcinogenesis.
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8.2 Transcription-Mediated Mechanism of Peroxisome Proliferation
It is known that the induction of peroxisomal p-oxidation and CYP4A1 in response to 
peroxisome proliferators probably occurs via activation of the Peroxisome Proliferator- 
Activated Receptor (Issemann & Green, 1990). Since the demonstration that the PPAR 
recognises a response element (PPRE) present in the 5-upstream region of the rat peroxisomal 
acyl CoA oxidase gene, a number of other PPRE's have been identified. PPRE'S have been 
found in the genes for the rat peroxisomal trifunctional enzyme (Zhang et al, 1992, Bardot et al, 
1993), the rat peroxisomal 3-ketothiolase gene (Kleiwer et al, 1992), CYP4A6, the major rabbit 
lauric acid hydroxylase (Muerhoff et al, 1992) and the rat liver fatty acid binding protein 
(Issemann et al, 1992). Further, it has been demonstrated that PPAR activates these genes 
through heterodimer formation with the retinoid X receptor (Issemann et al, 1993, Bardot et al, 
1993). I have confirmed this latter finding in a transfection model established in our laboratory 
using the peroxisome proliferator-responsive rat hepatoma cell line, H4IIEC3. Figure 8.2 
shows a scheme for the involvement of the PPAR in peroxisome proliferation.
The mechanism be which the PPAR is activated is still widely debated. Although PPAR's can 
be activated by a number of structurally diverse peroxisome proliferators there is no 
unequivocal evidence at this time of these xenobiotic compounds binding directly to the 
receptor. Lewis and Lake (1993) however examined the PPAR ligand binding domain (based 
upon amino acid sequence) using a molecular modelling approach. These workers have 
identified a putative PP-binding site consiting of isoleucine-354, lysine-358, phenylalanine-359 
and phenylalanine-361. In this model the carboxylate anion of the peroxisome proliferator 
interacts with the e-amino group of lysine-358, the two phenylalanine residues interact with the 
aromatic ring of the inducer by 7C-7C stacking and the isoleucine 354 forms a hydrophobic 
interaction with the cognate portions of the peroxisome proliferator. A good correlation was 
noted between the peroxisome proliferator binding and the ability of the inducers to activate the 
receptor in either COS-1 cells or in rat hepatocyte cultures. Indeed it has been demonstrated that 
peroxisome proliferators can displace radiolabelled linoleic acid from the protein fraction of a
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cell line transfected with PPAR in a vaccinia virus transcription vector (C. Elcombe, personal 
communication).
It is known that the 70kD and 90kD heat shock proteins are associated with the steroid hormone 
receptors and are vital in controlling receptor function (Landers and Spelsberg, 1992) for 
example, dissociation of HSP90 from the glucocorticoid receptor results in activation of the 
receptor without ligand binding (Daniel et al, 1991). It has been demonstrated that peroxisome 
proliferators can bind to heat shock proteins in vitro (Alvarez et al, 1990) and this may provide 
a mechanism of activation of the PPAR (by peroxisome proliferators sequestering heat shock 
proteins).
Another possible mechanism of PPAR activation involves calcium signalling and 
phosphorylation of the receptor. Many steroid hormone receptors have been found to be 
phosphorylated (Daniel et al, 1991) affecting the transcriptional efficiency of these receptors - 
activation being possible in the absence of ligand binding. Calcium signalling via protein kinase 
C can be modulated by peroxisome proliferators (Bennett and Williams, 1992) and 
phosphorylation events may therefore play a role in mediating the activation of the PPAR. The 
relevance of modulation of intracellular calcium concentrations to the mechanism of peroxisome 
proliferation is discussed below.
The endogenous ligand for the PPAR has not, as yet been defined. It has been reported by 
several workers that long chain fatty acids can activate the PPAR (Gottlicher et al, 1992, 
Schmidt et al, 1992) but the relative potency compared to the activation by the peroxisome 
proliferators themselves is low. In contrast, Keller et al (1993) demonstrated that 
polyunsaturated fatty acids activated the Xenopus laevis PPAR receptor as effectively as the 
most potent peroxisome proliferator. It may also be possible that a fatty acid metabolite may act 
as the ligand for the PPAR, for example, the co-hydroxy metabolite of arachidonic acid.
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The work detailed herein substantiates the work by Issemann et al (1993) and Bardot et al
(1993) confirming that PPAR acts coordinately as a heterodimer with the retinoid X receptor, 
RXR (as shown in Figure 8.2). The detailed function of this heterodimerisation is unclear at 
this stage although it has been demonstrated that the DNA-binding capacity of receptors such as 
the thyroid hormone receptor, the retinoic acid receptor and the vitamin D3 receptor with their 
target response elements is potentiated by the heterodimerisation of the receptor with RXR 
(Zhang et al, 1992, Kleiwer 1992, Carlberg et al, 1993).
It is likely that the ability of the RXR to contribute to receptor binding and activation is 
dependent upon the response element within the promoter, and also the cell type, thus providing 
fine tuning of the response. The PPRE's identified to date all show slight variations in the 
TGACCT direct repeat and it is these differences which may lead to differences in PPAR/RXR 
binding, thus leading to differential induction of associated genes by the PPAR/RXR 
heterodimer (Green, 1992).
This latter degree of fine tuning of the réponse to peroxisome proliferators could be enhanced 
by the existence of multiple isoforms of the PPAR. It is known that as well as the mouse PPAR 
(Issemann & Green, 1990) there are 3 PPARs (a, P, y) present in Xenopus laevis (Dreyer et al, 
1992), one in rat (Gottlicher et al, 1992), one in human (Sher et al, 1993) and a human PPAR- 
like receptor, Nuc-1 (Schmidt et al, 1992). Further, it is likely that there are more PPAR 
isoforms present in mouse, rat and human particularly as it is known 3 isoforms of RXR exist 
(a, P, y) (Mangelsdorf et al, 1990). The presence of these isoforms could also contibute to the 
fine tuning of the response by each having different affinities for ligands and DNA binding sites 
and perhaps differential inducibilities by peroxisome proliferators.
This similarity in binding sites and the subtlety of control may well produce an opportunity for 
error or misrecognition within the cell. The retinoic acid receptor, for example is known to 
regulate the action of protooncogenes in controlling cell growth and differentiation. This 
receptor however recognises the same response element as the PPAR (the only difference being
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in the spacing of the direct repeat sequences). It is conceivable therefore that the PPAR/RXR 
heterodimer produced in response to peroxisome proliferators may also mimic the action of the 
retinoic acid receptor thus stimulating activation of the cell cycle controlling oncogenes.
It is clear however, that the maximal cooperative effect between PPAR and RXR occurs in the 
presence of the RXR ligand, 9-cis retinoic acid. It has also been reported that retinoids can be 
peroxisome proliferators in cultured hepatocytes (Hertz and Bar-Tana, 1992). Shackleton
(1994) reported that hepatic cytosols from clofibric acid-treated rats had induced alcohol 
dehydrogenase activity compared to controls. At least one alcohol dehydrogenase is inducible 
by retinoic acid, via the retinoic acid receptor and this has been suggested to result in increased 
formation of retinoic acid in a positive feedback loop (Harding and Duester, 1992). The 5'- 
flanking region of this alcohol dehydrogenase gene contains a sequence identical to the PPRE 
found in the acyl CoA oxidase and bifunctional genes (Kleiwer et al, 1992). Alcohol 
dehydrogenase is the rate limiting step in the synthesis of retinoic acid from retinol (Edenberg 
and Brown, 1992). Therefore alcohol dehydrogenase may be involved in the process of 
peroxisome proliferation - both in the oxidation of fatty acids and increasing the formation of 
retinoic acid by a positive feedback loop. It can be postulated that the prolonged action of this 
positive feedback loop could be responsible for some of the longer term effects of peroxisome 
proliferators - perhaps the low level prolonged cell proliferation which is hypothesised to lead 
eventually to clonal expansion of selected cells and ultimately carcinogenesis.
It is interesting to note that Schule et al (1991) described the down-regulation of transcriptional 
activation of the nuclear protooncogene c-jun by the retinoic acid receptor. In contrast, the 
Retinoid X Receptor fails to repress jun/AP-1 activity (Schule et al, 1991) demonstrating a 
significant difference between the two pathways by which retinoids exert their effects. It is 
possible however that the equilibrium between retinoic acid and 9-cis-retinoic acid provides a 
level of control- one suppressing and one allowing AP-1 mediated growth. A positive feedback 
loop driving the production of retinoic acid may therefore, ultimately drive AP-1 mediated 
growth.
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The work outlined in this thesis has demonstrated that peroxisome proliferators are capable of 
inducing PPAR mRNA in vivo and an autoregulatory feedback loop can therefore be postulated 
as the mechanism of regulation of the PPAR (McNae et al, 1994). The work of Milton (1989) 
showed that CYP4A is induced at a very early time point after administration of peroxisome 
proliferators and prior to the induction of peroxisomal p-oxidation. It is therefore possible that 
the initial increase in fatty acid oxidation provides sufficient of the endogenous ligand for PPAR 
to trigger the subsequent increase in peroxisomal p-oxidation and production of further PPAR 
molecules via an autoregulatory loop. It should be noted, however that an inhibitor of CYP4A1, 
1-aminobenzotriazole did not inhibit PPAR activation by fatty acids in transfected hepatocytes, 
indicating that CYP4A1 activity is not obligatory for PPAR activation (Gottlicher et al, 1993). 
The initial increase in fatty acid oxidation being responsible for the triggering of the PPAR- 
mediated response is supported by the observation that the induction of peroxisomal P- 
oxidation is dependent upon a phase of protein synthesis (Gibson, 1992). This early protein 
synthesis could be synthesis of CYP4A1 although the participation of other regulatory proteins 
(perhaps PPAR?) can not be excluded.
The existence of two positive feedback loops (Figure 8.2) explains the magnitude of the enzyme 
induction in response to peroxisome proliferators (30-fold induction of peroxisomal p-oxidation 
and 160-fold induction of carnitine acyl transferase being reported (Lazarow and De Duve, 
1976, Reddy and Lalwani, 1984)). It seems that the peroxisome proliferator may act to 
inappropriately maintain these positive feedback loops resulting in the disturbance of normal 
cellular homeostasis and ultimately carcinogenesis.
Emerging evidence has suggested that the peroxisome proliferators can raise cytosolic calcium 
levels in hepatocytes by mobilisation of intracellular calcium stores and as a direct result of 
inhibition of microsomal calcium-dependent ATPase (Bennett & Williams, 1992). Further, the 
calcium channel blocker, nicardipine has been shown to block the peroxisome proliferator- 
induced gene changes (Itoga et al, 1990). Intracellular calcium signalling and protein kinase C 
have also been shown to play roles in cell proliferation. Phorbol esters (which directly activate
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protein kinase C) and calcium ionophores that increase the cytoplasmic calcium concentration by 
allowing calcium to enter the cell from the extracellular fluid, act synergistically to stimulate cell 
proliferation in T-cell lymphocytes (Truneh et al, 1985). Kaibuchi et al (1986) have shown that 
platelet derived growth factor and fibroblast growth factor rapidly activate protein kinase C, 
induce calcium mobilisation and also induce the protooncogene c-myc.
It seems therefore that peroxisome proliferators play a role in the mobilisation of cellular 
calcium levels and cause very significant changes in cell proliferation and enzyme induction. 
Further, as discussed above, many steroid hormoneshave been found to be phosphorylated 
(Danielson, 1991) and this may provide a control mechanism for activation of the receptor. 
Overall, it is tempting to speculate that there may be a synergy between PPAR-mediated gene 
inductions, calcium mobilisation, protein kinase C activation and cell proliferation.
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8.3 Conclusion
In conclusion, both the peroxisome proliferator clofibrate and the non-genotoxic carcinogen, 
phenobarbitone have been shown to induce the protooncogenes c-myc, c-fos and c-jun in those 
tissues which undergo growth in response to the compound. Initiation of cells with 
diethylnitrosamine prior to phenobarbitone had no impact on these inductions. Therefore, as a 
prescreen, induction of these protooncogenes is insufficient to be exclusively predictive of non- 
genotoxic carcinogenesis potential. However, the changes are closely associated with the 
process of cell proliferation and therefore increased mitogenesis and tumour promotion in 
response to non-genotoxic carcinogens. In the longer term, the hepatocarcinogenicity of 
peroxisome proliferators may be controlled via positive feedback mechanisms controlling both 
PPAR and retinoic acid levels in the cell.
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8 .4  Future Work
1. To further investigate the role of protooncogenes in non-genotoxic carcinogenesis, two 
approaches are possible. Firstly, to continue to examine the regulation of the nuclear 
protooncogenes involved in cell cycle control {c-myc, c-fos, c-jun) and establish 
whether the PPAR plays a role in controlling these genes. Secondly, a broader approach 
could be taken, extending the scope of the analysis to look at other mechanisms of 
protooncogene activation, for example examination of Ha-ras point mutations by site- 
directed mutagenesis.
2. Investigations into the possible interactions between the AP-1 transcriptional activator 
and the PPAR/RXR should be explored initially using gel retardation and footprinting 
techniques, the DNA binding site of the AP-1 could be established.
3. Further attempts to investigate the impact of boosting endogenous PPAR using 
transfection techniques should be made. Using transfection into primary hepatocytes (to 
avoid using transformed and therefore already 'abnormal' cell lines) the effect of 
increasing endogenous PPAR levels on the protooncogene profile of the cells can be 
explored. A dose response or time course approach to cell proliferation may be of 
interest.
The use of transfection techniques such as this with guinea pig primary hepatocytes may 
serve to identify the parts of the cellular 'machinery' in which the guinea pig may be 
deficient and therefore refractory to peroxisome proliferators.
4. To further investigate the role of calcium in peroxisome proliferator-induced gene 
induction and cell proliferation, the influence of a number of structurally diverse 
peroxisome proliferators (with differing potencies) on calcium perturbation and cellular 
proliferation should be examined. One possible methodology would be in vitro
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using hepatocyte suspensions with a cell proliferation marker such as tritiated thymidine
incorporation or 5-bromo-2'-deoxyuridine labelling. The effect of each peroxisome 
0
proliferator on cajium perturbation could be followed using a fluorimetric method with 
Fura-2 as an indicator.
234
REFERENCES
235
Alvarez K, Carrillo A, Yuan PM, Kawano H, Morimoto RI, Reddy JK (1990) Identification 
of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein 
HSP70 family. Proc. Natl Acad. Sol 87, 5293-5297
Alvarez E, Northwood IC, Gonzalez FA, Latour DA, Seth A, Abate C, Curran T, Davis RJ 
(1991) Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein 
phosphorylation. J. Biol Chem. 266. 15277-15285
Alwine JC , Kemp DJ, Stark OR (1977) Method for detection of specific RNAs in agarose 
gels by transfer to diazobenzyloxymethyl-paper and hybridisation with DNA probes. Proc. 
Natl Acad. Scl USA 74 (12), 5350-5354
Ames BM, Gold LS (1990) Too many rodent carcinogens : mitogenesis increases 
mutogenesis. Science 249. 970-971
Ames BM, McCann J, Yamasaki E (1975) Methods for detecting carcinogens and mutagens 
with the Salmonella/mammalian microsome mutagenicity test. Mutat. Res. 31, 347-364
Aoyama T, Hardwick IP, Imaoka S, Funae Y, Gelboin HV, Gonzalez FJ (1990) Clofibrate- 
inducible rat hepatic P450's IVAl and IVA3 catalyse the O)- and (co-l)-hydroxylation of fatty 
acids and the co-hydroxylation of prostaglandins Ei and F2 a- 7. Lipid Res. 31, 1477-1482.
Ashby J, Brady A, Elcombe CR, Elliott BM, Ishmael J, Odum J, Tugwood ID, Kettle S, 
Purchase IFH (1994) Mechanistically-based Human Hazard Assessment of Peroxisome 
Proliferator-induced Hepatocarcinogenesis. Human and Experimental Toxicology 13. 
Supplement 2
Ashby J, Tennant RW (1988) Chemical structure. Salmonella mutagenicity and extent of 
carcinogenicity as indicators of genotoxic carcinogenesis among 22 chemicals tested in rodent 
by the US NCI/NTP. Muiat. Res. 204, 17-115
Ashby J, Tennant RW, Zeiger E, Statiewicz S (1989) Classification according to chemical 
structure, mutagenicity to Salmonella and level of carcinogenicity of a further 42 chemicals 
tested for carcinogenicity by the US National Toxicology Program. Mutat. Res. 223, 73-103
A zarnoff DL, Reddy J, Hignite C, Fitzgerald T (1976) Structure activity relationships of 
clofibrate-like compounds on lipid metabolism. Proc. 6th Inti Pharmacol Meet., 4, 137-147
Bacher MA, Gibson GG (1988) Chlorophenoxyacid herbicides induce microsomal 
cytochrome P450 IVAl (P452) in rat liver. Chem. Biol Int. 145-156
Badr MZ, Handler JA, Whittaker M, Kauffman FC, Thurman RG (1990) Interaction between 
plasticizers and fatty acid metabolism in the perfused rat liver and in vivo. Biochem. Pharmacol 
39,715-721
Barass NC, Price RJ, Lake BG, Orton TC (1993) Comparison of the acute and chronic 
effects of the peroxisome proliferators methylclofenapate and clofibric acid in rat liver. 
Carcinogenesis 14. 1451-1456
Bardot O, Aldridge TC, Latruffe N, Green S (1993) PPAR-RXR heterodimer activates a 
PPRE upstream of the bifunctional enzyme gene. Biochem. Biophys. Res. Commun. 192. 37- 
45
Bars RG, Elcombe CR (1991) Dose-dependent acinar induction of cytochromes P450 in rat 
liver. Evodence for a differential mechanism of induction of P4501A1 by beta-naphthoflavone 
and dioxin. Biochem. J. 277. (Pt 2), 577-580
236
Becker CM, Harris RA (1983) Influence of valproic acid on hepatic carbohydrate and lipid 
metabolism. Arch. Biochem. Biophys. 223. 381-392
Beckett RB, Weiss R, Stitzel RE, Cenedella RJ (1972) Studies on the hepatomegaly caused 
by the hypolipidaemic drugs nafenopin and clofibrate. Toxicol. Appl. Pharmacol. 23,42-53
Beer DG, Neveu MJ, Paul DL, Rapp UR, Pitot HC (1988) Expression of the c-ra f 
protooncogene, gammaglutamyltranspeptidase, and gap junction protein in rat liver neoplasms. 
Cancer Res. 4^. 1610-1616.
Bennett AM, Williams GM (1992) Reduction of rat liver endoplasmic reticulum Ca2+- 
ATPase activity and mobilisation of hepatic intracellular calcium by ciprofibrate, a peroxisome 
proliferator. Biochem. Pharmacol. 43, 595-605.
Bentley P, Bieri F, Mitchell FE, Waechter F, Staubli W (1987) Investigation of the 
mechanism of liver tumour induction by peroxisome proliferators. Arch. Toxicol. Suppl. 10, 
157-161
Bentley P, Calder I, Elcombe C, Grasso P, Wiegand HG, Stringer DA (1993) Hepatic 
Peroxisome Proliferation. Fd. Cosmet. Toxicol. 21, 857-907
Berridge M J (1987) Inositol lipids and cell proliferation. Biochem. Biophys. Acta 907. (1), 
33-45
Bieri F, Bentley P, Waechter F, Staubli W (1986) The use of primary cultures of adult rat 
hepatocytes to investigate mechanisms of action of nafenopin, a hepatocarcinogenic peroxisome 
proliferator. Fd. Cosmet. Toxicol. 24, 709-TI3
Bieri F, Meier U, Staubli W, Muakkassah-Kelly SF, Waechter F, Sagelsdorff P, Bentley P
(1991) Studies on the mechanism of induction of microsomal cytochrome P450 and 
peroxisomal bifunctional enzyme mRNA's by nafenopin in primary cultures of adult rat 
hepatocytes. Biochem. Pharmacol. 44, 310-312
Birnboim HC (1983) A rapid alkaline extraction method for the isolation of plasmid DNA. 
Meths. Fnzymology. 100. 243-255
Bjorkhem I, Hamberg M (1971) Oxidation of fatty acids. II. Enzymatic oxido-reduction of 
17-hydroxy stearic acid. J. Biol. Chem. 246. 7417
B ronfm an M, Inestrosa NC, Leighton F (1979) Fatty acid oxidation by human liver 
peroxisomes. Biochem. Biophys. Res. Commun. 88 (3) 1030-1036
Bronfman M, Amigo L, Morales MN (1986) Activation of hypolipidaemic drugs to acyl 
coenzyme A thioesters. Biochem J. 239.781-784
Bronfman M, Orellana A, Morales MN, Bieri F, Waechter F, Staubli W, Bentley P (1989) 
Potentiation of diacylglycerol-activated protein kinase C by acyl coenzyme A thioesters of 
hypolipidaemic drugs. Biochem. Biophys. Res.Commun. 159. 1026-1031
Brown K, Quintillana M, Ramsden M, Kerr IB, Young S, Balmain A (1986) V-ras genes 
from Harvey and B ALB murine sarcoma viruses can act as initiators of two stage mouse skin 
carcinogenesis. Cell, 46,447-47
Burbach KM, Poland A, Bradfield CA (1992) Cloning of the Ah receptor cDNA reveals a 
distinctive ligand activated transcription factor. Proc. Natl. Acad. Sci. USA 8185-8189
237
Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT (1985) Ethoxy-, 
pentoxy- and benzoxyphenones and homologues : a series of substrates to distinguish between 
different induced cytochromes P450. Biochem. Pharmacol. M  (18) 3337-3345
Burnette WN (1981) "Western blotting": electrophoretic transfer of proteins from SDS- 
PAGE to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated 
protein A Ana/. Biochem. 112. 195-203
Bursch W, Lauer B, Timmermann-Troisner I, Barthel G, Schuppler J, Schulte-Hermann R 
(1984) Controlled death (apoptosis) of normal and putative pre-neoplastic cells in rat liver 
following withdrawal of tumour promoters. Carcinogenesis, 5,457-458
Butterworth BE, Bermudez E, Smith-Oliver T, Earle L, Cattley R, Martin J, Popp JA, 
Strom ST, Jirtle R, Michalopoulos G (1984) Lack of a genotoxic activity of di(2- 
ethylhexyl)phthalate (DEHP) in rat and human hepatocytes. Carcinogenesis, 5, 1329-1335
Cannon JR, Eacho PI (1991) Interaction of LY171883 and other peroxisome proliferators 
with fatty acid binding protein isolated from rat liver. Biochem. J. 280 (2) 387-391
Capdevila JH, Falck JR, Estabrook RW (1992) Cytochrome P450 and the arachidonate 
cascade. FASEB J. 6, 731-736
Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W (1993) 
Two nuclear signalling pathways for vitamin D. Nature 361.657-660
Cathala G, Savouret JF, Mendez B, West BC, Karin M, Martial JA, Baxter JD (1983) 
Laborat-ory Methods. A method for isolation of intact translationally active ribonucleic acid. 
D m  2 (4), 329-335.
Cattley RC, Mars man DS, Popp JA (1989a) Failure of the peroxisome proliferator Wy- 
14,643 to initiate growth selectable foci in rat liver. Toxicology ,56, 1-9
Cattley RC, Marsman DS, Popp JA (1989b) Differences between the promoting activities of 
the peroxisome proliferator Wy-14,643 and phénobarbital in rat liver. Cancer Res. 49, 3246- 
3251
Cherkaoui-Malkl M, Lone YG, Corral-Debrinki M, Latruffe N (1990) Differential 
protooncogene mRNA induction from rats treated with peroxisome proliferators. Biochem. 
Biophys. Res. Commun. 173 (3), 855-861
Chinje EC, Kentish P, Jamot B, George M, Gibson GG (1994) Induction of the CYP4A 
subfamily by perfluorodecanoic acid : the rat and the guinea pig as susceptible and non- 
susceptible species. Toxicol. Letts. 71, 69-75.
Chirgwin AE, Przybylz RJ, MacDonald RJ, Rutter WJ (1979) Isolation of biologically active 
ribonucleic acid from sources enriched in nhotmcXtdiSQ.Biochemistry 18, 5294-5299
Churchill MEA, Travers AA (1991) Proteins that recognise structural features in DNA. TIBS 
,16 ,92-97
Cidlowski JA, Cidlowsky NB (1981) Regulation of glucocorticoid receptors by 
glucocorticoids in cultured HeLa S3 cells. Endocrinol. 109, (6), 1975-1982
Close I, Shackleton G, Goldfarb PS, Gibson GG, Sharma R, Howes, D (1992) Influence of 
single and concurrent phenobarbione and clofibrate administration on cytochrome P450 mixed 
function oxidase activities and peroxisome proliferation in rat liver. J. Biochem. Toxicol. 1, 
193-197
238
Cohen AJ , Grasso P (1981) Review of the hepatic responses to hypolipidaemic drugs in 
rodents and assessment of its toxicological significance to man. Fd Cosmet. Toxicol. 19, 585- 
605
Cole MD (1986) The myc oncogene : its role in transformation and differentiation. Ann Rev 
Genet. 20, 361-384
Columbano A, Ledda-Columbano GH, Coni P, Pichira-Coni G, Curto M, Pani P (1991) 
Differential effect of compensatory cell proliferation and mitogen-induced direct hyperplasia on 
hepatocarcinogenesis. In Chemically-induced cell proliferation : implications fo r  risk 
assessment. Wiley Liss, New York. pp217-225
Conney AH (1967) Pharmacological implications of microsomal enzyme induction. 
Pharmacol. Rev. 19, 317-366
Copple DM, Rush GF, Richardson FC (1992) Effects of methapyrilene measured in 
mitochondria isolated from naive and methapyrilene-treated rat and mouse hepatocytes. Toxicol. 
Appl. Pharmacol. 116. 10-16
Corcos D, Defer N, Raymondgean M, PAris B, Corral M, Tichonicky L, Kruh J, Glaise D, 
Saulnier A, Gugen-Guillouzo C (1984) Correlated increase of the expression of c-ras genes in 
chemically-induced hepatocarcinomas. Biochem. Biophys. Res. Commun. 122, 259-264
Corral M, Tichonicky L, Guigen-Guillouzo G, Corcos D, Raymondgean M, Paris B, Kruh J, 
Defer N (1985) Expression of c-fos oncogene during hepatocarcinogenesis, liver regeneration 
and in synchronised HTC cells. Fxp. Cell. Res. 160. 427-434
C urran  T, Van Beveren C, Verma IM (1985) Viral and c e l lu la rp ro te in s  are complexed 
with a 39,000 dalton cellular protein. Molec. Cell. Biol. 5, 167-172
C urran T, Franza BR (1988) Fos and Jun - the AP-1 connection. Cell, 55, (3), 395-397
Daniel V, Maksymowych AB, Alnemri ES, Litwack G (1991) Cell-free synthesis of rat 
glucocorticoid receptor in rabbit reticulocyte lysate. In vitro synthesis of receptor in Mr 90,000 
heat shock protein-depleted lysate. J. Biol. Chem. 266. (2), 1320-1325.
Danielson M (1991) Structure of the glucocorticoid receptor. Chapter 2 in : Nuclear hormone 
receptors. Molecular mechanisms, cellular functions and clinical abnormalities. MG Parker (ed) 
Academic Press, New York. pp39-78
De Duve C, Baudhin P (1966) Peroxisomes (microbodies and related particles). Physiol. 
Rev. 46, 323-357
De La Iglesia FA, Pinn SM, Lucas J, McGuire EJ (1981) Micron. Microsc. Acta. _12i 97-98
De La Iglesia FA, Lewis IE, Bucharian RA, Marcus EL, McMahon G (1982) Light and 
electron microscopy of liver in hypolipoproteinemic patients under long-term gemfibrozil 
treatment. Atherosclerosis, 43, 19-37
Denis M, Cuthill S, Wikstrom AC, Pellinger L, Gustafsonn JA (1988) Association of the 
dioxin receptor with the Mr 90,000 heat shock protein. A structural kinship with the 
glucocorticoid receptor. Biochem. Biophys. Res. Commun. 155. 801-807
Doolittle RF, Hunkapiller NMW, Hood LE, Devare SG, Robbins KC, Aaronson SA, 
Antoniades HN (1983) Simian sarcoma virus one gene, v-sis is derived from the gene (or 
genes) encoding a platelet-derived growth factor. Nature 305.605
239
Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W (1992) Control of the
peroxisomal p-oxidation pathway by a novel family of steroid hormone receptors. Cell, 68. 
879-887
Eacho PI, Lanier TL, Brodhecker CA (1991) Hepatocellular DNA synthesis in rats given 
peroxisome proliferating agents : comparison of Wy-14,643 to clofibric acid, nafenopin and LY 
171883. Carcinogenesis, \2, 1557-1561.
Earnshaw  D, Dale JW, Goldfarb PSG, Gibson GG (1988) Differential splicing in the 3' 
non-coding region of the rat cytochrome P452 (P450IVA1) mRNA. Febs Lett, 236 (2) 357-361
ECETOC. (1992) Monograph No 17 Hepatic Peroxisome Proliferation, ECETOC, Brussels
E denberg H J, Brown CJ (1992) Regulation of human alcohol dehydrogenase genes. 
Pharmacogenetics, 2, 185-196.
Edwards JE  , Dalton AJ (1942) Induction of cirrhosis of the liver and of hepatomas in mice 
with carbon tetrachloride. J. Natl. Cancer Inst. 3 , 19-2S
Eisenman RN (1989) Nuclear oncogenes In : Oncogenes and the molecular origins of 
cancer pp175-221. Weinberg RA (ed.) Cold Spring Harbour Laboratory Press, New York
Elcombe CR, Mitchell AM (1986) Peroxisome proliferation due to di(2-ethylhexyl)phthalate 
(DEHP) : Species difference and possible mechanisms. Fnviron. Health Perspect. 70,211-219
Ellin A, Jakobsson SV, Schenkman JB, Orrenius S (1972) Cytochrome P450k of rat kidney 
cortex microsomes : its involvement in fatty acid and (-1) hydroxylation. Arch. Biochem. 
Biophys. 150. 64-71
Fahim i HD, Baumgart E, Volkl A (1993) Ultrastructural aspects of the biogenesis of 
peroxisomes in rat liver. Biochimie. 75. 201-208
Fahim i HD, Sies H (1987) Peroxisomes in Biology and Medicine. Springer-Verlag, 
Heidelberg
Fahl WE, Lalwani ND, Watanabe T, Goel SK, Reddy RK (1983) DNA damage related to 
increased hydrogen peroxide generation by hypolipidaemic drug-induced liver peroxisomes. 
Proc. Natl. Acad. Sci. USA, 8L  7827-7830
F arber E (1982) Chemical carcinogenesis. A biologic perspective. Am. J. Pathology, 106. 
269-296
Fearon ER, Vogelstein, B (1990) A genetic model for colorectal tumorigenesis. Cell, 61. 
759-767
Feinberg  AP, Vogelstein B (1983) A technique for radiolabelling DNA restriction 
endonuclease fragments to high specific activity. Anal. Biochem. 132. 6
Feinberg  AP, Vogelstein B (1984) A technique for radiolabelling DNA restriction 
endonuclease fragments to high specific activity. Add. Anal. Biochem. 137, 266-267
Feller DR, Intrasuksri U (1993) Mechanism of peroxisome proliferation by perfluorinated 
fatty acids in primary cultures of rat hepatocytes. Abstract, Society o f Toxicology Conference, 
New Orleans
240
Flatm ark  T, Nilsson A, Kvannes J, Eikhom TS, Fukami MH, Kryvi H, Christiansen EN 
(1988) On the mechanism of induction of the enzyme systems Biochem. Biophys. Acta, 962, 
122-130
Fujita K, Ohuchi N, Yau T, Okumura M, Fukushima Y, Kanakura Y, Kitamura Y, Fujita Jet 
al (1987) Frequent overexpression but not activation by point mutation, of ras genes in primary
h i i m n n  g a s t r i r .  r . a n r e r g  n n x trn p n tp rn ln p y  9 3  1 3 3 9 - 1 3 4 2  _
Frenkel RA, Slaughter CA, Orth K, Moomaw CR, Hicks SH, Snyder JM, Bennet M, 
Prough RA, Putnam RS, Milewich L (1990) Peroxisome proliferation and induction of 
peroxisomal enzymes in mouse and rat liver by dehydroepiandosterone feeding. /. Steroid 
Biochem. 35, 333-342
Gallick GE, Kurzrock R, Kloetzer WS, Arlinghaus RB, Gotterman JV (1985) Expression of 
p21 ras in fresh primary and metastatic human colorectal cancers. Proc. Natl. Acad. Sci. USA., 
82, 1795-1799
G ariot P, Barrat E, Mejean L, Pointel JP, Drouin P, Debry G (1983) Fenofibrate and human 
liver. Lack of proliferation of peroxisomes. Arch. Toxicol. 53 (2) 151-163
Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafsson JA (1993) Interaction of the 
peroxisome-proliferator-activated receptor and retinoid X receptor. Proc. Natl. Acad. Sci. USA 
91(4) 1440-1444
Gebel T, Arand M, Oesch F (1992) Induction of the peroxisome proliferator-activated 
receptor by fenofibrate in rat liver. FEBS Letts, 309. 37-40
G erbacht U, Bursch W, Kraus P, Putz B, Reinacher M, Timmermann-Troisner I, Schulte- 
Hermann R (1990) Effects of the hypolipidaemic drugs nafenopin and clofibrate on phenotypic 
expression and cell death (apoptosis) in altered foci of rat liver. Carcinogenesis. H , 617-624.
Gerosa MA, Talarico D, Fogani C, Raimondi E, Colombatti M, Tridente G, De Carli L, Della 
Valle G (1989) Overexpression of N-ras oncogene and epidermal growth factor receptor gene in 
human glioblastomas. J. Natl. Cancer. Inst. 81(1) 63-67.
Ghersi-Egea JF , Walther B, Minn A, Siest G (1987) Quantitative measurement of cerebral 
cytochrome P450 by second derivative spectrophotometry. J. Neurosci. M eth.J^, 261-269
Gibson GG (1992) Co-induction of cytochrome P4504A1 and peroxisome proliferation : a 
causal or casual relationship. Xenobiotica. 22. 1101-1109
Gibson GG (1989) Comparative aspects of the mammalian cytochrome P450IV gene family. 
Xenobiotica. 19. 1123-1148
Gibson GG, Orton TC, Tamburini PT (1982) Cytochrome P450 induction by clofibrate. 
Purification and properties of a hepatic cytochrome P450 relatively specific for the 12- and 11- 
hydroxylation of dodecanoic acid (lauric acid). Biochem. J. 293, 161-168
Gibson GG, Skett, P (1986) Introduction to Drug Metabolism. Chapman and Hall (London)
Gibson GG, Tamburini PP (1984) Cytochrome P450 spin state: inorganic biochemistry and 
functional significance. Xenobiotica 14,27-47
241
Gius D, Cao XM, Rauscher FJ,III, Cohen DR, Curran T, Sukhatme VP (1990) 
Transcriptional activation and repression by Fos are independent functions; the C terminus 
represses immediate-early gene expression via CArG elements. Molec. Cell. Biol. 10, 4243- 
4255
Glover DM, Hames BD (eds) (1990) Oncogenes. IRL Press at Oxford University Press
Goldfarb P (1990) Molecular mechanisms of P450 gene regulation. Biochem. Soc. Trans. 
18,30-32
Gonzalez F J (1989) The molecular biology of cytochrome P450s. Pharmacol. Rev. 40, 243- 
288
Gonzalez F J (1992) Human cytochromes P450 : problems and prospects. Trends Pharmacol. 
Sci., 13, 346-352
Gorgas K (1987) Morphogenesis of peroxisomes in lipid-synthesising epithelia. In : 
Peroxisomes in Biology and Medicine, eds Fahimi HD, Sies H. Springer-verlag, Berlin
Gottlicher M, Demoz A, Svensson D, Toilet P, Berge RK, Gustafsson J-A (1993) Structural 
and metabolic requirements for the activators of the peroxisome proliferator-activated receptor. 
Biochem. Pharmacol. 46, 2177-2184.
Gottlicher M, Widmark E, Li Q, Gustafsson J-A (1992) Fatty acids activate a chimera of the 
clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA, 
82, 4653-4657
Grasso P, Hinton RH (1991) Evidence for and possible mechanisms of non-genotoxic 
carcinogenesis in rodent liver. Mutation Research 248,271-290
Gray TJB, Beamand JA, Lake BG, Foster JR, Gangolli SD (1982) Peroxisome proliferation 
in cultured rat hepatocytes produced by clofibrate and phthalic acid ester metabolites. Toxicol. 
Letts. 10, 273-279
Green S (1991) The search for molecular mechanisms of non-genotoxic carcinogenesis. 
Mutation Research. 248. 371-374
G reen S (1992) Receptor mediated mechanisms of peroxisome proliferators. Biochem. 
Pharmacol. 43, (3), 393-401.
Green S (1993) Nuclear hormone receptors : promiscuous liaisons. Nature 361. 590-591
Gronemeyer H (1992) Control of transcription activation by steroid hormone receptors. 
FASEB J. 6, 2524-2529
Guengerich FP (1988) Roles of cytochrome P450 enzymes in chemical carcinogenesis and 
cancer chemotherapy. Cancer Res. 48, 2946-2954.
Guengerich FP (1991) Reactions and significance of cytochrome P450 enzymes. J. Biol. 
Chem. 266. 10019-10022
G uengerich FP, Shimada T, Raney KD, Yun CH, Meyer DJ, Ketterer B. Harris TM, 
Groopman JD, Kadlubar FF (1992) Elucidation of catalytic specificities of human cytochrome 
P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology. Env. 
Health. Persp. 98, 75-80.
Hanefield M, Kremmer C, Kadner E (1983) Relationship between morphological changes 
and lipid-lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria 
and peroxisomes in man. Atherosclerosis, 43, 239-246
242
Harding PP, Duester G (1992) Retinoic acid activation and thyroid hormone repression of the 
human alcohol dehydrogenase gene ADH3. J. Biol Chem. 267. 14145-14150
Hardwick JP  (1991) CYP4A subfamily : Functional analysis by immunocytochemi stry and 
in situ hybridisation. Methods EnzymoL 206. 273-283
Hardwick JP, Gonzalez FJ, Kasper CB (1983) Transcriptional regulation of rat liver epoxide 
hydratase, NADPH-cytochrome P450 oxidoreductase, and cytochrome P450b genes by 
phénobarbital. J. Biol Chem. 258. 8081-8085
Hardwick JP, Song B-J, Huberman E, Gonzalez FJ (1987) Isolation, complementary DNA 
sequence, and regulation of rat hepatic lauric acid w-hydroxylase (cytochrome P450 LAw). 
Identification of a new cytochrome P450 gene family. J. Biol Chem. 266. 7864-7869
Hawkins JM , Jones WE, Bonner FW, Gibson GG (1987) The effect of peroxisome 
proliferators on the microsomal, peroxisomal and mitochondrial enzyme activities in the liver 
and kidneys. Drug Metab. Rev. 18. 441-515
He J-S, Fulco AJ (1991) A barbiturate-regulated protein binding to a common sequence in the 
cytochrome P450 genes of rodents and bacteria. J. Biol Chem. 266. 7864-7869
Hertz R, Bar-Tana J (1992) Induction of peroxisomal p-oxidation genes be retinoic acid in 
cultured rat hepatocytes. Biochem. J. 281,41-43
Hess R, Staubli W, Reiss W (1965) Nature of the hepatomegalic effect produced by 
ethylchlorophenoxy isobutyrate in the rat. Nature 208, 856-858
Hinton RH, Grasso P (1994) Hepatotoxicity : In Press.
Houslay MD (1991) 'Crosstalk': a pivotal role for the protein kinase C in modulating 
relationships between signal transduction pathways. Eur. J. Biochem. 195 9-27
Hsieh LL, Shinozuka H, Weinstein IB (1991) Changes in the expression of cellular 
oncogenes and endogenous retrovirus-like sequences during hepatocarcinogenesis induced by 
peroxisome proliferators. Br. J. Cancer, M , 815-820
H unter T (1991) Cooperation between oncogenes. Cell 64, 249-270
H unter T, K arin M (1992) The regulation of transcription by phosphorylation. Cell 70, 375- 
387
Issem ann I, Green S (1990) Activation of a member of the steroid hormone receptor 
superfamily by peroxisome proliferators. Nature 347. 645-649
Issemann I, Prince RA, Tugwood JD, Green S (1992) A role for fatty acids and liver fatty 
acid binding protein in peroxisome proliferation? Biochem. Soc. Trans. 20 (4) 824-827
Issemann I, Prince RA, Tugwood JD, Green S (1993) The retinoid X receptor enhances the 
function of the peroxisome proliferator activated receptor. Biochimie, 25,251-256
Itoga H, Tamura H, Watanabe T, Suga T (1990) Characteristics of the suppressive effect of 
nicardipine on peroxisome induction in rat liver. Biochim. Biophys. Acta, 1051. 21-28.
Jirtle  RL, Meyer SA, Brockenbrough JS (1991) Liver tumour promoter phénobarbital : a 
biphasic modulator of hepatocyte proliferation. Prog. Clin. Biol Res. 369. 209-216.
243
Johannesen KAM, DePierre JW (1978) Measurement of cytochrome P450 in the presence of 
large amounts of contaminating haemoglobin and methaemoglobin. Anal. Biochem. M  (2), 
725-732
Kaibuchi K, Tsuda T, Kikuchi A, Tanimoto T, Yamashita T, Takai Y (1986) Possible 
involvement of protein kinase C and calcium ions in growth factor-induced expression of c-myc 
oncogene in Swiss 3T3 fibroblasts. J. Biol. Chem. 261. 4534-4540.
Kasai H, Crain PF, Kuchino Y, Nishimura S, Ootuyama A, Tanooka H (1986) Formation of 
8-hydroxyguanine moiety in cellular DNA by agents producing oxygen radicals and evidence 
for its repair. Carcinogenesis, 7, 1849-1851
Kaufman M, Pinsky L, Feder-Hollander R (1981) Defective up-regulation of the androgen 
receptor in human androgen sensitivity. Nature 293, 735-737
K eller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahl W (1993) Fatty acids and 
retinoids control lipid metabolism through activation of peroxisome proliferator-activated 
receptor-retinoid X receptor heterodimers. Proc. Natl. Acad.Sci. USA 90, 2160-2164
Kelly K, Cochran BH, Stiles CD, Leder P (1983) Cell-specific regulation of the c-myc gene 
by lymphocyte mitogens and platelet-derived growth factor. Cell, 35± 603-610
K im ura S, Hanioka N, Matsunaga B, Gonzalez FJ (1989a) The clofibrate-inducible CYP4A 
gene family 1. Complete intron and exon sequence of the CYP4A1 and CYP4A2 genes, unique 
exon organisation, and identification of a conserved 19-bp upstream element. DNAS_, 503-516
K im ura S, Hardwick JP, Lozak CA, Gonzalez FJ (1989b) The rat clofibrate inducible 
CYP4A gene subfamily U. cDNA sequence of 4A3, mapping of the Cyp4a locus to mouse 
chromosome 4, and coordinate and tissue specific regulation of the CYP4A genes. DNA 8, 
517-525
Kitagawa T, Watanabe R, Sugano H (1980) Induction of gamma-glutamyl transpeptidase by 
dietary phenobarbitone in 'spontaneous' hepatic tumours of C3H mice. Gann 71, 536-452
Kleiwer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM (1992) Convergence of 9- 
cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation 
of their receptors. Nature 358.771-774
Klingenberg M (1958) Pigments of rat liver microsomes. Arch. Biochem. Biophys. 75, 
376-386
Knudsen AG J r . (1971) Mutation and cancer : statistical study of retinoblastoma. Proc. Natl. 
Acad. Sci. 6S, 820-823
Kozuka H, Watanabe T, Horie S, Yamada J, Suga T, Ikeda T (1991) Characteristics of 
peroxisome proliferation : Co-induction of peroxisomal fatty acid oxidation related enzymes 
with microsomal laurate hydroxylase. Chem. Pharm. Bw//._39,1267-1271
K ram ar R, Huttinger M, Gmeiner B, Goldenberg H (1978) |3-oxidation in peroxisomes of 
brown adipose tissue. Biochem. Biophys. Acta 531. 353-356
K raupp-G rasl B, Huber W, Putz B, Gerbracht U, Schulte-Hermann R (1990) Tumour 
promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci 
in rat liver. Cancer Res. 3701-3708
K ruijer W, Cooper JA, Hunter T, Verma IM (1984) Platelet-derived growth factor induces 
rapid but transient expression of the c-fos gene and protein. Nature, 312 (5996), 711-716.
244
Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, Ohtssuka E, Nisjimura S (1987) 
DNA templates comptaining 8-hydroxydeoxyguanosine are misread both at the modified base 
and at adjacent residues. Nature, 327.77-79
Kunz W, Schaude G, Scmid W, Seiss M (1966) Stimulation of liver growth by drugs. I. 
Morphological analysis. In : Experimental studies of the effects of drugs on the liver. Proc. 
Eur. Soc. Drug Toxicity. 7, pp 113-137
Laemmli UK (1971) Cleavage of structural proteins during the assembly of the bacteriophage 
T4. Nature 227. 680-685
Lafarge-Frayssinet C, Frayssinet C (1990) Oncogenes and tumour promotion. Bull. Cancer 
P am . 77 (5), 475-478
Lake BG, Gangolli SD, Grasso P, Lloyd AG (1975) Studies on the hepatic effects of orally 
administered di-(2-ethylhexyl)phthalate in the rat. Toxicol. Appl. Pharmacol. 32 (2), 355-367
Lake BG, Evans JG, Gray TJB, Korosi SA, North CJ (1989) Comparative studies on 
nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig and 
marmoset. Toxicol. Appl. Pharmacol. 99, 148-160
Lalw ani ND, Reddy MK, Mangkornkanok-Mark M, Reddy JK (1981) Induction, 
immunochemical identity and immunofluorescence localisation of an 80000 molecular 
peroxisome proliferation associated polypeptide (PPA-80) and peroxisomal enoyl CoA 
hydratase. Biochem. J. 198. 177-186
Lalwani ND, Fahl WE, Reddy JK (1983) Detection of a nafenopin-binding protein in rat liver 
cytosol associated with the induction of peroxisome proliferation by hypolipidaemic 
compounds. Biochem. Biophys. Res. Commun. 116. 388-393
Lampe MA, Kammerer RC (1987) Cytochrome P450-dependent binding of methapyrilene to 
DNA in vitro. Carcinogenesis^, 1525-1529
Landers JP , Spelsberg TC (1992) New concepts in steroid hormone action : transcription 
factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit. 
Rev. Eukaryotic Gene Expression 2, 19-63
Lazarow PB (1982) Compartmentation of beta-oxidation of fatty acids in peroxisomes. In : 
Metabolic compartmentation. Ed. H. Sies. Acad. Press NY pp317-329
Lazarow PB, De Duve C (1976) A fatty acyl CoA oxidising system in rat liver peroxisomes; 
enhancement by clofibrate, a hypolipidaemic drug. Proc. Natl. Acad. Sci. USA. 73, 2043-2046
Ledda-Colum bano GM, Coni P, Curto M, Giacomini L, Faa G, Sarma DS, Columbano A
(1992) Mitogen-induced liver hyperplasia does not substitute for compensatory regeneration 
during promotion of chemical hepatocarcinogenesis. Carcinogenesis, 13 (3), 379-383.
Ledwith BJ, Manam S, Triolo P, Joslyn DJ, Galloway SM, Nichols WW (1993) Activation 
of immediate-early gene expression by peroxisome proliferators in vitro. Mol. Carcinogenesis, 
8, 20-27
Lee WM, Lin C, Curran T (1988) Activation of the transforming potential of the human fos 
protooncogene requires message stabilisation and results in increased amounts of partially 
modified fos protein. Molec. Cell. Biol. 8, 5521-5527
Le H ir M, Dubach U C (1982) Peroxisomal and mitochondrial p-oxidation in the rat kidney : 
Distribution of fatty acyl-coenzyme A oxidase and 3-hydroxy acyl CoA dehydrogenase 
activities along the nephron. J. Histochem. Cytochem. 30, 441-444
245
L ehrach  H, Diamond D, Wozney JM, Boedtker H (1977) RNA molecular weight 
determinations by gel electrophoresis under denaturing conditions, a critical reexamination. 
Biochem. 16, (21), 4743-4751.
Leighton F, Poole B, Beaufay H, Baudhin P, Coffey JW, Fowler S, De Duve C (1968) The 
large scale preparation of peroxisomes, mitochondria and lysosomes from the livers of rats 
injected with Triton WR-1339. J. Cell. Biol. 37,482-513
Lewis DF, Lake BG, Gray T, Gangolli SD (1987) Structure activity requirements for 
induction of peroxisomal enzyme activities in primary rat hepatocyte cultures. Arch. Toxicol. 
Suppl. 11, 39-41.
Lewis DF, Lake BG (1993) Interaction of some peroxisome proliferators with the mouse 
liver peroxisome proliferators-activated receptor (PPAR): a molecular modelling and 
quantitative structure-activity relationship (QSAR) study. Xenobiotica, 23 ,79-96
Lijinsky W, Reuber M, Blackwell BN (1980) Liver tumours induced in rats induced by oral 
administration of the anti-histaminic methapyrilene hydrochloride. Science, 209. 817-819
Lock EA, Mitchell AM, Elcombe CR (1989) Biochemical mechanisms of induction of hepatic 
peroxisome proliferation. Ann. Rev. Pharmacol. Toxicol. 29, 145-163
London WT (1981) Primary hepatocellular carcinoma. Humanpathology.\2, 1085-1097
L u b e t RA , Mayer RT, Cameron JW, Nims RW, Burke MD (1985) Dealkyation of 
pentoxyresorufin : A rapid and sensitive assay for measuring induction of cytochrome(s) P450 
by phenobarbitone or other xenobiotics in the rat. Arch. Biochem. Biophys. 238, 43-48.
M ader S, Kumar V, de Vemeuil H, Chambon P (1989) Three amino acids of the oestrogen 
receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive 
element. Nature, 338. 271-274.
M aje ru s  PW , Connolly TM, Ross TS, Ishii H, Deckmyn H (1986) The role of 
phosphoinositides in cell physiology. Symposium on Fundamental Cancer Research, 39, 157- 
163.
Makowska J  (1989) PhD thesis. University of Surrey
M angelsdorf DJ, Ong ES, Dyck JA, Evans RA (1990) Nuclear receptor that identifies a 
novel retinoic acid response pathway. Nature, 345, 224-229.
M an n aerts  GF, Debeer LJ, Thomas J, De Schepper PJ (1979) Mitochondrial and 
peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and 
clofibrate-treated rats. J. Biol. Chem. 2M, 4845-4595
M annaerts GF, Van Veldhoven PP (1993) Metabolic pathways in mammalian peroxisomes. 
Biochimie. 75. 147-158
M arkavirich BM, Clark JH (1979) Two binding sites for estradiol in rat uterine nuclei : 
relationship to uterotropic response. Endocrinology, 105_(6), 1458-1462
Markwell MAK, Tolbert NE, Bieber LL (1976) Comparison of the carnitine acyl transferase 
activities from rat liver peroxisomes and microsomes. Arch. Biochem. Biophys. 176.479-488
M arsm an DS, Cattley RC, Conway J, Popp JA (1988) Relationship of hepatic peroxisome 
proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome 
proliferator di-(2-ethylhexyl)phthalate and Wy-14,643 in rats. Cancer Res., 48, 6739-6744.
246
M arsm an DS, Goldsworthy TL, Popp JA (1992) Contrasting hepatocytic peroxisome 
proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 
and clofibric acid. Carcinogenesis 13,1011-1017
M cCoy M, Toole JJ, Cunningham JM, Chang EH, Lowy DR, Weinberg RA (1983) 
Characterisation of a human colon/lung carcinoma oncogene. Nature 302,79
McGiff JC  (1991) Cytochrome P450 metabolism of arachidonic acid. Ann. Rev. Pharmacol 
Toxicol 31. 339-369
M cNae FR, Sharma RS, Gibson GG (1994) Molecular toxicology of Peroxisome 
Proliferators. Eur. J. Drug. Metab. Pharmacokin., 3, 219-223
McSween RNM, Scott AR (1973) Hepatic cirrhosis : a clinico-pathologic review of 520 
cases. J. Clin. Pathol 26, 936-942
McSween RNM (1985) Liver, biliary tract and pancreas. In Muirs Textbook o f Pathology. 
IR Andison (ed.) 12th edition. Edward Arnold, London. pp20.1-20.66
Milton MN, Elcombe CR, Kass GEN, Gibson GG (1988) Lack of evidence for a hepatic 
peroxisome proliferator receptor and an explanation for the binding of hypolipidaemic drugs to 
liver homogenates. Biochem. Pharmacol. 37,793-798
Milton MN (1989) PhD thesis. University of Surrey
M ilton MN, Elcombe CR, Gibson GG (1990) On the mechanism of induction of microsomal 
cytochrome P450IVA1 and peroxisomal proliferation in rat liver by clofibrate. Biochem. 
Pharmacol. 40, 2727-22732
M irsalis JC  (1987) Genotoxicity, toxicity and carcinogenicity of the antihistamine 
methapyrilene. Mutat. Res. 185. 309-317
Mitchell FE, Price SC, Hinton RH, Grasso P, Bridges JW (1985) Time and dose-response 
study of the effects of the plasticizer di(2-ethylhexyl)phthalate. Tolxicol Appl Pharmacol 
371-392
Mitchell FE, Bridges JW, Hinton RH (1986) Effects of mono(2-ethylhexyl)phthalate and its 
straight chain analogues mono-n-hexyl phthalate and mono-n-octyl phthalate on lipid 
metabolism in isolated hepatocytes. Biochem Pharmacol 35  ^2941-2947
M itchell P J, Tijan R (1989) Transcriptional regulation in mammalian cells by sequence- 
specific DNA binding proteins. Science 245. (4916), 371-378
Moody DE, Reddy JK (1976) Morphometric analysis of the ultrastructural changes in rat liver 
induced by the peroxisome proliferator SaH-42348. J. Cell Biol 71,768-780
M uerhoff AS, Griffin KJ, Johnson EF (1992) Characterisation of a rabbit gene encoding a 
clofibrate-inducible fatty acid omega-hydroxylase : CYP4A6. Arch. Biochem. Biophys. 296. 
66-72
Nebert DW, Adensik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus 
IC, Johnson EF, Kemper B, Levin B, Phillips IR, Sato R, Waterman MR (1987) The P450 
superfamily : recommended nomenclature. DNA 6,1-11
Nelson DR, Kamamtaki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, 
Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW (1993) The P450 
superfamily : Update on new sequences, gene mapping, accession numbers, early trivial names 
of enzymes and nomenclature. DNA and Cell Biology 10(1), 1-14
247
Neuhoff V, Arold N, Taube D, Ehrhardt W (1985) Clear background and highly sensitive 
protein staining with Coomassie Blue dyes in polyacrylamide gels : a system analysis. 
Electrophoresis 6,427-448
Neveu M J, Hully JR, Babcock KL, Hertzberg EL, Nicholson BJ, Paul DL, Pitot HC (1994) 
Multiple mechanisms are responsible for altered expression of gap junction genes during 
oncogenesis in rat liver. J. Cell Science, 107. 83-95
Oesch F, Hartmann R, Timms C, Strolin-Benedetti M, Dostert P, Worner W, Schladt L 
(1988) J. Cancer Res. Clin. Oncol. 114. 341-346.
Oliver MF, Heady JA, Morris JM, Cooper J (1978) A cooperative trial in the primary 
prevention of ischaemic heart disease using clofibrate. Britich Heart Journal, 40,19-37
O lson CT, Anderson ME (1983) The acute toxicity of perfluorooctanoic and 
perfluorodecanoic acids in male rats and effects on tissue fatty acids. Toxicol. Appl. Pharmacol. 
70 (3), 362-372.
O'Malley BW (1989) Did eukaryotic steroid receptors evolve from intracrine gene regulators? 
Endocrinology. 125 Gl. 1119-1120
O ’Malley BW (1991) Steroid hormone receptor as transactivators of gene expression. Breast 
Cancer Research and Treatment 18,67-71
O m ura T, Sato R (1965) The carbon monoxide binding pigment of liver microsomes I. 
Evidence of its haemoprotein nature. J. Biol. Chem. 239, 2370-2378
Orellana A, Hidalgo PC, Morales MN, Mezzano D, Bronfman M (1990) Palmitoyl CoA and 
the acyl CoA thioester of the peroxisome proliferator, ciprofibrate, potentiate diacylglycerol- 
activated protein kinase C by decreasing phosphatidyl serine requirement. Eur. J. Biochem. 
190. 57-61
O rtiz de Montellano PR, Chan WK, Tuck SF, Kaikus RM, Bass NM, Peterson JA (1992) 
Mechanism-based probes of the topology and function of fatty acid hydroxylases. FASEB J. ^  
695-699
O rton TC, Parker GL (1982) The effect of hypolipidaemic agents on the hepatic drug- 
metabolising enzyme system of the rat. Induction of cytochrome(s) P450 with specificity 
towards terminal hydroxylation of lauric acid. Drug. Metab. Dispos. 10 (2) 110-115
O sm undsen H, Bremer J, Pedersen JI (1991) Metabolic aspects of p-oxidation. Biochem. 
Biophys Acta. 1085. 141-158.
Osumi T, Hashimoto T (1979) Peroxisomal p-oxidation system of rat liver. Co-purification 
of enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase. Biochem. Biophys. Res. 
Commun. 89, 580-584
Osumi T, Hijikata M. Ishii N, Miyazawa S, Hashimoto T (1987) In Peroxisomes in Biology 
and Medicine, Fahimi HD & Sies H (eds) Springer, Berlin, Heidelberg, New York. ppl05- 
114.
Osumi T, Yokota S, Hashimoto T (1990) Proliferation of peroxisomes and induction of 
peroxisomal beta-oxidation enzymes in rat hepatoma H4IIEC3 by ciprofibrate. J. Biochemistry 
108(4)614-621.
248
Osumi T, Wen J-K, Hashimoto T (1991) Two cis-acting regulatory sequences in the 
peroxisome proliferator-responsive enhancer region of the rat acyl-CoA oxidase gene. 
Biochem. Biophys. Res. Commun. 175 (3) 866-871
Palosaari PM, Hiltunen JK (1990) Peroxisomal bifunctional protein from rat liver is a 
trifunctional enzyme possessing 2-enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase
and A3, A2-enoyl-CoA isomerase activities. J. Biol. Chem. 265. 2446-2449
P arker G, Orton TC (1980) In Biochemistry, Biophysics and Regulation o f Cytochrome 
P450. Gustaffson J, Duke J, Mode A, Rafter J (Eds) Elsevier, North Holland Press, pp373- 
377
Pinkus R, Bergelson S, Daniel V (1993) Phénobarbital induction of AP-1 binding activity 
mediates activation of glutathione S-transferase and quinone reductase gene expression. 
Biochem. J, 290 (3) 637-640
Pitot HC (1989) Progression : The terminal stage of carcinogenesis. Jpn. J. Cancer Res. 80, 
599-607 ~
Piva R, Bianchini E, Kumar VL, Chambon P, Senno L del.(1988) Estrogen-induced increase 
of estrogen receptor RNA in human breat cancer cells. Biochem. Biophys. Res. Commun. 155 
(2) 943-949
Powell WS (1984) Properties of leukotriene B4 20-hydroxylase from polymorphonuclear 
leukocytes. J. Biol. Chem. 259. 3082-3089
Preston-M artin S, Pike MC, Ross RK, Henderson BE (1991) Epidemiological evidence for 
the increased cell proliferation model of carcinogenesis. Prog. Clin. Biol. Res. 369. 21-34
Rao MS, Thorgeirsson S, Reddy MK, Lalwani ND, Evarts RE, Usman MI, Singh B, Reddy 
JK (1986) Induction of peroxisome proliferation in hepatocytes transplanted into the anterior 
chamber of the eye. A model for the evaluation of xenobiotic-induced effects. Am. J. Pathol. 
124. 519-527
Rao MS, Reddy JK (1987) Peroxisome proliferation and hepatocarcinogenesis. 
Carcinogenesis 8,631-636
Reddy JK , Rao MS, Azamoff DL, Sell S (1979) Mitogenic and carcinogenic effects of a 
hypolipidaemic peroxisome proliferator (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid 
(Wy-14,643) in rat and mouse liver. Cancer Res. 39.152-161
Reddy JK , Azamoff DL, Hignite CE (1980) Hypolipidaemic peroxisome proliferators form a 
novel class of chemical carcinogen. Nature, 283. 397-400
Reddy JK , Lalwani ND (1984) Carcinogenesis by hepatic peroxisome proliferators : 
Evaluation of the risk of hypolipidaemic drugs and industrial plasticizers to humans. CRC Crit. 
Rev. Toxicol. 12, 1-58.
Reddy MK, Lalwani ND, Qureshi SA, Reddy JK (1982) Induction of hamster hepatic
peroxisomal p-oxidation and peroxisome-proliferation-associated 80,000 molecular weight 
polypeptide by hypolipidaemic dmgs. Hum. Toxicol. 1, 135-147
249
Reddy JK , Lalwani ND, Qureshi SA, Reddy MK, Moehle CM (1984) Induction of hepatic 
peroxisome proliferation in non-rodent species, including primates. Am. J. Pathol. 114. 171- 
183
Reddy JK , Goel SK, Nemali MR, Carrino JJ, Laffler TG, Reddy MK, Sperbeck SJ, Osumi 
T, Hashimoto T, Lalwani ND, Rao MS (1986) Transcriptional regulation of peroxisomal fatty 
acyl CoA oxidase and enoyl CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by 
peroxisome proliferators. Proc. Natl. Acad. Sci. 1747-1751
Reitz RH, Quast JF, Scott WT, Watanbe PG, Gehring PJ (1980) Pharmacokinetics and 
macromolecular effects of chlorofom in rats and mice : Implications for carcinogenic risk 
estimation. In Water chlorinaton control : Environmental impact and health effects. RL Jolly, 
WH Bungs, RB Cummings (eds.) Ann Arbor Scientific Publishers, pp983
Reznic HM, Lijinsky W (1981) Morphology of early changes in liver carcinogenesis induced 
by methapyrilene. Arch. Toxicology, 49 (1), 79-83
Richm ond RE, Pereira MA, Carter JH, Carter HW, Long RE (1988) Quantitative and 
qualitative immunohistochemical detection of myc and src oncogene proteins in normal, nodule 
and neoplastic liver. J. Histochem. Cytochem. 36, 1058-1059
Risse G, Joose K, Neuberg M, Bruller J, Muller R (1988) Asymmetrical recognition of the 
palindromic AP-1 binding site (TRE) by Fos protein complexes. EMBO J. 8, 3825-3832
Rothm an JE  (1989) Polypeptide chain binding proteins : catalysts of protein folding and 
related processes in cells. Cell, 59. 591
Rouiller C, Bernhard W (1956) Microbodies and the problem of mitochondrial regeneration 
in liver cells. J. Biophys. Biochem. Cytol. Suppl. 2, 355-359
Rowe VK, Wolf MA, Neil CS, Smyth HF (1959) The toxicological basis of threshold limit 
values. 2. Pathological and biochemical criteria. Am. Ind. Hyg. 20, 346-349
Rumsby P C, Davies MJ, Price RJ, Lake BG (1993) Effect of some peroxisome proliferators
on transforming growth factor |3l (TGF-(3l), insulin-like growth factor II/mannose-6- 
phosphate (IGFII/Man6P) receptor and a peroxisome proliferator-activated receptor (PPAR) 
gene expression in rat liver. Abstract Society o f Toxicology, New Orleans No. 1560
Ryan DE, Thomas PE, Komeniowski D, Levin W (1979) Separation and purification of 
highly purified forms of liver microsomal cytochrome P450 from rats treated with 
polychlorinated biphenyls, phenobarbitone and 3-methylcholanthrene. /. Biol. Chem. 252. 
1365-1374.
Sager R (1989) Tumour suppressor genes: the puzzle and the promise. Science 246. 1406- 
1412
Sambrook J , Fritsch EF, Maniatis T (1989) Molecular Cloning, a laboratory manual. Cold 
Spring Harbour Press. 2nd edition
Sassone-Corsi P, Lamph WW, Kamps M, Verma IM (1988)/o5'-associated cellular p39 is 
related to nuclear transcription factor AP-1. Cell 54k 553-560
Schenkman JB, Sligar SG, Cinti DL (1981) Substrate interactions with cytochrome P450. 
Pharmacol. Ther. 12,43-71
250
Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan G A (1992) Identification of a 
new member of the steroid hormone receptor superfamily that is activated by a peroxisome 
proliferator and fatty acids. M ol Endocrinol 6, 1634-1641
Schule R, Rangarajan P, Yang N, Kleiwer S, Ransone LJ, Bolado J, Verma IM, Evans RM 
(1991) Retinoic acid is a negative regulator of AP-1 responsive genes. Proc. Natl Acad. Scl 
USA. 88, 6092-6096.
Schultz AM, Copeland T, Oroszlan S, Rapp UR (1988) Identification and characterisation of 
c-raf phosphoproteins in transformed murine cells. Oncogene 2 , 187-MI
Schulte-Hermann R (1979) Adaptive liver growth induced by xenobiotic compounds. Arch. 
Toxicol Suppl. 2, 113-124
Schulte-H erm ann R, Ohde G, Schuppler J, Timmermann-Troisner I (1981) Enhanced 
proliferation of putative preneoplastic cells in rat liver following treatment with the tumour 
promoters phénobarbital, hexachlorocyclohexane, steroid compounds and nafenopin. Cancer 
Res., 41, 2556-2562
Schulte-H erm ann R, Timmermann-Troisner I, Schuppler J (1983) Promotion of 
spontaneous preneoplastic cells in rat liver as a possible explanation of tumour promotion by 
non-mutagenic compounds. Cancer Res. 43, 839-844
Schwartz AG, Lewbart ML, Pashko LL (1988) Novel dehydroepiandosterone analogues 
with enhanced biological activity and reduced side effects in mice and rats. Cancer Research 48 
(17) 4817-4822.
Sen R, Baltimore D (1986) Inducibility of kappa immunoglobulin enhancer-binding protein 
Nf-kappa B by a posttranslational mechanism. Cell 47 (6), 921-928
Shackleton GS (1994) Ph.D thesis. University of Surrey.
Sharm a RK, Lake BG, Foster J, Gibson GG (1988a) Microsomal cytochrome P452 
induction and peroxisome proliferation by hypolipidaemic agents in rat liver. Biochem. 
Pharmacol. 37, 1193-1201
Sharm a RK, Lake BG, Foster J, Gibson GG (1988b) Co-induction of microsomal P452 and 
the peroxisomal fatty acid b-oxidation pathway in rat by clofibrate and di-(2-ethylhexyl) 
phthalate : Dose response studies. Biochem. Pharmacol 37, 1203-1206
Sher T, Yi H-F, McBride W, Gonzalez FJ (1993) cDNA cloning, chromosomal mapping and 
functional characterisation of the human peroxisome proliferator activated receptor. Biochem. 
32, 5598-5604
Siglin JC , Weghorst CM, Klaunig JE (1991) Role of hepatocyte proliferation in a- 
hexacholorocyclohexane and phénobarbital tumour promotion in B6C3F1 mice. Prog, Clin. 
Biol R e s .3 æ , 407-416
Simmon VF, Kauharen K, Tardiff, RG (1977) Mutagenic activity of chemicals founds in 
drinking water.Dev. Toxicol Environ. Sci. 2, 249.
Singh I, Moser HW, Moser AB, Kashimoto Y (1981) Adrenoleukodystrophy : impaired 
oxidation of long chain fatty acids in cultured skin fibroblasts an adrenal cortex. Biochem. 
Biophys. Res. Commun. 102. 1223-1229
251
Singh I, Poulos A (1988) Distinct long chain and very long chain fatty acyl CoA synthetases 
in rat liver peroxisomes and microsomes. Arch. Biochem. Biophys. 2 ^ ,  486-495
Slamon DJ (1987) Protooncogenes and human cancers. N. Engl. J. Med.3 \ l . 955
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast 
cancer : crooelation of relapse and survival with amplification of the HER-2/»gw oncogene. 
Science 325. 177
Sligar SG, Cinti DL, Gibson GG, Schenkman JB (1979) Spin state control of the hepatic 
cytochrome P450 redox potential. Biochem. Biophys. Res. Commun. 90, 925-932
Sm ith WC, Nakshatri H, Leroy P, Rees J, Chambon P (1991) A retinoic acid response 
element is present in mouse cellular retinol binding protein I (mCRBPI) promoter. EMBO J. 
10, 2223-2230.
Smith MR, Matthews NT, Jones KA, Kung H-F (1993) Biological actions of oncogenes. 
Pharmac. Ther. 58. 211-236
Sobcak J , Toumier M-F, Lotti A-M, Duguet M (1989) Gene expression in regenerating liver 
in relation to cell proliferation and stress.Èwr./. Biochem. 180.49-53.
Soit D, Farber E (1976) New priniciple for the analysis of chemical carcinogenesis. Nature 
(London), 263 701-703.
Song BJ, Gelboin HV, Park SS, Yang CS, Gonzalez FJ (1987) Complementary DNA and 
protein sequences of the ethanol-inducible rat and human cytochome P450's. Transcriptional 
and post-transcriptional regulation of the rat enzyme. J. Biol. Chem. 264. 3568-3572.
Steinmetz KL, Tyson CK, Meierhenry EF, Spaulding JW, Mirsalis JC (1988) Examination 
of genotoxicity, toxicity and morphological alterations in hepatocytes following in vivo and in 
vitro exposure to methapyrilene. Carcinogenesis 9,959-963
Stern DF, Roberts AB, Roche NS, Spom MB, Weinberg RA (1986) Differential responses of 
myc and ras-transfected cells to growth factors : selective stimulation of myc-transfected cells 
by epidermal growth factor. Mol. Cell. Biol.6, 870-877
Stevenson DE, McClain RM, Popp JA, Ward JM, Pitot HC (Eds) (1990) Mouse liver 
carcinogenesis : mechanisms and species comparisons. Wiley Liss, New York.
Stowers SJ, Wiseman RW, Ward JM, Miller EC, Miller JA, Anderson MW, Eva A (1988) 
Detection of activated protooncogenes in N-nitrosodiethylamine-induced liver tumours : A 
comparison between B6C3Flmice and Fischer F344 rats. Carcinogenesis, 9, 271-286
Strom SC, Faust JB (1990) Oncogene activation and hepatocarcinogenesis. Pathobiology 58. 
153-1647
Styles JA , Kelly M, Pritchard NR, Elcombe CR (1988) A species comparison of acute 
hyperplasia induced by the peroxisome proliferator methylclofenapate : involvement of the 
binucleated hepatocyte. Carcinogenesis, 9 {9), 1647-1655
Sundseth SS, Waxman DJ (1992) Sex-dependent expression and clofibrate-inducibility of 
cytochrome P4504A fatty acid ©-hydroxylases. J. Biol. Chem., 2Ç1, 3915-3921.
252
Suzuki T, Imagawa M, Yamada R, Yokoyama K, Kondo S, Itakura K, Muramatsu M (1994) 
Acute changes in liver gene expression in the N-nitrosodiethylamine-treated rat. 
Carcinogenesis, 15 (8), 1759-1761.
Svoboda DJ, Azamoff D (1966) Response of hepatic microbodies to a hypolipidaemic agent, 
ethylchlorophenoxybutyrate, J. Cell. Biol. 30,442-445
Tabin C, Bradley S, Bargmann C, Weinberg R, Papageorge A, Scolnick E, Dhar R, Lowy D, 
Chang E (1982) Mechanism of activation of a human oncogene. Nature 300, 143
Tagaki A, Sai K, Umemura T, Hasegawa R, Kurokawa Y (1990) Relationship between 
hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats 
following long term exposure to three peroxisome proliferators. Cancer Letts., 53, 33-38
T a m b u rin i PP , Masson HA, Bains SK, Makowski RJ, Morris B, Gibson GG (1984) 
Multiple forms of hepatic cytochrome P450. Eur. J. Biochem. 139. 235-246.3
Tannock IF, Hill RP (1987) In The Basic Science o f Oncology. Pergamon Press (1987) 
pp89-106.
Thomas PS (1983) In Wu R, Grossman L, Moldave K (eds). Methods in Enzymology, 100. 
Academic Press, NY. p255-266
Thompson NL, Mead JE, Braun L, Goyette M, Shank RR, Fausto N (1986) Sequential 
protoncogene expression during rat liver regeneration. Cancer Res. 46, 3111-3117
Truneh A, Albert P, Goldstein P, Schmitt-Verhulst A-M (1985) Early steps in lymphocyte 
activation bypassed by synergy between calcium ionophores and phorbol ester. Nature, 313. 
318-320.
Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S (1992) The 
mouse peroxisome proliferator activated receptor recognises a response element in the 5'- 
flanking sequence of the rat acyl CoA oxidase gene. EMBO J., 11(2), 433-439.
Umesono K, Evans RM (1989) Determinants of target gene specificity for steroid/thyroid 
hormone receptors. Cell S l  (7), 1139-1146
Umesono K, Murakami KK, Thompson CC, Evans RM (1991) Direct repeats as selective 
response elements for the thyrid hormone, retinoic acid, and vitamin D3 receptors. Cell, 65 (7), 
1255-1266.
Vogelstein B, Gillespie D (1979) Preparative and analytical purification of DNA from 
agarose. Proc. Natl. Acad. Sci. 76, 615-619.
W ada F, Usami M, Goto M, Hayashi T (1971) Studies on the physiological significance of 
fatty acid ©-oxidation. /. Biochem. 70  ^1065-1067
W atanabe T, Horie S, Yamada J, Isazi M, Nishigaki T, Naito J, Suga T (1989) Biochem. 
Pharmacol. 38. 367-371
W aterfield MD, Scrace GT, Whittle N, Stroobant BP, Johnson A, Wasteson A, Westermark 
B, Heldin CH, Huang JS, Deuel TF (1983) PDGF is structurally related to the putative 
transforming protein P28 sis of simian sarcoma virus. Nature 304. 35
W atson AJ, Wier-Brown KI, Bannister RM, Cho FF, Reisz-Poroszasz S, Fujii-uriyama Y, 
Sogawa K, Hankinson O (1992) Mechanism of action of a repressor of dioxin dependent 
induction of Cyplal gene transcription.Mo/. Cell. Biol. 12 (5) 2115-2123
253
W axman DJ, Azarnoff L (1992) Phénobarbital induction of cytochrome P450 gene 
expression. Biochem. J. 281. 577-592
Weibel ER, Staubli W, Gnagi HR, Hess FA (1969) Correlated morphometric and 
biochemical studies on the liver cell. /. Cell. Biol. 42, 68-112
Weil CS, McCollister DD (1963) Safety evaluation of chemicals. Relationship between short 
and long-term feeding studies in designing effective toxicity tests. J. Agric. Food. Chem. 11, 
486-489
W einberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM (1986) The gene 
encodes a thyroid hormone receptor. Nature 324. 641-646
White BA, Bancroft FC (1982) Cytoplasmic dot hybridisation. Simple analysis of relative 
mRNA levels in multiple small cell or tissue samples. J. Biol. Chem. 257. 8569-8572.
White RE, Coon MJ (1980) Oxygen activation by cytochrome P450. Ann. Rev. Biochem. 
49, 315-356
W h itm an  M , Cantley L (1988) Phosphoinositide metabolism and the control of cell 
proliferation. Biochem. Biophys. Acta, 948. 327-344
W ilkinson M, Doskow J, Lindsey S (1990) RNA blots : staining procedures and 
optimisation of conditions. Nucleic Acids Research 19 (3), 679.
W illiams GM, Mori H, McQueen CA (1989) Structure-activity relationship in the rat 
hepatocyte DNA-repair test for 300 chemicals. Mutat. Res. 221, 263-286
Willis (1967) Pathology o f tumours. 4th edition. Butterworths (London).
Yamamoto KK, Gonzalez GA, Biggs WH, Montminy M (1988) Phosphorylation-induced 
binding and transcriptional efficacy of nuclear factor CREB Nature 334 (6182), 494-498
Yarden Y, Ullrich A (1988) Growth factor receptor tyrosine kinases. Ann. Rev. Biochem. 
57, 443-478
Zhang B, Marcus SL, Sajjadi EG, Alvares K, Reddy JK, Subramani S, Rachubinski RA, 
Capone JP (1992) Identification of a peroxisome proliferator-responsive element upstream of 
the gene encoding for rat peroxisomal enoyl-CoA hydratase/3-Hydroxyacyl-CoA 
dehydrogenase. Proc. Natl. Acad. Sci. USA. 7541-7545
254
APPENDIX 1 
DNA PROBE BANK
Vi
ÇJo
- w
%
J
o
u u u u u u u u u u u u u ug ooo o o oo  oo g ooo § Ooo O O oo  oo o ooo oo o o oo  oo p u ug ooo g U U U U U U§ g ooo g g §
I
I
%
Î
g
(S
g
111111f i f g 1 1 1 1 1 1 1cL d . d d d d d
e
I
%
z<
PQ
M
0g
1
Q
I
I
Oh
■§I u  ua  pq 1
CS ON C4 CS ON cn ’C ON 00CS CS CS CJ
ONcn u cn cn Ë £2 O N CSd PC: d u (U a y y U HPQ D PQ PQ D Ü PQ D D DA A CL CL CL CL CL CL CL CL
o o O O CS O O O O NO in«0 o i n r~ CS q ON CS
(S d d
00 o O o o o o 00 00 u CJ
u  u  w w
Ohon
o .
o
I
Tf
'g “g g
u  u  o  uPU u  la ra
■§
ON ON
ON 0 \
ON
ON
C7N
y U U U u u u U
D D D O o D D O
CL CL CL CL CL CL CL CL
o O o O o o O O
NO cn T f q
d d d f —4 1-H d CS
I
I
o
oo
g
j
i aH Ic/3
0
1 
t
I
1pq
Î
c
I
c
1a
c c d =§s 3 3 3s e s6 s s •T
U u u
I 1s 1 Îs sI
I
O
£ I
I
H
I
•M
I I
1
I I
'§ Î
I  s  «S
i  I  S
m
«
s
1 I Im j I6
ON O n o v-4 O n CS
cn o NO S ' O n NO r : T f O n
O n ON CS
&
NO NO NO NO NO NO O nc NO NO NO
'x < <
§
PQ U U u A
1
M<u tH CS CS CS CS CS CS CS CS c n
g Pk d d d d d d d d d d
§ >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4
U u u U U u U U U u u u U u I
i
Pi
a I
u u u u u u u u u u u u u u  u  u  u  u  u  u  u  u  u  u
o o o o o
O O 0 O 0 O 0 O O O 0 O 0 O O 0 0 O 0 O 0 O C 5 O 0 O 0 O O O 0 O 0 O 0 O 0 O O 0 O O O 0 O 0 O O• • I I I I I I I I I I I I I I I I I I I I , I
p p p
g g ooo
i
t
II
M
o
§
y
0
1
i
Q u% gu
œ
69
d  d
5  u  u
g
u
w
î
i l
U p q p q p q u u p q S p q u p q o o U p q p Q o o ü
d  do o
^  u  u
PQ ffi W  W
g
a
00
00
pc:o
m s
ON
Z<
P3
M
PQ
I
t
Q
CS CS CS cn CS
CS CS CS VO CScn m Tf cn cn
Pi Pi s Pi H Pi
PQ PQ PQ < PQ
CL CL CL CL CL CL
I
P
I
uo
p
<
"2M
es
a  g 2  2 "  % % . 1 i  8CL CL
U  U
=â
CS CS CSCS CS CS
cn cn cn
Pi Pi PC:
PQ PQ PQCL CL CL
oo «n
r
o ,  £
00 00 
CL CL
a
I
a
H
I î i I
ü  Ü  Ü
I î
ü
H  H I i
{
Pi
a
Pi
i
00 cn
H  E- I I
ON NO m ON
00 O n 00
VO V)
VI Vi u VI
V UD o«W«M «5
$
Ks
o \ITi
U
S I I
I
3
f
O
CS
1
u
î
è Û
(U
00
%
o \
l >
!
3
V O
2
à
I
en
3
î î
Pi
"d
d
th oo
es m
d%
Pi
è
1
es
o \
m
U N IV E R SITY  O F  S U R R E Y  LIBR AR Y
ON
I
o o O o o o Q o o o o o o o in o o o o o o o o NOON in o oo NO CS in o 00 oo oo cn o NO 00 o o CS in
CS VÔ cn CS oo CS CS* CS CS CS cn NO cn cn NO CS d
00 00 00 00 00 00 u 00 o 00 00 00 o o o o 00 00 00 00 00 o 00 00
H
CS
mm
VOsT
z
I
ON
ON
I
I
I
I
ê
1c
'Eh
■§
i
••5
•S
I
PQ
I
